Public Health Goal for PERCHLORATE in Drinking Water

Prepared by

Pesticide and Environmental Toxicology Branch
Office of Environmental Health Hazard Assessment
California Environmental Protection Agency

January 2011
# LIST OF CONTRIBUTORS

<table>
<thead>
<tr>
<th>PHG PROJECT MANAGEMENT</th>
<th>REPORT PREPARATION</th>
<th>SUPPORT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Project Director</strong></td>
<td><strong>Authors</strong></td>
<td><strong>Administrative Support</strong></td>
</tr>
<tr>
<td>Anna Fan, Ph.D.</td>
<td>Craig Steinmaus, M.D.</td>
<td>Hermelinda Jimenez</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michael Baes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Janet Rennert</td>
</tr>
<tr>
<td><strong>PHG Program Leader</strong></td>
<td><strong>Primary Reviewers</strong></td>
<td><strong>Library Support</strong></td>
</tr>
<tr>
<td>Robert A. Howd, Ph.D.</td>
<td>Mark Miller, M.D.</td>
<td>Charleen Kubota, M.L.S.</td>
</tr>
<tr>
<td></td>
<td>Joseph Brown, Ph.D.</td>
<td></td>
</tr>
<tr>
<td><strong>Comment Coordinator</strong></td>
<td><strong>Final Reviewers</strong></td>
<td><strong>Web site Posting</strong></td>
</tr>
<tr>
<td>Michael Baes</td>
<td>Anna Fan, Ph.D.</td>
<td>Laurie Monserrat</td>
</tr>
<tr>
<td></td>
<td>George Alexeeff, Ph.D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Howd, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>
This Public Health Goal (PHG) technical support document provides information on health effects from contaminants in drinking water. PHGs are developed for chemical contaminants based on the best available toxicological data in the scientific literature. These documents and the analyses contained in them provide estimates of the levels of contaminants in drinking water that would pose no significant health risk to individuals consuming the water on a daily basis over a lifetime. The PHG is a drinking water goal only; therefore, this document does not evaluate the safe levels of perchlorate in foods or other sources.

The California Safe Drinking Water Act of 1996 (Health and Safety Code, Section 116365) requires the Office of Environmental Health Hazard Assessment (OEHHA) to perform risk assessments and publish PHGs for contaminants in drinking water based exclusively on public health considerations. Section 116365 specifies that the PHG is to be based exclusively on public health considerations without regard to cost impacts. The Act requires that PHGs be set in accordance with the following criteria:

1. PHGs for acutely toxic substances shall be set at levels at which no known or anticipated adverse effects on health will occur, with an adequate margin of safety.
2. PHGs for carcinogens or other substances that can cause chronic disease shall be based upon currently available data and shall be set at levels that OEHHA has determined do not pose any significant risk to health.
3. To the extent the information is available, OEHHA shall consider possible synergistic effects resulting from exposure to two or more contaminants.
4. OEHHA shall consider the existence of groups in the population that are more susceptible to adverse effects of the contaminants than a normal healthy adult.
5. OEHHA shall consider the contaminant exposure and body burden levels that alter physiological function or structure in a manner that may significantly increase the risk of illness.
6. In cases of insufficient data to determine a level of no anticipated risk, OEHHA shall set the PHG at a level that is protective of public health with an adequate margin of safety.
7. In cases where scientific evidence demonstrates that a safe dose-response threshold for a contaminant exists, then the PHG should be set at that threshold.
8. The PHG may be set at zero if necessary to satisfy the requirements listed above.
9. OEHHA shall consider exposure to contaminants in media other than drinking water, including food and air and the resulting body burden.
10. PHGs published by OEHHA shall be reviewed every five years and revised as necessary based on the availability of new scientific data.

PHGs published by OEHHA are for use by the California Department of Public Health (DPH) in establishing primary drinking water standards (State Maximum Contaminant Levels, or MCLs). Whereas PHGs are to be based solely on scientific and public health considerations without regard to economic cost considerations, drinking water standards adopted by DPH are to consider economic factors and technical feasibility. Each standard adopted shall be set at a level that is as close as feasible to the corresponding PHG, placing emphasis on the protection of public health. PHGs established by OEHHA are not regulatory in nature and represent only non-mandatory goals. By federal law, MCLs established by DPH must be at least as stringent as the federal MCL if one exists.

PHG documents are used to provide technical assistance to DPH, and they are also informative reference materials for federal, state and local public health officials and the public. While the PHGs are calculated for single chemicals only, they may, if the information is available, address hazards associated with the interactions of contaminants in mixtures. Further, PHGs are derived for drinking water only and are not intended to be utilized as target levels for the contamination of other environmental media.

Additional information on PHGs can be obtained at the OEHHA web site at www.oehha.ca.gov.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIST OF CONTRIBUTORS</td>
<td>II</td>
</tr>
<tr>
<td>PREFACE</td>
<td>III</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>V</td>
</tr>
<tr>
<td>PUBLIC HEALTH GOAL FOR PERCHLORATE IN DRINKING WATER</td>
<td>1</td>
</tr>
<tr>
<td>SUMMARY</td>
<td>1</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>4</td>
</tr>
<tr>
<td>CHEMICAL PROFILE</td>
<td>4-11</td>
</tr>
<tr>
<td>Chemical Identity</td>
<td>4</td>
</tr>
<tr>
<td>Physical and Chemical Properties</td>
<td>5</td>
</tr>
<tr>
<td>Production and Uses</td>
<td>5</td>
</tr>
<tr>
<td>ENVIRONMENT OCCURRENCE AND HUMAN EXPOSURE</td>
<td>5</td>
</tr>
<tr>
<td>Air</td>
<td>6</td>
</tr>
<tr>
<td>Soil</td>
<td>6</td>
</tr>
<tr>
<td>Water</td>
<td>6</td>
</tr>
<tr>
<td>Food</td>
<td>8</td>
</tr>
<tr>
<td>METABOLISM AND PHARMACOKINETICS</td>
<td>11</td>
</tr>
<tr>
<td>Absorption</td>
<td>11</td>
</tr>
<tr>
<td>Distribution</td>
<td>11</td>
</tr>
<tr>
<td>Metabolism</td>
<td>13</td>
</tr>
<tr>
<td>Excretion</td>
<td>14</td>
</tr>
<tr>
<td>Physiological/Nutritional Role</td>
<td>14</td>
</tr>
<tr>
<td>Thyroid Physiology</td>
<td>14</td>
</tr>
<tr>
<td>TOXICOLOGY</td>
<td>18</td>
</tr>
<tr>
<td>Toxicological Effects in Animals</td>
<td>19</td>
</tr>
<tr>
<td>Acute Toxicity</td>
<td>19</td>
</tr>
<tr>
<td>Subchronic Toxicity</td>
<td>20</td>
</tr>
<tr>
<td>Genetic Toxicity</td>
<td>22</td>
</tr>
<tr>
<td>Developmental and Reproductive Toxicity</td>
<td>23</td>
</tr>
<tr>
<td>Immunotoxicity</td>
<td>30</td>
</tr>
<tr>
<td>Neurotoxicity</td>
<td>31</td>
</tr>
<tr>
<td>Endocrine Toxicity</td>
<td>31</td>
</tr>
</tbody>
</table>
Carcinogenicity ........................................................................................ 34
Toxicological Effects in Humans .............................................................. 36
  Acute Toxicity ....................................................................................... 36
  Subchronic Toxicity ................................................................................ 36
  Genetic Toxicity ...................................................................................... 37
  Chronic Toxicity ..................................................................................... 37
  Developmental and Reproductive Toxicity ........................................... 37
  Endocrine Toxicity ................................................................................ 54
    Clinical Dosing Studies ..................................................................... 54
  Immunotoxicity ...................................................................................... 69
  Hematological Effects ........................................................................... 69
  Carcinogenicity ..................................................................................... 70
  Adverse Health Effects Associated with Iodide and Thyroid Deficiency 70
    Thyroid Problems in Pregnant Women with Low Iodide Intake ...... 70
DOSE-RESPONSE ASSESSMENT .................................................................. 99
  Noncarcinogenic Effects ...................................................................... 99
CALCULATION OF THE PHG .................................................................. 107
  Noncarcinogenic Effects ...................................................................... 107
    Acceptable Daily Dose (ADD) ............................................................ 107
    Public Health Protective Concentration (C) ........................................ 109
  Carcinogenic Effects .......................................................................... 111
RISK CHARACTERIZATION ..................................................................... 112
OTHER REGULATORY STANDARDS ......................................................... 114
REFERENCES .......................................................................................... 116
CALCULATION OF THE PHG USING NHANES 2001-2 DATA .......... 151
PUBLIC HEALTH GOAL FOR PERCHLORATE IN DRINKING WATER

SUMMARY

The Office of Environmental Health Hazard Assessment (OEHHA) hereby proposes a Public Health Goal (PHG) of 1 part per billion (ppb) (equivalent to 1 µg/L) for perchlorate in drinking water. Perchlorate is an oxidizing chemical used in a variety of industrial processes. Perchlorate can occur in the environment either through industrial contamination or from natural sources. Perchlorate exposure in the U.S. is ubiquitous, mostly from ingestion of perchlorate in contaminated food or water. In a recent survey involving an essentially random sample of people from the U.S., perchlorate was detected in the urine of every one of the 2820 subjects tested (Blount et al., 2006).

In this PHG document, OEHHA used a decreased uptake of iodide by the thyroid gland as the critical event for assessing the risks due to perchlorate toxicity. The primary action of perchlorate in humans is inhibition of iodide uptake into the thyroid gland. The function of the thyroid gland is the production of thyroid hormone. Iodide is a key component in the structure of thyroid hormone, and by blocking its uptake into the thyroid, perchlorate can potentially cause a decreased production of this hormone. Thyroid hormone is necessary for a variety of basic human physiologic functions, including controlling basal metabolic rates; protein, carbohydrate, and fat metabolism; protein synthesis; and proper differentiation and development of cells, including neuronal cells; and the cognitive and physical development of the fetus, infant, and child.

Decreases in thyroid hormone have been associated with impaired neurodevelopment in children, increases in cardiovascular disease risk factors, and other adverse effects. Importantly, recent research suggests that even small decreases in this hormone during neurodevelopment are associated with significant decreases in IQ and other adverse neurologic effects in the child. This includes decreases in thyroid hormone that occur within what have typically been defined as normal reference ranges.

The proposed perchlorate PHG of 1 ppb is intended to help prevent any perchlorate-related decrease in iodide uptake by the thyroid that could lead to decreased thyroid hormone production and that could disrupt the important functions of this hormone.

This proposed PHG was derived by first calculating an Acceptable Daily Dose (ADD). This is consistent with the approach taken by the National Academy of Sciences (NAS, 2005). The ADD is defined as the estimated maximum daily dose which can be consumed by humans for an entire lifetime without toxic effects, and is similar in definition to the reference dose (RfD) used by the U.S. Environmental Protection Agency (U.S. EPA). In this document, the ADD was estimated using data from the human study by Greer et al. (2002). This is the same study used in developing the 2004 OEHHA perchlorate PHG, and the same study used by the National Academy of Sciences (2005) in developing its perchlorate reference dose. In this study, a daily oral dose of perchlorate was administered to groups of male and female volunteers for 14 days at doses of 0.007, 0.02, 0.1, or 0.5 mg/kg-day. Reductions in iodide uptake by the thyroid gland were seen at all four dose levels, with statistically significant reductions at the
highest three doses. These results were plotted and the dose-response relationship was used to estimate the dose of perchlorate likely to cause a five percent decrease in iodide uptake. This dose was defined as the Benchmark Dose (BMD), and its lower 95% confidence interval was defined as the BMDL. A five percent decrease in iodide uptake was used as the BMD since this is the lowest level of effect that can be identified with statistical significance in many animal and human studies. This is the same method and data set used to establish the 2004 OEHHA perchlorate PHG, and the BMD (6.8 µg/kg-day) and BMDL (3.7 µg/kg-day) are the same.

In the next step, the ADD of 0.37 µg/kg-day was calculated by dividing the BMDL by an uncertainty factor of 10. The National Academy of Sciences also used a 10-fold uncertainty factor in developing its perchlorate reference dose (NAS, 2005). This uncertainty factor was used because the Greer et al. study involved only healthy adult volunteers. However, as we discuss in this document, a fairly extensive body of evidence suggests that certain population subgroups may be much more susceptible to the effects of perchlorate than healthy adults. In our review of the literature, we determined that infants are particularly susceptible to perchlorate, although other groups were identified as likely having increased susceptibility, including the fetus, pregnant women, those with low intakes of iodine, and those exposed to other chemicals in food and water that, like perchlorate, also block iodide uptake into the thyroid.

The ADD was then used to develop the proposed PHG in the following two steps. First, the ADD, which is expressed in units of microgram (µg) of perchlorate ingested in one day per kilogram (kg) of body weight (i.e., µg/kg-day), is converted into an acceptable drinking water perchlorate concentration (in units of µg of perchlorate per liter (L) of drinking water). This was done by dividing the ADD by a drinking water intake rate expressed in terms of liters of water consumed per day per kilogram of body weight. This procedure is consistent with the process of using the National Academy of Sciences perchlorate reference dose (Renner, 2005). Because infants may be particularly susceptible to perchlorate, the upper 95th percentile value for drinking water intake per body weight for infants aged 0-6 months of 0.234 L/kg-day was used in these calculations.

In the second step, an adjustment was made to account for perchlorate intake from sources other than drinking water. Because the ADD is the acceptable daily dose for all sources of perchlorate intake combined (i.e., food plus water), estimated intakes from food must be accounted for when developing a proposed PHG for drinking water. This is required under Health and Safety Code 116365 (c)(1)(C)(iv). In our review, it was determined that food was the only other significant source of perchlorate exposure in the large majority of people. Intake from food is accounted for by multiplying the ADD by the relative source contribution (RSC), defined as the fraction of total perchlorate intake (food plus water) expected to come from water. Since infants were identified as the susceptible group, the amount of perchlorate expected to come from food was estimated using the median perchlorate levels in infant formula (Schier et al., 2009).

Based on these data, OEHHA calculated a RSC of 0.73. These two steps were used to develop a proposed public health-protective concentration (C) based on the following calculations: $C = \text{ADD} \times \text{RSC} \div \text{drinking water rate} = 0.37 \text{ µg/kg-day} \times 0.73 \div 0.234 \text{ L/kg-day} = 1 \text{ µg/L}$ (or ppb). This value was used as the basis of the proposed PHG.
The current OEHHA PHG of 6 ppb was set in 2004. The methods used to develop the proposed PHG described here are similar to those used to develop the 2004 PHG in that both are based on the same thyiodal iodine uptake inhibition data from the Greer et al. (2002) study, and the BMD and BMDL calculations are the same in both analyses. The major difference between the 2004 PHG calculations and the present proposal is that the 2004 PHG document focused on pregnant women and their fetuses as the primary susceptible population, whereas the proposed PHG focuses on infants. This new focus is based on several factors.

First, studies from California and elsewhere provide evidence that thyroid hormone levels in infants were adversely affected by perchlorate at exposure levels that were much lower than the levels shown to cause no effects in healthy adults (Kelsh et al., 2003; Brechner et al., 2000; Buffle et al., 2006; Steinmaus et al., 2010; Li et al., 2000a; Crump et al., 2000). Second, new data suggests that many infants may not be receiving adequate iodine in their diets. In a study of nursing mothers in Boston, 47 percent of breast milk samples did not contain enough iodine to meet the infant iodine intake recommended by the Institute of Medicine (Pearce et al., 2007). Since the mechanism of perchlorate toxicity is a reduced iodide uptake into the thyroid, perchlorate-related toxicity is likely to be greater in infants who are already deficient in iodine. Third, young infants have low stores of thyroid hormone (less than one day's worth, compared to several week’s worth in adults) (van den Hove et al., 1999). Because of these low stores, infants may be less able to tolerate transient periods of decreased iodide uptake and decreased thyroid hormone production compared to adults. Fourth, human data show that perchlorate can interact with other contaminants to produce a greater effect (Blount et al., 2006, Steinmaus et al., 2007). Finally, new data available from the U.S. EPA show that drinking water intakes per body weight are higher in infants than previously thought. This means that infants are likely to have greater perchlorate exposure per body weight for a given concentration of perchlorate in drinking water than was estimated in the 2004 OEHHA PHG.

Incorporation of these new data on infants resulted in two key changes in the proposed PHG compared to the 2004 PHG, and are the reasons why the proposed PHG (1 ppb) is lower than the 2004 PHG (6 ppb). First, based on an enhanced susceptibility in infants, as discussed above, and the fact that the Greer et al. study included only healthy adults, OEHHA has increased the uncertainty factor applied to infants from the factor of 3 used in the 2004 PHG to a factor of 10 used in this proposed PHG. Second, the new drinking water consumption rates for infants are based on both total direct (i.e., from tap water) and indirect water (i.e., tap water added to make foods) intake, and are higher than those used in the 2004 PHG document.

In summary, the primary toxic mechanism of perchlorate is a reduction in iodide uptake into the thyroid gland. If severe enough, this can lead to reduced thyroid hormone production. Adequate supplies of thyroid hormone are vital for a variety of physiologic processes, and even small reductions in thyroid hormone have been associated with increased cardiovascular disease risk factors, abnormal fetal brain development, and altered childhood cognition. The purpose of this proposed PHG is to help prevent perchlorate-related reductions in thyroidal iodide uptake and subsequent decreases in
thyroid hormone production that may be associated with any of these adverse health effects. Currently, there is no federal MCL for perchlorate; the California MCL is 6 ppb.

INTRODUCTION

The purpose of this document is to re-evaluate current scientific information on perchlorate in order to update the health-protective estimate for perchlorate concentration in drinking water. PHGs are based on a comprehensive analysis of information on the toxicology of the compounds, and are based solely on protection of public health without regard to cost impacts or other factors. PHGs for carcinogens are set at a de minimis risk level of one in a million (10⁻⁶), assuming a lifetime of exposure to the chemical in the drinking water. PHGs for non-carcinogens are based on levels estimated to be without risk of any adverse effects for exposures up to a lifetime, to the general population as well as any significant identifiable sensitive subpopulations.

Perchlorate is a ubiquitous environmental contaminant. It is apparently formed by sunlight or lightning interacting with oxygen and chlorine in the atmosphere, and falls to the earth in rain (Dasgupta et al., 2005; Mohan, 2010). Plants can accumulate perchlorate from the water they take up. Perchlorate is also released to the environment from its use in highway flares, fireworks and other explosives, and rocket fuel. People are primarily exposed to perchlorate through consumption of food and water.

Exposure to perchlorate may cause harmful health effects due to its competition with iodide for uptake into the thyroid gland. Iodide is used by the thyroid gland to make the thyroid hormones thyroxine and triiodothyronine (also known as T4 and T3). Decreased uptake of iodide can decrease production of thyroid hormone and impair normal metabolism and growth. Several other chemicals that people are commonly exposed to, such as nitrate, thiocyanate, and bromide, can also compete with iodide for uptake into the thyroid. Maintenance of normal production of thyroid hormone depends on the availability of iodide, obtained mostly from the diet, as well as the combined effects of the various competitors for iodide uptake.

This document represents an update of an earlier health risk assessment of perchlorate conducted by OEHHA that resulted in publication of a PHG in 2004. This revision takes into account information which suggests that infants can be especially susceptible to perchlorate. This revision also incorporates the higher drinking water consumption values described by U.S. EPA (2004), to be more protective of the entire population.

CHEMICAL PROFILE

Chemical Identity

Perchlorate (ClO₄⁻) is the most oxygenated member of a series of four anions made up of chlorine and oxygen. The anion has a charge of negative one, and can form an acid or a salt in combination with H⁺ or another cation such as sodium, potassium or ammonium ion. Perchlorate salts are ionic, and dissociate completely when dissolved in water. This risk assessment is for the perchlorate anion in water, regardless of the cation.
Physical and Chemical Properties

Ammonium perchlorate (NH₄ClO₄), the salt used as an oxidizer in rocket propellants, is a white, crystalline solid. As ammonium perchlorate is the major source of most of the perchlorate that has been detected in drinking water sources in California and Nevada (U.S. EPA, 1998a), it is used as the model compound to illustrate some of the physical and chemical properties of perchlorate salts (Table 1).

Table 1. Physical and Chemical Properties of Ammonium Perchlorate (from HSDB, 2010)

<table>
<thead>
<tr>
<th>Property</th>
<th>Value or Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Weight</td>
<td>117.49</td>
</tr>
<tr>
<td>Color/Physical State</td>
<td>White orthorhombic crystals</td>
</tr>
<tr>
<td>Melting Point</td>
<td>130°C, starts to decompose at 439°C</td>
</tr>
<tr>
<td>Solubility in water</td>
<td>200 g/L at 25°C</td>
</tr>
<tr>
<td>Solubility in organic solvents</td>
<td>Soluble in methanol, slightly soluble in ethanol and acetone, almost insoluble in ethyl acetate, ether</td>
</tr>
<tr>
<td>Density</td>
<td>1.95 g/cm³</td>
</tr>
</tbody>
</table>

Production and Uses

Ammonium perchlorate is used as an oxidizer in solid rocket propellant. Sodium perchlorate is used in slurry explosives, and potassium perchlorate is used in road flares and air bag inflation systems.

The manufacture of perchlorate salts begins with the electrolysis of brine (sodium chloride in water) to first form sodium chlorate (NaClO₃) and then sodium perchlorate (NaClO₄). This is reacted with ammonium chloride to form ammonium perchlorate (NH₄ClO₄) and sodium chloride. The solution is cooled, and the ammonium perchlorate crystals are dried and packaged.

Ammonium perchlorate is mixed with metallic aluminum in a synthetic rubber base to make rocket fuel. This type of fuel is used in the Minuteman missile, which has been deployed in the United States since 1961. Perchlorate salts are also used as a component of air bag inflators, in nuclear reactors and electronic tubes, as additives in lubricating oils, in tanning and finishing leather, as a mordant for fabrics and dyes, and in electroplating, aluminum refining, rubber manufacture, and the production of paints and enamels (U.S. EPA, 2002).

ENVIRONMENTAL OCCURRENCE AND HUMAN EXPOSURE

Perchlorate can apparently be formed by sunlight or lightning interacting with oxygen and chlorine in the atmosphere (Dasgupta et al., 2005; Mohan, 2010). As perchlorate falls to the earth in rain, it can distribute at low levels throughout the environment, in
both soil and water. Plants can accumulate perchlorate from the water they take up (U.S. EPA, 2001a; Jackson et al., 2005; Sanchez et al., 2005 a,b, 2008).

Perchlorate is also released to the environment from its use in highway flares, fireworks and other explosives, and rocket fuel. Perchlorate salts have been widely used as an oxidizer in solid propellants for rockets and missiles since the mid-1940s. Because of its finite shelf life, the propellant containing perchlorate has been periodically washed out of the United States’ missile and rocket inventory to be replaced with a fresh supply (U.S. EPA, 1998a). As a consequence of this use, large volumes of perchlorate have been disposed of since the 1950s. Some of this has leached into soil, and into aquifers used for drinking water. Perchlorate is highly mobile in aqueous systems and can persist for many decades under typical ground and surface water conditions (U.S. EPA, 1998a).

Air

Some unreacted perchlorate is occasionally released to the atmosphere during the launch of solid fuel rockets. Releases have also occurred as a consequence of open burning and detonation of old rocket fuel or surplus materials. No data were found on levels of perchlorate in ambient air.

Perchlorate dust can also be suspended in air, and can be inhaled by individuals working in areas where perchlorate is manufactured (Lamm et al., 1999).

Soil

Because of the finite shelf life of perchlorate used in rocket fuel, large volumes of rocket fuel containing perchlorate have been periodically washed out of the United States’ missile and rocket inventory to be replaced with a fresh supply (U.S. EPA, 1998a). Releases to the environment might also have occurred because of the past open burning and open detonation of perchlorate-containing material. As a result of past disposal practices, soil and groundwater near the facilities that had been engaged in rocket fuel manufacturing and disposal are contaminated. Another way in which soil can become contaminated is by irrigation with perchlorate-contaminated water.

A report by TRC Environmental Corporation (1998) raised the concern that some chemical fertilizers may be contaminated with perchlorate. In the past, some fertilizers derived from Chilean caliche (a natural perchlorate source) were found to be contaminated with perchlorate. Since this discovery, the producer of Chilean caliche has changed its practice and eliminated the perchlorate contamination. U.S. EPA (2001b) tested a variety of fertilizers collected from representative sites around the nation and did not find perchlorate contamination to be a problem.

Water

Drinking water sources have become contaminated with perchlorate as a consequence of soil pollution in areas where solid rocket fuel has been manufactured, used, or disposed. Perchlorate salts are soluble in water and once dissolved, perchlorate ion can persist in surface and ground waters for several decades (U.S. EPA, 1998a).
Until March 1997, the detection limit for perchlorate in water was rather high, at 400 µg/L (ppb). In March 1997, California Department of Health Services (DHS), now the California Department of Public Health (DPH), developed a more sensitive analytical procedure, using ion chromatography, and achieved a detection limit in the 4-5 ppb range (DHS, 2000). Shortly thereafter, the new technology was adopted by a number of commercial laboratories. EPA Method 314.0 (Federal Register, 2000) now exists for analysis of perchlorate in water and has a detection level as low as 0.5 ppb.

Since March 1997, California DPH has reported measurements of perchlorate concentrations in thousands of drinking water sources and wells throughout the state. Between April 2004 and April 2009, perchlorate concentrations above 4 ppb were reported in 297 drinking water sources in California (Table 2).

### Table 2. Reported Perchlorate Detections in California 2004-2009 (from DPH, 2009)  

<table>
<thead>
<tr>
<th>County</th>
<th>Peak ≥ 4 µg/L</th>
<th>Peak ≥ 6 µg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Sources</td>
<td>No. of Systems</td>
</tr>
<tr>
<td>Los Angeles</td>
<td>117</td>
<td>33</td>
</tr>
<tr>
<td>Riverside</td>
<td>68</td>
<td>9</td>
</tr>
<tr>
<td>San Bernardino</td>
<td>58</td>
<td>15</td>
</tr>
<tr>
<td>Orange</td>
<td>21</td>
<td>11</td>
</tr>
<tr>
<td>Tulare</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>Santa Clara</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Kern</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Sacramento</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>San Diego</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Madera</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>San Joaquin</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Tehama</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>San Luis Obispo</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Monterey</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Sutter</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Ventura</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>297</td>
<td>92</td>
</tr>
</tbody>
</table>

*a Data are draft, and represent results from over 10,200 drinking water sources.

*b This table presents sources with more than one perchlorate detection in the DPH database, where “sources” may include both raw and treated sources, distribution systems, blending reservoirs, and other sampled entities. Data do not include agricultural sources, monitoring wells, or more than one representation of the same source (i.e., a source with both a raw and treated entry, distribution system or blending reservoir is counted as a single source).*
Urbansky et al. (2000) analyzed samples of eight domestic brands and eight imported brands of bottled water and did not find perchlorate (with a detection limit of 5 ppb) in any of the samples.

**Food**

Perchlorate has been used as a growth promoter in leguminous plants (Verteleetskaya et al., 1974; as cited in Von Burg, 1995), livestock (sheep and cattle) and poultry (Yakimenko et al., 1981; as cited in Von Burg, 1995). Research from the former Soviet Union indicated that weight gains in livestock of 3 to 31 percent were obtained by addition of ammonium perchlorate to the feed. Feed expenditure was also reduced 7-18 percent. The optimum dose was estimated to be 2-5 mg/kg (Grayson, 1978). Weight gains in livestock may be secondary to hypothyroidism and decreased metabolic rates.

Plants take up perchlorate from water, and probably also from fertilizers which contain perchlorate (U.S. EPA, 2001a; Trumpolt et al., 2005). In a greenhouse study, U.S. EPA researchers watered lettuce plants with one of five different concentrations of perchlorate (0.1, 0.5, 1.0, 5.0, and 10.0 µg/mL) for a period of 90 days following planting. They found perchlorate levels rose steadily over the first 50-60 days, and then generally leveled off. The amount of perchlorate detected in the leaves correlated with the water concentration. At about 50 days into the study, the lettuce irrigated with 10.0 µg/mL (ppm) perchlorate had a perchlorate content of about 300 µg/g on a wet weight basis (U.S. EPA, 2002).

Scientists at Texas Tech (Lubbock, Texas) developed sensitive methods for assaying perchlorate in biological samples and reported perchlorate accumulation in a variety of crops as well as in animals, trees and aquatic plants (Smith et al., 2002, 2004; Tan et al., 2004; Yu et al., 2004; Jackson et al., 2005). Concentration factors well over 100-fold, compared to the concentration in the water, were reported in some plants. Sanchez et al. (2005a,b) showed that perchlorate accumulated in lettuce and other leafy vegetables when grown with Colorado River water contaminated with perchlorate at low ppb levels. Later studies by the same workers documented uptake in a wider variety of crops (Sanchez et al., 2006, 2008).

In 2004-5, the U.S. FDA measured perchlorate concentrations in many different types of foods. Results for 27 foods and beverages collected from areas where perchlorate was known to contaminate drinking water were reported (U.S. FDA, 2009). Multiple assays were conducted on each product, for a total of 775 results. Reported average values ranged from 0.15 ppb (µg/L) in potatoes (set at one-half the limit of detection, since all values were non-detect) to 92.4 ppb in “greens.” Shrimp was second-highest, at 19.83 ppb. Cow’s milk averaged 5.81 ppb.

Using food consumption estimates from the U.S. Department of Agriculture’s Continuing Survey of Food Intake by Individuals (CSFII 1994-96 and 1998 Supplemental Children’s Survey), U.S. FDA estimated dietary perchlorate consumption for various population groups. Mean perchlorate intake of persons aged 2 years and above was estimated to be 0.053 µg/kg-day. The estimated mean intakes for children aged 2-5 years, and for females aged 15-45 years, were 0.17 and 0.037 µg/kg-day, respectively. The estimated 90th percentile intake were 0.12 µg/kg-day for all people age 2 years and older; 0.34
µg/kg-day for children aged 2-5 years; and 0.074 µg/kg-day for females aged 15-45 years.

More recently, U.S. FDA has included perchlorate analysis in its Total Diet Study, which involves a periodic analysis of 285 foods selected to be representative of the total U.S. diet. As reported by Murray et al. (2008), food products were sampled in 2005-2006. Estimates of perchlorate intake were made using the CSFII data as described above. Upper and lower bound consumption estimates for various population groups are shown in Table 3. These perchlorate exposure estimates tend to be higher than the earlier FDA estimates, but they cover more foods.

Table 3. Estimated Perchlorate Intakes from U.S. FDA’s Total Dietary Survey: Results for 2005–2006 (as reported in U.S. EPA, 2008b)

<table>
<thead>
<tr>
<th>Population group</th>
<th>Perchlorate intake from food µg/kg-day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lower-bound</td>
</tr>
<tr>
<td>Infants</td>
<td>6-11 mo</td>
</tr>
<tr>
<td>Children</td>
<td>2 yr</td>
</tr>
<tr>
<td>Children</td>
<td>6 yr</td>
</tr>
<tr>
<td>Children</td>
<td>10 yr</td>
</tr>
<tr>
<td>Teenage Girls</td>
<td>14-16 yr</td>
</tr>
<tr>
<td>Teenage Boys</td>
<td>14-16 yr</td>
</tr>
<tr>
<td>Women</td>
<td>25-30 yr</td>
</tr>
<tr>
<td>Men</td>
<td>25-30 yr</td>
</tr>
<tr>
<td>Women</td>
<td>40-45 yr</td>
</tr>
<tr>
<td>Men</td>
<td>40-45 yr</td>
</tr>
<tr>
<td>Women</td>
<td>60-65 yr</td>
</tr>
<tr>
<td>Men</td>
<td>60-65 yr</td>
</tr>
<tr>
<td>Women</td>
<td>70+ yr</td>
</tr>
<tr>
<td>Men</td>
<td>70+ yr</td>
</tr>
</tbody>
</table>

There are concerns that breast milk may represent an exposure pathway for infants. In a study reported by Yu (2000), groups of female rats were treated with perchlorate in drinking water at 0, 0.01, 0.1, 1, and 10 mg/kg-day throughout gestation and lactation. On postnatal day 10, the rats were milked. Yu found the levels of perchlorate in milk were about twice as high as the corresponding levels in maternal serum across all doses, suggesting that perchlorate is actively sequestered into milk. Clewell et al. (2003) reported that perchlorate was indeed transferred to the pup through suckling as perchlorate was detected in milk, as well as in the neonate serum, gastrointestinal contents, and skin.
Human mammary gland during lactation has been shown to express the NIS and may have the capability to actively secrete perchlorate into the breast milk (Vayre et al., 1999; Tazebay et al., 2000). Another concern is that iodide in breast milk is necessary for thyroid hormone synthesis by the newborn. Perchlorate inhibits the NIS in the lactating mammary gland and can interfere with the secretion of iodide into breast milk. This reduction in iodide transfer has been seen in cows and goats (Howard et al., 1996; Lengemann, 1973; Mountford et al., 1987).

Rice et al. (2007) analyzed the relationship between perchlorate in feed given to dairy cows and the resulting levels in milk. They reported that significant perchlorate exposures occurred from perchlorate in corn silage, alfalfa, and grass. Sanchez et al. (2008) also showed that perchlorate in alfalfa makes a major contribution to perchlorate levels in the milk of dairy cows.

Kirk et al. (2005) analyzed perchlorate concentrations in 47 different samples of dairy milk from 11 different states and 36 human milk samples from lactating women from 18 different states. Detectable levels of perchlorate were found in all but one of the samples tested. The mean perchlorate concentration in the breast milk samples was 10.5 µg/L. Iodine concentrations in milk were inversely correlated with perchlorate concentrations, but only in the six samples with perchlorate concentrations above 10 µg/L (Coefficient of variation (R²) > 0.9). In a later study, Kirk et al. (2007) measured perchlorate levels in 10 lactating women in six breast milk samples per day per woman for three days. The mean perchlorate concentration was 5.8 µg/L (Standard deviation (SD) ± 6.2 µg/L). Considerable variability was seen both among and between individuals.

Pearce et al. (2007) measured breast milk perchlorate levels in 57 women from the Boston area and in 17 different infant formulas. Perchlorate was detectable in all 49 breast milk samples tested and in all 17 infant formula samples tested. The median breast milk perchlorate concentration was 9.1 µg/L. This was about 3 times higher than the median perchlorate concentrations in the urine samples of these women. There was no correlation between breast milk iodine and perchlorate concentrations (R² = 0.05, p = 0.1), and no correlation in those women with breast milk perchlorate concentrations above 10 µg/L. The median breast milk iodine concentration was fairly low (median = 155 µg/L; range, 2.7 -1968) and the authors estimated that 47 percent of the breast milk samples did not contain enough iodine to meet the infant iodine intake recommended by the Institute of Medicine.

Dasgupta et al. (2008) measured perchlorate, thiocyanate, and iodine in the urine and breast milk of 13 breastfeeding women. The mean breast milk perchlorate concentration was 9.3 µg/L (SD ± 7.5 µg/L). Selectivity factors were determined for each chemical based on the relative excretion of each in breast milk and urine. Total perchlorate excretion was based on urinary and breast milk excretion only and possible excretion via other pathways was ignored. The median fraction of total excretion in the milk for perchlorate, thiocyanate, and iodine were 0.541, 0.053, and 0.177. The selectivity factors for perchlorate over iodide transport, and thiocyanate over iodide transport, were 3.14 and 0.27, respectively. The authors note that these transport selectivities are an order of magnitude lower than those indicated in in vitro studies. The authors did not specifically report a correlation coefficient for the relationship between breast milk iodine and perchlorate.
perchlorate concentrations but do note that in their plot of these data (their Figure 3) that there were no subjects in the high iodine-high perchlorate quadrant.

**METABOLISM AND PHARMACOKINETICS**

**Absorption**

Test data from human studies indicated that perchlorate is readily absorbed from the gastrointestinal tract and excreted primarily via the urine. Eichen (1929; as cited in Stanbury and Wyngaarden, 1952) administered orally 1-2 g perchlorate to patients and recovered 70 percent of the dose in the urine in 12 hours and 85-90 percent in 24 hours. In a similar experiment, two human subjects each drank a solution of 794 mg of sodium perchlorate dissolved in 100 mL of water (Durand, 1938). Fifty percent of the administered dose was recovered in the urine by five hours and 95 percent in 48 hours. These human data suggest absorption of perchlorate through the oral route is virtually complete.

Besides the thyroid, the NIS appears to be expressed and active in mammary gland, salivary glands, gastric mucosa, and placenta (Vayre et al., 1999; Tazebay et al., 2000; de la Vieja et al., 2000; Mitchell et al., 2001). These transport systems exhibit functional similarities with their thyroid counterpart and may play a role in the absorption of iodide into the body.

Because perchlorate is completely ionized in aqueous systems, its permeability through intact skin is expected to be limited (U.S. EPA, 1998a). Inhalation exposure during showers is considered possible but not likely to be an important route of exposure. This is because the droplets produced in showers are generally too large to be inhaled. Exposure to vapors of the chemical via the inhalation route is expected to be negligible because of the low vapor pressure of perchlorate salts at room temperature. However, inhalation of airborne perchlorate particles could be an important exposure route in occupational settings. Lamm et al. (1999) studied a group of workers in a perchlorate production plant and reported that there was a correlation between airborne perchlorate dust concentration and the amount of perchlorate excreted in urine.

**Distribution**

Anbar et al. (1959) injected white rats and rabbits intraperitoneally with radiolabeled potassium perchlorate (approximately 3-14 mg per animal) and measured the specific activity per gram of tissue in various organs from 30 minutes to 12 hours post administration. The ratio of the specific activity of perchlorate in thyroids versus the specific activity in blood reached a limiting value of 4.3 ± 0.3 in both rats and rabbits, at about 6 hours after the injection. These data demonstrate that the thyroid of these species concentrates perchlorate ions. There were also indications that perchlorate is retained in the salivary gland and testes.

Chow et al. (1969) measured perchlorate uptake using radiolabeled perchlorate in male Sprague-Dawley rats. Rats were injected with 0.1, 0.2, or 5.0 meq/kg of perchlorate (14, 28, or 690 mg/kg, respectively) two hours prior to sacrifice. At the low and middle
doses, radiolabeled perchlorate concentrations in the thyroid were higher than those in the blood. At the high dose, perchlorate concentrations in the thyroid and blood were about the same. In a similar study, rats were exposed to 0.69, 1.4, 2.8, 6.9, or 14 mg/kg of perchlorate. The apparent accumulation of perchlorate in the thyroid, as reflected by the thyroid/blood ratio (which ranged from 31.1 to 2.5), was found to be inversely related to the perchlorate dose (U.S. EPA, 2002).

Chow and Woodbury (1970) also studied perchlorate accumulation by the thyroid. They administered perchlorate by intraperitoneal injection at 0.69, 14, or 280 mg/kg to groups of male Sprague-Dawley rats. The treated rats were sacrificed at 0.033, 0.067, 0.13, 0.2, 0.5, 1.0, 2.0, and 4.0 hours after dosing. The amount of perchlorate accumulation in the thyroid compared to that in the plasma was highest at the lowest dose. At the higher doses (at or above 14 mg/kg), the level of perchlorate in the thyroid was lower than in the plasma.

It has been shown that perchlorate inhibits iodide transport into the thyroid. Thyroid tissues can also concentrate several related monovalent anions. Measurement of the ability to be concentrated by thyroid tissues, or to inhibit iodide transport, has resulted in the following potency series for monovalent anion-based inhibition of iodide transport in thyroid slices: $\text{TeO}_4^-$ ≥ $\text{ClO}_4^-$ > $\text{ReO}_4^-$ > SCN$^-$ > BF$_4^-$ > I$^-$ > NO$_3^-$ > Br$^-$ > Cl$^-$. (Wolff, 1964; as cited in Wolff, 1998). These relative potencies are based on in vitro data and high anion concentrations. It is not clear whether they also apply to in vivo scenarios, real-life human situations, or lower environmentally relevant exposure levels. Anbar et al. (1959) showed that the inhibition of iodide transport by perchlorate is a truly competitive process. They intraperitoneally injected $^{36}$Cl-labeled perchlorate and iodide ions in various concentrations to groups of rats and found that either iodide or perchlorate could inhibit the accumulation of the other anion by the thyroid (Table 4).

Recently, the apparent accumulation of perchlorate by the thyroid of rodents has been disputed. Citing in vitro electrophysiological data, de la Vieja (2000) suggested perchlorate acts as a blocker of NIS, but it is not translocated via NIS into the cell. De la Vieja (2000) theorized that because $^{36}$Cl chlorate ($\text{ClO}_3^-$) is a byproduct of the reaction employed to chemically synthesize $^{36}$Cl perchlorate for the uptake study, it is possible that $^{36}$Cl chlorate, rather than perchlorate, accounts for the measured radioactivity, given that chlorate is readily translocated via NIS into the cell.

Table 4. The Ratio between Concentrations of Iodide and Perchlorate Ions in the Thyroid (from Anbar et al., 1959)

<table>
<thead>
<tr>
<th>Iodide dose (mmol)</th>
<th>Perchlorate dose (mmol)</th>
<th>Ratio* $\text{I}^-$/ClO$_4^-$</th>
<th>60 min</th>
<th>120 min</th>
<th>360 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.14</td>
<td>0.028</td>
<td></td>
<td>4.7</td>
<td>6.9</td>
<td>3.3</td>
</tr>
<tr>
<td>0.14</td>
<td>0.14</td>
<td></td>
<td>2.1</td>
<td>2.7</td>
<td>2.2</td>
</tr>
<tr>
<td>0.028</td>
<td>0.14</td>
<td></td>
<td>0.53</td>
<td>0.58</td>
<td>0.67</td>
</tr>
</tbody>
</table>

*Ratio = concentration of iodide in thyroid / concentration of perchlorate in thyroid.

Goldman and Stanbury (1973) administered $^{36}$Cl-labeled potassium perchlorate to male Sprague-Dawley rats by intraperitoneal injection (approximately 40 µg stable perchlorate...
per injection). The rats were maintained on a low iodide diet for 4-5 weeks prior to perchlorate administration. The level of perchlorate in the thyroid peaked at four hours after administration, then declined to approximately five percent of its peak at 96 hours. The decay followed an exponential function with a half-life of 20 hours. When the levels of radioactivity in the serum and the urine are plotted against time, they also followed an exponential function with a half-life of approximately 20 hours. Goldman and Stanbury (1973) also showed that most of the administered perchlorate was excreted in the urine. The retention of the radiolabel in selected tissues 96 hours after the administration of perchlorate is shown in Table 5.

There are also data indicating that perchlorate can pass through the placenta and affect the fetal thyroid. Thyroid enlargement and reduction of thyroidal iodide uptake have been detected in fetuses of laboratory animals exposed to perchlorate (see the discussion in the Developmental and Reproductive Toxicity section.)

Table 5. Percent Dose of $^{36}$Cl/g Tissue 96 Hours after Intraperitoneal Injection of $^{36}$Cl-perchlorate (from Goldman and Stanbury, 1973)

<table>
<thead>
<tr>
<th>Organ</th>
<th>Percent dose/g tissue$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid</td>
<td>0.142 ± 0.1</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.125 ± 0.09</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.098 ± 0.03</td>
</tr>
<tr>
<td>Liver</td>
<td>0.048 ± 0.04</td>
</tr>
<tr>
<td>Brain</td>
<td>Background</td>
</tr>
</tbody>
</table>

$^a$Mean ± standard deviation; each value represents five animals.

Selivanova and Arefaeva (1986) administered a single oral dose of perchlorate to rats and observed a two-phase biological decay curve. The first biological half-life ranged from 1-2 hours and accounted for a calculated 96 percent of the dose. The second-phase half-life, which accounted for only four percent of the administered dose, ranged from 72 to 80 hours. Yu et al. (2000) injected perchlorate intravenously at doses of 0.01, 0.1, 1, and 3 mg/kg to male Sprague-Dawley rats and monitored the serum concentration of perchlorate over time. The estimated early- and terminal-phase half-lives of perchlorate were 2-3 hours and 12-26 hours, respectively.

The differences in biological half-lives of perchlorate in rats in the studies above (Goldman and Stanbury, 1973; Selivanova and Arefaeva, 1986; Yu et al., 2000) are partly due to the three different routes of administration. The difference may also be explained by the fact that the rats in the study reported by Goldman and Stanbury (1973) had been maintained on a low iodide diet for 4-5 weeks before the administration of perchlorate.

**Metabolism**

There are data to suggest that perchlorate is not metabolized in humans (Anbar et al., 1959). Four patients were orally administered 200 mg of radiolabeled perchlorate (5 μCi), double labeled with $^{36}$Cl and $^{18}$O. The perchlorate was excreted unchanged in
the urine with the two labels ($^{36}$Cl and $^{18}$O) remaining associated in the same molecule. The results also showed that there was no reduction of perchlorate in vivo, as there was very little radioactivity associated with Cl$^-$ and ClO$_3^-$ ions in urine.

**Excretion**

As described above, 95 percent of a dose of sodium perchlorate administered orally to human subjects was eliminated in the urine by 48 hours after administration (Durand, 1938). Lamm et al. (1999) monitored urinary perchlorate levels of two workers during three days with measurable occupational perchlorate exposure and during the subsequent three days without known perchlorate exposure. The perchlorate body burden, as measured using urinary perchlorate concentrations, increased over the three days of work exposure, with decreases between the 12-hour work shifts. The elimination of perchlorate after the last exposure period appeared to follow a first-order kinetics pattern. The average perchlorate elimination half-lives measured for the two workers were 7.9 and 8.2 hours.

Greer et al. (2002) administered oral doses of perchlorate in water to human volunteers and estimated half-life values ranging from 6.0 to 9.3 hours, with an average value of 8.1 hours. These are similar to those reported in Lamm et al. (1999).

Selivanova and Arefaeva (1986) administered a single oral dose of perchlorate to rats, rabbits, and calves at 2, 20, 200, and 600 mg/kg in a single oral dose. They reported that in all cases, little or no perchlorate could be detected in the blood after 72 hours. A majority of the administered perchlorate was excreted in the urine; the feces excreted $< 8.5$ percent. Yu et al. (2000) injected perchlorate intravenously to rats at doses of 0.01, 0.1, 1, or 3 mg/kg and reported that between 72 percent and 97 percent of the administered dose was excreted in the urine over a 24-hour period.

**Physiological/Nutritional Role**

Perchlorate has no known nutritional role. In 1952, investigators observed that perchlorate displaces iodide from the rat thyroid (Wyngaarden et al., 1952). Since then perchlorate has been widely used in studies on the thyroid to block entry of iodide into the thyroid, or to cause discharge of noncovalently bound iodide previously accumulated in the thyroid (Wolff, 1998).

It was reported that when ammonium perchlorate was added to the feed of farm animals, weight gain was increased by 3-31 percent. The optimum dose ranged from 2 to 5 mg/kg (Grayson, 1978; Yakimenko et al., 1981; as cited in Von Burg, 1995). This is most likely a non-nutritive effect associated with the inhibition of thyroid hormone production and subsequent hypothyroidism.

**Thyroid Physiology**

Because the primary mechanism of perchlorate toxicity is related to the thyroid gland and thyroid hormone, we briefly review thyroid physiology. The principal hormones secreted by the thyroid are thyroxine (T4) and triiodothyronine (T3). Iodide is a key component
of both. While T4 is produced only by the thyroid gland, about 80 percent of T3 is formed outside the thyroid by deiodination of T4. T4 and T3 influence the growth and maturation of tissues, cell respiration and total energy expenditure, and the turnover of essentially all substrates (including carbohydrates, cholesterol, and proteins), vitamins, and hormones (including the thyroid hormones themselves).

The major components of thyroid hormone are iodide and tyrosine. Tyrosine is generally not the rate-limiting component. Iodine is a trace element, and its uptake into the thyroid can be rate-limiting in thyroid hormone production. Ingestion is the main route of iodine intake. Once ingested, iodine is reduced to iodide (I-) in the gastrointestinal tract and is readily absorbed into the bloodstream.

Thyroid tissue has a special ability to selectively concentrate iodide from the blood where the concentration is usually very low. The thyroid can actively transport iodide into the thyroid such that the iodide concentration in the thyroid can be several hundred-fold higher than concentrations outside the thyroid. Such concentrations are presumably required to promote efficient thyroid hormone production and patients lacking the ability to concentrate iodide have goiters and are hypothyroid (Wolff, 1998). The molecule that is responsible for transport of iodide into the thyroid is called the sodium-iodide symporter (NIS). The structure and regulation of NIS have been characterized (de la Vieja et al., 2000). Recently mouse NIS has been cloned and transferred into normally non-iodide-transporting cells, and these cells show perchlorate-sensitive iodide uptake capability (Perron et al., 2001). These researchers also found evidence to indicate that the NIS is present in tissues other than the thyroid, including the stomach, lactating mammary gland, small intestine, skin, and brain.

In humans, a majority of T4 and T3 in plasma is bound to proteins. In normal plasma, the T4 protein binding distribution is: 80 percent to thyroxine-binding globulin, 15 percent to transthyretin, and 5 percent to albumin and lipoproteins. For T3, the distribution is 90 percent bound to thyroxine-binding globulin and the rest to albumin and lipoproteins, with little binding to transthyretin. Very small proportions of T4 and T3 are free (not protein bound) in plasma, 0.03 and 0.3 percent, respectively. Only the free hormone enters cells, exerts its biologic action, and determines thyroid physiologic status (Dillmann, 2000).

Control of T4 and T3 concentrations in blood is mainly regulated by a negative feedback loop involving three organs: the thyroid gland, which produces thyroid hormones; and the pituitary gland and hypothalamus, which respond to and help maintain optimal levels of thyroid hormones (Figure 1). When levels of thyroid hormone decline, the hypothalamus secretes thyrotropin-releasing hormone (TRH), which stimulates the pituitary to produce thyroid-stimulating hormone (TSH), which then prompts the thyroid gland to produce T4 and T3. The stimulated thyroid actively transports iodide into the thyroid gland, and then into thyroid hormone molecules. T4 and T3 are metabolized in the liver and other tissues. Some thyroid hormone derivatives are excreted in the bile, and some of the iodine in them is reabsorbed. Cells in the hypothalamus and pituitary gland respond to circulating levels thyroid hormones, i.e., when hormone levels are high, there is a signal to reduce the output of TRH and TSH. Similarly, when thyroid hormone levels are low, the pituitary is prompted to release more TSH, which stimulates the thyroid to increase thyroid hormone output. This negative feedback loop helps the body to respond to
varying demands for thyroid hormone and to maintain hormone homeostasis. Circulating T4, T3, and TSH can readily be measured in the serum of experimental animals and humans and serve as biomarkers of exposure and effect of agents that disrupt thyroid-pituitary status (U.S. EPA, 1998a, and 1998b; Hill et al., 1989).

Figure 1. Hypothalamic-Pituitary-Thyroid Axis (from U.S. EPA, 1998b)

In mammals, when demands for more thyroid hormone are small, existing thyroid follicular cells can meet the demand. With increased need, as a result of certain chemical exposures or chronic iodine deficiency, the thyroid responds by increasing the size (hypertrophy) and number (hyperplasia) of thyroid follicular cells to enhance hormone output. With continued TSH stimulation, there is actual enlargement of the thyroid gland (goiter) and, at least in rodents, neoplasia of the thyroid follicular cells could eventually occur. Since TSH-producing pituitary cells are also stimulated, they too sometimes undergo hyperplasia and neoplasia (U.S. EPA, 1998b).

Too much or too little thyroid hormone can lead to illness. Thyrotoxicosis occurs when tissues are exposed to excess amounts of thyroid hormones, resulting in specific metabolic changes and pathophysiologic alterations in organ function. The most frequent cause of thyrotoxicosis is Graves’ disease, accounting for 60 to 90 percent of cases (Dillmann, 2000). Graves’ disease is an autoimmune disorder with B-lymphocytes producing immunoglobulins, some of which bind to and activate the TSH receptor, stimulating excess thyroid growth and hormone secretion. Hypothyroidism results from decreased secretion of thyroid hormone from the thyroid gland; it can be caused by destruction of thyroid tissues or defects of thyroid hormone production (e.g., congenital enzyme defects, congenital mutations in TSH receptor, iodine deficiency or excess). In some rare occasions, hypothyroidism can also be caused by pituitary or hypothalamic diseases.
The most severe neurological impairment resulting from decreased thyroid hormone production or iodine deficiency is cretinism. Characteristics of cretinism include mental retardation, spastic dysplasia, and problems with gross and fine motor control. In some extreme forms, the affected individuals cannot walk or stand. A number of studies indicate that even less severe iodine deficiency can reduce maternal serum thyroid hormone levels and may subsequently impair the brain development of the offspring (Glorieux et al., 1988; Rovet et al., 1987; Tillotson et al., 1994; Vermiglio et al., 1990; Pop et al., 1999, 2003; Haddow et al., 1999; Bleichrodt and Born, 1994). These studies are reviewed in further detail in the following sections. The nature and severity of the adverse effects are related to the degree of iodine deficiency or the extent of maternal thyroid hormone decrease.

Most data suggests that fetal damage during development is inversely related to maternal serum T4 levels (Pop et al., 2003; Kooistra et al., 2006). Maternal serum free T4 (fT4) is able to pass through the placenta and is converted to T3 in the fetal brain. The T3 generated in the fetal brain is believed to be necessary for the development of the brain, specifically the cerebral cortex, the extrapyramidal system, and the cochlea (Porterfield, 2000). The availability of a minimum level of maternal fT4 is crucial for proper fetal brain development in the first and second trimesters, as the fetal thyroid is not fully mature and functional during that time period. Figure 2 shows the approximate timing of major insults to the brain resulting from hypothyroxinemia (a low level of serum T4), superimposed on major neurodevelopmental events (Morreale de Escobar et al., 2000).

Figure 2. Approximate Timing of Major Insults to the Brain Resulting From Hypothyroxinemia, Superimposed on Major Neurodevelopmental Events.
TOXICOLOGY

The primary action of perchlorate in the human body is that it blocks iodide uptake in the thyroid gland. The function of the thyroid gland is the production of thyroid hormone. Iodide is a key component in the structure of thyroid hormone, and by blocking its uptake into the thyroid gland, perchlorate can potentially cause a decreased production of thyroid hormone.

As perchlorate competitively blocks iodide from entering the thyroid gland, many of the adverse effects of perchlorate exposure in the low dose range are expected to be similar to those of iodine deficiency. For this reason, an overview of some of the adverse health effects of iodine deficiency is provided in this section.

With inadequate iodine intake, both thyroid hormone synthesis and secretion can decline. The pituitary gland responds to low iodine levels by secreting more TSH, which in turn can cause thyroid hypertrophy and iodine deficiency goiter. Children who are born in areas of severe iodine deficiency may also suffer from cretinism. The main cause of this disease is iodine deficiency, but it is aggravated by dietary goitrogens, selenium deficiency, and autoimmune hypothyroidism. The manifestations of endemic iodine deficiency range from goiter or mild mental retardation in euthyroid subjects to severe mental deficiency and neurologic defects in those with greater degrees of hypothyroidism. Two subtypes of endemic cretinism have been described, neurologic cretinism and myxedematous cretinism. Hypothyroidism leads to a slowing of metabolic processes and in its most severe form leads to the accumulation of mucopolysaccharides in the skin, causing a non-pitting edema termed myxedema. Neurologic cretinism is more common. It is characterized by the delayed growth of long bones, neurological complications such as deaf mutism, mental retardation, and spasticity. Myxedematous cretinism is less common. It is characterized by delayed growth of long bones and myxedema, and there are fewer neurologic problems than are seen in neurologic cretinism. It has been postulated that neurologic damage in the absence of neonatal hypothyroidism can be due to maternal hypothyroxinemia early in gestation (Burrow et al., 1994) (also see Figure 2).

Hypothyroxinemia or hypothyroidism during pregnancy has been linked to adverse neuropsychological development and a reduction of IQ of the child (Glorieux et al., 1988; Rovet et al., 1987; Tillotson et al., 1994; Vermiglio et al., 1990; Haddow et al., 1999; Pop et al., 1999, 2003; Klein et al., 2001; Kooistra et al., 2006; Vermiglio et al., 2004). Pop et al., (2003) reported an 8-10 point decrease in mental developmental scores in 1-2 year old children of mothers who had fT4 levels in the lower 10th percentile during the 12th week of gestation compared to children of women who had fT4 levels in the 50th-90th percentiles during this same period. Similar findings have been reported for Neonatal Behavioral Assessment Scale scores and Wechsler Intelligence Scale scores in separate studies (Kooistra et al., 2006; Vermiglio et al., 2004). Vermiglio et al. (2004) reported evidence of a linear relationship between IQ at age 8-10 and maternal fT4 levels at 8 and 13 weeks of gestation (r =0.56, p <0.005) (Vermiglio et al., 2004). This correlation was seen throughout the range of maternal fT4 levels. This suggests that even small decrements in maternal fT4, even those that occur within the “normal” ranges of fT4, can result in impaired neuropsychological development of the child. These studies
are discussed in more detail in the section below on adverse neurological outcomes of thyroid dysfunction.

It has been shown that pregnancy puts stress on the maternal thyroid (Glinoer, 2001). In areas of iodine deficiency, there is an increased risk of abnormally low serum T4 and T3 levels and goiter in pregnant women. The nature and severity of changes in thyroid functions are related to the severity of iodine deficiency. For this reason, pregnant women with marginal or frank iodide deficiency and their fetuses have been identified as potentially sensitive subpopulations in this document.

**Toxicological Effects in Animals**


**Acute Toxicity**

In acute toxicity testing, animals generally died within the first few days after oral administration of high doses of ammonium perchlorate (750 to 4,200 mg/kg). Autopsy findings included necrosis and hemorrhaging of the mucous membranes of the stomach. Intestinal damage, pulmonary edema, and vascular dilation and congestion of the spleen, brain and sinuses were also noted (Von Burg, 1995).

Table 6, showing acute LD₅₀ values for perchlorate salts in several species, is modified from Von Burg (1995), compiled from Schilt (1979), U.S. EPA (1971), Shigan (1963), and Joesten and Hill (1966). The lethal dose for the various perchlorate salts when administered to mice by intraperitoneal injection varied over a 50-fold range.

Mannisto et al. (1979) administered potassium perchlorate to male Sprague-Dawley rats in drinking water for four days at concentrations of 0, 10, 50, 100 or 500 mg/L. At the end of the exposure period, they measured blood levels of TSH and thyroid hormones (T3 and T4). Significant changes (increased TSH and decreased T3 and T4) were observed in the 100 and 500 mg/L (15.3 and 76.3 mg/kg-day) exposure groups. In the 50 mg/L (7.6 mg/kg-day) exposure group, there was a significant decrease in concentration of T3 and T4; the TSH level was increased, but the increase was not statistically significant.
Table 6. Acute LD$_{50}$ Values for Perchlorate Salts (Modified from Von Burg, 1995; Schilt, 1979; U.S. EPA, 1971; Shigan, 1963; Joesten and Hill, 1966)

<table>
<thead>
<tr>
<th>Species</th>
<th>Route of administration</th>
<th>Cation</th>
<th>Dose (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>NH$_4^+$</td>
<td>3,500 to 4,200</td>
</tr>
<tr>
<td>Mouse</td>
<td>Oral</td>
<td>NH$_4^+$</td>
<td>1,900 to 2,000</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Oral</td>
<td>NH$_4^+$</td>
<td>750 to 1,900</td>
</tr>
<tr>
<td>Guinea Pig</td>
<td>Oral</td>
<td>NH$_4^+$</td>
<td>3,310</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Li$^+$</td>
<td>1,160</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Mg$^{++}$</td>
<td>1,500</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Na$^+$</td>
<td>1,150</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Mn$^{++}$</td>
<td>410</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Fe$^{+++}$</td>
<td>370</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Co$^{++}$</td>
<td>160</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Ni$^{++}$</td>
<td>100</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Cu$^{++}$</td>
<td>29</td>
</tr>
<tr>
<td>Mouse</td>
<td>i.p.</td>
<td>Zn$^{++}$</td>
<td>76</td>
</tr>
</tbody>
</table>

Subchronic Toxicity

In many animal studies, perchlorate has been shown to perturb thyroid hormone regulation, induce hypertrophy and hyperplasia in thyroid follicular cells, and cause an increase in thyroid weight.

Shigan (1963) administered ammonium perchlorate to “white rats” at 650 mg/kg-day for one month and did not observe noticeable cumulative properties. They also exposed “white rats” to ammonium perchlorate for three months at 190 mg/kg-day and found the treatment affected the regulation of the involuntary nervous system, caused changes in the protein fractions of the blood serum, and disrupted the liver’s ability to produce glycogen for carbohydrate storage.

In a follow-up study, Shigan (1963) treated rabbits and “white rats” with 0, 0.25, 2.0, and 40 mg/kg-day of potassium perchlorate for 9 months. Many study details, such as the sex and number of animals in each dose group and the dosing medium, were not reported. In the two highest dose groups, the authors found a significant increase in the amount of iodide excreted from the thyroid. It is not clear if the reported effect was seen in both species (U.S. EPA, 2002).

Caldwell et al. (1995) administered ammonium perchlorate to groups of Sprague-Dawley rats (six males and six females per group) in drinking water for 14 days at concentrations of 0, 1.25, 5.0, 12.5, 25, 50, 125 or 250 mg/L. The corresponding doses (male/female) in mg/kg-day are 0, 0.11/0.12, 0.44/0.47, 1.11/1.23, 2.26/3.06, 4.32/4.91, 11.44/11.47, and 22.16/24.86 mg/kg-day, respectively. At the end of the exposure period, thyroids were
weighed, thyroid histopathology and morphometry examinations were performed, and thyroid hormone levels were measured with a radioimmune assay technique. The researchers reported that perchlorate exposure decreased circulating T3 and T4 and increased serum TSH. There is also evidence that rT3 (formed mostly in extrathyroidal tissues) and thyroglobulin levels were also increased. They also found that perchlorate exposure was associated with decreases in thyroid gland follicular lumen size and increases in relative thyroid weights. At the lowest dose, 0.1 mg/kg-day, statistically significant changes in serum T4 were observed in both sexes; this level can be identified as a LOAEL.

Springborn Laboratories (1998) administered ammonium perchlorate via drinking water to male and female Sprague-Dawley rats (10 rats/sex/dose) at doses of 0, 0.01, 0.05, 0.2, 1.0, and 10 mg/kg-day for 14 and 90 days. An additional 10 rats/sex/dose were sacrificed after a 30-day recovery period following cessation of the 90-day exposure at doses of 0, 0.05, 1.0, and 10 mg/kg-day, to evaluate reversibility of any observed lesions. No statistically significant toxicological findings were observed among the groups with respect to clinical observations, body weights, food or water consumption, ophthalmology, hematology, or clinical chemistry. The researchers reported perchlorate exposure was associated with increased thyroid weights, thyroid follicular cell hypertrophy, and thyroid colloid depletion. Mean thyroid weights of male rats in the highest dose group were significantly increased after 14 and 90 days of exposure, while mean thyroid weights of female rats in the highest dose group were significantly increased after 90 days of exposure. No thyroid pathology was observed in other dose groups. After a 90-day exposure period followed by a 30-day recovery period, there was no increase in thyroid weight in either male or female rats in the 0.05, 1.0, and 10 mg/kg-day dose groups (Siglin et al., 2000).

After 14 days of exposure, mean serum TSH levels were significantly increased in males at 0.2 mg/kg-day and higher, and in females at 0.05 mg/kg-day and higher, compared with the controls. Mean serum T4 levels were significantly decreased in both sexes at 10 mg/kg-day. Mean serum T3 levels were significantly decreased in males at levels of 0.01 mg/kg-day and higher. No statistically significant differences in T3 levels were observed in the female treatment groups.

After 90 days of treatment, mean TSH levels were significantly increased in males at 0.2 mg/kg-day and higher, and in females at 10 mg/kg-day only. Mean T3 and T4 levels were significantly decreased in both sexes at 0.01 mg/kg-day and higher. Based on this data set, a LOAEL of 0.01 mg/kg-day can be identified.

Following a 90-day exposure period and a 30-day recovery period, TSH levels were significantly increased in all three female recovery groups (0.05, 1.0, and 10 mg/kg-day), whereas no significant differences in TSH levels were observed in the male recovery groups. Mean T4 levels were significantly lowered in all three male recovery groups (0.05, 1.0, and 10 mg/kg-day), whereas no significant differences in T4 levels were observed in the female groups. Mean T3 level was significantly lower in females at 10 mg/kg-day. No statistically significant differences in T3 levels were observed in the male recovery groups (Siglin et al., 2000). The authors did not speculate on the differences between the male and female data.
Siglin et al. (2000) noted there was a change in the mean TSH levels in the male and female control groups between 14 days and 120 days. They also found changes in mean T3 levels of control females over the course of the study. It was not clear if the observed variability in mean control hormone levels was reflective of normal age-related variations or due to other factors such as the relatively small sample sizes.

**Genetic Toxicity**

Ammonium perchlorate was tested in a battery of genotoxicity tests, and found to be negative in all tests (U.S. EPA, 2002). Ammonium perchlorate was negative in the reverse mutation assay in *Salmonella typhimurium* (TA98, TA100, TA1535, TA1537) with and without S9 activation (ManTech Environmental Technology, 1998). The Ames tests were later repeated by the National Institute of Environmental Health Sciences. Strains TA102 and TA104 were added to cover the possibility that ammonium perchlorate causes mutation by producing active oxygen species or other DNA damaging radicals. The repeat tests also used the pre-incubation test methodology as it provides better contact between the test material and the target organism. Ammonium perchlorate was negative in the reverse mutation assay in *S. typhimurium* (TA98, TA100, TA1535, TA97, TA102, and TA104) with and without S9 activation, thus confirming the original Ames test results (Zeiger, 1998).

Ammonium perchlorate was negative in the L5178Y/TK+/− mouse lymphoma assay without S9 activation. Results of the mouse lymphoma assay with S9 activation were equivocal because of low frequency of mutations in the positive controls (ManTech Environmental Technology, 1998). The test was later repeated. In this assay, concentrations of ammonium perchlorate in the treatment medium of 50 to 5,000 µg/mL were negative in the L5178Y/TK+/− mouse lymphoma mutagenesis assay in the absence and presence of Arochlor-induced rat liver S9 (BioReliance, 1999). The results of the repeat study provided support for the negative results reported in the first study.

Ammonium perchlorate was tested negative in in vivo micronuclei assays in mice and rats. In the mouse micronucleus assay, five male and five female Swiss CD-1 mice were dosed by gavage at 0, 62.5, 125, 250, 500, or 1,000 mg/kg for three consecutive days. No increases in the frequency of micronuclei were found for any dose group (ManTech Environmental Technology, 1998). There is some uncertainty whether the maximum tolerated dose was reached in the study. Typically, the assay is performed at 85 percent of the maximum tolerated dose, and the 1,000 mg/kg-day dose represents approximately 50 percent of the LD50. Furthermore, there was no indication of toxicity to the bone marrow cells because the polychromatic erythrocyte/normochromatic erythrocyte ratio was not different from the controls. The test was later repeated by the National Institute of Environmental Health Sciences. Male B6C3F1 mice were injected interperitoneally with 0, 125, 250, 500, 1,000, 1,500, and 2,000 mg/kg ammonium perchlorate in buffered saline. Five mice per group were treated daily for three consecutive days, and were sacrificed 24 hours after the last injection. All animals in the 1,500 and 2,000 mg/kg groups died after the first injection and 4/5 animals in the 1,000 mg/kg group died after the second injection. All animals in the 125, 250, and 500 mg/kg groups survived the treatment. No increases in micronuclei were seen at any of the test doses, and the trend
test was not positive (Zeiger, 1999). The negative results of the repeat study support the results of the first study.

The 90-day subchronic bioassay using Sprague-Dawley rats also evaluated micronuclei induction (Siglin et al., 2000). Ten rats per sex were treated with ammonium perchlorate in drinking water for 90 days at 10 mg/kg-day. The results indicate that ammonium perchlorate under the test condition was not mutagenic to the bone marrow cells of male and female Sprague-Dawley rats. The chemical was not toxic to the bone marrow cells at the dose tested, as it did not reduce the ratio of polychromatic to normochromatic erythrocytes in male or female rats.

Based on the above in vitro and in vivo genotoxicity test results, ammonium perchlorate does not appear to be mutagenic or clastogenic. Therefore, genotoxicity is not considered a potential mode of carcinogenic action for perchlorate.

**Developmental and Reproductive Toxicity**

A number of toxicity studies have shown that perchlorate exposure causes a variety of adverse health effects in the offspring of the test animals.

**Developmental Toxicity**

Postel (1957) gave a one percent solution of potassium perchlorate to eleven guinea pigs in the second or third week of pregnancy. The control group consisted of three pigs receiving a diet containing 0.48 µg/g and 50 mg of ascorbic acid orally twice a week. The treated pigs were divided into four groups which received 0, 8, 16, or 32 µg, respectively, of triiodothyronine (T3) by subcutaneous injection each day. Control pigs and those receiving potassium perchlorate alone were given daily injections of saline solution. The mean exposure duration was 37 days (range 21-48 days). One hour before the removal of the fetuses, radioactive sodium iodide was injected subcutaneously to the mother. Radioactivity of the blood and thyroids of the mothers and fetuses were analyzed.

Postel reported that massive enlargement of the fetal thyroid was observed in all the perchlorate treated groups, with or without T3 injection. The overall mean weight was 491 mg/100 g body weight, compared with a mean control fetal thyroid weight of 32 mg/100 g. Perchlorate did not cause enlargement of the maternal thyroid in any of the treatment groups, with or without T3 injection.

Postel (1957) also reported that the thyroid/serum radioiodide concentration ratio was approximately 175 in fetus and 50 in mothers in the control group. It was suggested that this finding supports the concept that the normal fetal thyroid is in a relatively hyperplastic state. The thyroid/serum radioiodide concentration ratios of both the perchlorate-treated mothers and their fetuses were significantly lower than those of the controls.

Lampe et al. (1967) gave perchlorate-treated food to 12 rabbits from the beginning of pregnancy through gestation day 21 or 28. The rabbits were dosed at 100 mg/kg-day. No concurrent controls were used. Ingestion of perchlorate was found to cause an increase in
maternal and fetal thyroid weights. On the 21st day of treatment, the maternal thyroid weights in treated animals were nearly three times higher than control thyroids; fetal thyroids from the treated animals were nearly four times the control weights. Continued intake of perchlorate further enhanced the increase in thyroid weight, particularly in the fetus. On the 28th day of treatment, the maternal thyroid weights in treated animals were nearly four times higher than control thyroid weights, and fetal thyroid weights from treated animals were nearly nine times higher than control thyroid weights.

Sztanyik and Turai (1988) investigated the safety of using potassium perchlorate or potassium iodide as blocking agents to prevent the uptake of radioiodine by fetuses. They injected these compounds in pregnant albino rats (body weight 200 to 250 grams) in amounts sufficient to “significantly decrease” uptake of radioiodine by the fetuses (0.1 to 6.0 mg potassium perchlorate per adult rat). There was no evidence of embryo- or fetotoxicity at these doses. In summary, the results of this study, and those of Postel (1957) and Lampe et al. (1967), all provide evidence that perchlorate can pass through the placenta from the mother to the fetus and effect the fetal thyroid in test animals.

A developmental neurotoxicity study of ammonium perchlorate in rats was conducted by Argus Research Laboratories (1998a; 1998b; 1998c). Ammonium perchlorate was administered to groups of 25 female Sprague-Dawley rats via drinking water at target doses of 0, 0.1, 1.0, 3.0, and 10 mg/kg-day. The dosing period was from the beginning of gestation (DG 0) to post-natal day 22 (PND22). Five dams per group were selected for sacrifice and blood collection on PND10. Pups (F1 generation) were counted and clinical signs recorded daily during pre- and post-weaning. Some of the pups were assigned to four different subsets for additional evaluations: Subset 1 for brain weight and neurohistological examination on PND12; Subset 2 for passive avoidance testing, water maze testing, and blood collection for thyroid and pituitary hormone analysis; Subset 3 for motor activity evaluation and auditory startle habituation; Subset 4 for regional brain weight evaluation and neurohistological examination on PNDs 82 to 85. U.S. EPA (2002) analyzed the F1 data and concluded that perchlorate treatment was associated with: (a) brain morphometric changes in the 10 mg/kg-day dose group and possibility also the 3 mg/kg-day dose group; (b) thyroid colloid depletion, hypertrophy, and hyperplasia in the 0.1 and 3 mg/kg-day dose groups; (c) thyroid hormone (T3 and T4) changes in the 0.1 and 1 mg/kg-day dose groups; and (d) increases in motor activity in some dosed animals.

Argus Research Laboratories (1999; York et al., 2001) reported a two-generation reproductive toxicity study in Sprague-Dawley rats. Male and female rats (30 rats/sex/group) of the first generation (P) were exposed to ammonium perchlorate in drinking water at 0, 0.3, 3, and 30 mg/kg-day. One male and one female were allowed a cohabitation period of a maximum of 14 days. Day 1 of lactation (LD1, postpartum) was defined as the day of birth. Rats that did not deliver a litter were sacrificed on gestation day 25 and examined for pregnancy status. At the end of the 21-day postpartum period, all surviving P1 rats were sacrificed. Pups not selected for continued evaluation were also sacrificed on LD21. The selected F1 pups were dosed during the post weaning, cohabitation, and lactation periods. All F1 generation dams and their litters (F2 generation) were sacrificed on LD21. York et al. (2001) reported that perchlorate is not a reproductive toxicant in the doses tested. In both the P and F1 adult rats, there were
no deaths, abortions, or premature deliveries. No changes were reported in any sperm parameters in either P or F1 adult male rats nor on mating or fertility parameters in either P or F1 adult female rats (estrous cyclicity, fertility index, number of days in cohabitation, and number of rats mated). Natural delivery and litter observations for both F1 and F2 generation pups were comparable among the treated and control groups. Treatment-related effects were not observed on the gestation index, the number of dams delivering litters, the duration of gestation, the average number of implantations, the average number of live pups, the viability and lactation indices, the sex ratios, or the pup body weights.

York et al. (2001) found that perchlorate exposure caused statistically significant, dose-dependent changes in thyroid weight, histopathology, and hormone levels in P, F1, and F2 generation rats. Relative thyroid weights were significantly increased in the 30 mg/kg-day dose group for both sexes in the P generation and for F2 generation pups. However, in the F1 generation adult rats, relative thyroid weights were significantly increased in all dose groups for females and in the 3 and 30 mg/kg-day dose groups for male rats. All three generations developed hypertrophy and hyperplasia of thyroid follicular epithelium that increased in incidence and severity in a dose-related manner. Dose-related changes in TSH, T3, and T4 were also observed in the treated rats. However, these changes were inconsistent among the different generations, sexes, and ages of animals.

U.S. EPA (2002) noted that two male rats from the high dose group (30 mg/kg-day) in the F1 generation (second parental generation) in the study had adenomas of the thyroid. These males were dosed from conception to 19 weeks of age. Without incorporating historical data, the difference between 0/30 in the control and 2/30 in the 30 mg/kg-day is not statistically significant by standard tests (e.g., Fisher’s exact). However, using two earlier reported background incidence rates of 3.6 percent and 3.9 percent for thyroid follicular cell adenomas in male Sprague-Dawley rats in 2-year studies and Bayesian analysis, U.S. EPA (2002) determined the increase in thyroid follicular cell adenoma at 19 weeks in male Sprague-Dawley rats exposed to 30 mg/kg-day to be statistically significant.

Effects of perchlorate on motor activity in Sprague-Dawley rats were studied by Bekkedal et al. (2000). The females were dosed with ammonium perchlorate in drinking water for two weeks at 0, 0.1, 1, 3, or 10 mg/kg-day prior to mating with the breeder males and through PND10. As dosing was stopped on PND 10, it is likely that the pups were not directly exposed to perchlorate in drinking water. On PND14, one male and one female were randomly selected from each litter to be used in the motor activity testing. These same animals were tested on PND14, PND18, and PND22. Pups were individually tested in automated Opto-Varimex Activity boxes where 9 different measures of activity were recorded for 90 minutes on each test day. Data were analyzed in 9, 10-minute blocks using a repeated measures ANOVA.

Bekkedal et al. (2000) reported no statistically significant differences for any of the 9 measures of motor activity, and there were no reliable interactions related to treatment. A general pattern in the results was noticed. The authors suggested that there was a divergence in activity between the control and treated groups which emerged late in the 90-minute testing sessions.
U.S. EPA and NIEHS used a Bayesian hierarchical model to analyze the motor activity data reported by Argus Research Laboratories (1998a) and Bekkedal et al. (2000). They built a linear mixed-effects regression model relating dose, sex, age, habituation time and a habituation time × dose interaction term to the expected number of ambulatory movements, with an animal-specific intercept included to account for within-animal dependency (U.S. EPA, 2002). U.S. EPA concluded that there was evidence of an increasing dose-response trend in motor activity in both data sets, and suggested that the lower limit on the estimated dose corresponding to a 10 percent increase in motor activity relative to control can be used as a surrogate for the NOAEL. Because of the variability in the Argus Research Laboratories (1998a) study, a NOAEL that relied on the Bekkedal et al. (2000) study was chosen at 1 mg/kg-day to represent effects on motor activity from these combined data.

Argus Research Laboratories (2001) studied the effects of perchlorate on thyroid and brain development both during gestation and postnatally. Perchlorate was administered in drinking water to female rats two weeks prior to cohabitation at 0, 0.01, 0.1, 1, or 30 mg/kg-day and continued through the day of sacrifice. F1 generation rats were not directly dosed but might have been exposed in utero during gestation and via maternal milk and maternal water during the postpartum period. The rats were selected only from female rats that had litters of at least 12 live offspring at the time of Caesarean-sectioning (Part A) or at the time of the first tissue collection (Parts B and C). P generation rats assigned to Parts B and C that delivered a litter were sacrificed on either PND 9 (Part B) or PND 21 (Part C). The thyroid and brain from one male and one female pup per litter were selected for histological and morphometric evaluation, with one set evaluated on PND4, PND9, and PND21. Details of the study and findings are described in the study report prepared by the Argus Research Laboratories (2001), and a summary of the findings and evaluations is provided below.

According to the report, there were no deaths, adverse clinical observations or necropsy findings during the premating, gestational and/or lactation periods that were treatment-related in Parts A, B, and C. There were 16 pregnant dams in Part A. No treatment-related changes were found in Caesarean-sectioning or litter parameters. There were 15 or 16 pregnant dams for Parts B and C that delivered. Natural delivery was unaffected by the treatment and all clinical and necropsy observations in the F1 generation pups were considered unrelated to the treatment.

The absolute and relative thyroid weights of dams at the highest dose were increased. The absolute thyroid weights of some pups exposed at 1 and 30 mg/kg-day were increased. Furthermore, the absolute thyroid weights of the PND9 male pups in the 0.01, 0.1, 1 and 30 mg/kg-day dose groups were significantly increased over the controls.

An exposure-related increase in the incidence and severity of decreased colloid was noted in dams in the 1 or 30 mg/kg-day groups. Similar observations were made on the fetuses at birth and pups at PND4 and PND9. An increased incidence of follicular cell hypertrophy and/or hyperplasia was found in dams in the 30 mg/kg-day dose group. An increased incidence of follicular cell hyperplasia was also found in the 1 mg/kg-day dams sacrificed on PND21.
In Part A, maternal TSH levels were significantly increased and T4 levels were significantly decreased at all exposure levels. Fetal TSH levels were significantly increased at 1 and 30 mg/kg-day while T3 was significantly decreased at all exposure levels. Changes of both the maternal and fetal thyroid hormone levels occurred in an exposure-dependent manner.

Maternal and fetal thyroid and pituitary hormone levels were also affected by various doses of perchlorate in Parts B and C. Most changes occurred in an exposure-dependent manner. In the PND21 male pups, TSH levels were significantly increased and T4 levels were significantly decreased at all exposure levels. T3 levels were also significantly decreased in the 1 and 30 mg/kg-day groups. In the PND21 female pups, TSH levels were increased at all exposure levels, reaching statistical significance in the 0.1, 1, and 30 mg/kg-day groups. T4 levels were decreased with increased exposure but did not reach statistical significance.

Size of various brain areas was also measured in brain sections from the PND9 and PND21 pups. Due to signs of disruption or damage found in the PND9 sections that might have compromised the measurements, U.S. EPA (2002) relied upon the PND21 measurements. In the PND21 brains, the striatum, cerebellum, and corpus callosum in the exposed animals all showed significant differences from those of controls with the lowest administered dose of ammonium perchlorate, 0.01 mg/kg-day. As shown in Figure 3, different brain regions show an inverted U or U-shape dose response. For instance, the corpus callosum showed a notable increase in linear extent of 24 percent or more at PND21 in the 0.01, 0.1, and 1 mg/kg-day dose groups; however, this effect was not observed at the highest dose group, 30 mg/kg-day. Using these data, U.S. EPA (2002) identified a LOAEL of 0.01 mg/kg-day for the adverse effects of ammonium perchlorate on the developing brain in rats. This is equivalent to 0.0085 mg/kg-day for the perchlorate anion alone.

The design and implementation of this study have been criticized, and U.S. EPA’s interpretation of the study data has been challenged (TERA, 2003). It was noted that the way the brain sections were prepared and the method used to measure different regions of the brain are susceptible to experimental artifacts. The study has no positive control and it is not clear if the observed neurodevelopmental changes are related to thyroid hormone disruption. The association of some of the brain measurements with perchlorate exposure has also been questioned since there were no clear linear dose-response relationships. There are also concerns about the statistical methods used in the U.S. EPA analysis.
Figure 3. Profile Analysis of Brain Morphometry Measurements for PND21 Rat Pup Brain Regions. The male and female linear thickness measurements were combined and normalized by the control mean of each region. The control data are represented by the horizontal line at 1.0. Profile analysis determines whether the vectors of measurements from each treatment group differ from each other and control in a dose-dependent fashion. The heavy line represents the ±99 percent confidence interval around the mean control values. Note that while this plot uses the normalized data to more easily illustrate the data vectors, the actual analysis was performed using raw data values (from U.S. EPA, 2002).

Thuett et al. (2002) studied the effects of in utero and lactational exposure to ammonium perchlorate on developing deer mice. Breeding pairs were dosed continuously with 0, 1 nM, 1 µM, or 1 mM of ammonium perchlorate in drinking water, from cohabitation until pups were sacrificed at postnatal day (PND) 21. Pups from the second litter were used for evaluation. The researchers found the treated groups tended to have smaller litter sizes than did controls, but a greater survival percentage. They reported that perchlorate is a developmental toxicant and showed variable effects with increasing concentrations. Body weights of the pups in the 1 µM group were consistently lower than in the controls and in other treatments after PND 1. They also reported that perchlorate treatment had an effect on the liver and heart weights. However, although liver weight alone was statistically different between treatments, liver weight when analyzed with body weight as a covariate showed no statistically significant difference. Heart weights for male pups were decreased in the 1 µM and 1 mM treatment groups. Heart weights decreased while body weight was increasing. Citing other study results, Thuett et al. (2002) suggested
that an inadequate level of thyroid hormones during cardiac muscle development can alter cardiac function and/or heart size.

Reproductive Toxicity

Female rats were dosed with perchlorate in drinking water during gestation. The daily intake rates were estimated to range from 237 mg/rat to 615 mg/rat (Brown-Grant, 1966; Brown-Grant and Sherwood, 1971, as cited in U.S. EPA, 2002). These researchers observed no significant differences in litter size, number of pups, and pregnancy rate. Relative thyroid weights of the dams and litters were increased significantly compared with the controls.

A developmental toxicity study was performed on New Zealand White rabbits (Argus Research Laboratories, 1998d). It involved 25 naturally-mated does per group exposed to ammonium perchlorate in drinking water at 0, 0.1, 1.0, 10, 30, and 100 mg/kg-day from gestation day 6 to gestation day 28. Observations were based on 22, 24, 23, 24, 24, and 23 pregnant does that survived to gestation day 29 in the 0, 0.1, 1, 10, 30, and 100 mg/kg-day dosage groups, respectively. Fetuses were delivered by Caesarean section. The authors reported that doses as high as 100 mg/kg-day did not affect litter parameters. All values were within the historical ranges of the testing facility. The litter averages for corpora lutea, implantations, litter sizes, live and dead fetuses, early and late resorptions, percent dead or resorbed conceptuses, percent male fetuses and fetal body weights were comparable and did not differ significantly in the six dosage groups. All placenta appeared normal and no doe had a litter consisting of only resorbed conceptuses (Argus Research Laboratories, 1998d). U.S. EPA (2002) analyzed the maternal hormone data and noted statistically significant decreases in T4 for the 1, 10, 30, and 100 mg/kg-day dose groups. There were no statistically significant changes in T3 or TSH at any dose.

Argus Research Laboratories (1998d) also reported that no fetal alterations (defined as malformations and variations) were attributable to exposure to ammonium perchlorate at doses as high as 100 mg/kg-day: (a) the incidences were not dosage-dependent; (b) the observation occurred in only one or two high dosage group fetuses; or (c) the incidences were within the averages observed historically at the testing facility.

OEHHA notes that rabbit is probably not an appropriate animal model for the study of adverse developmental effects of perchlorate. Studies have shown that the placental iodide transport in rabbit is capable of generating a fetal serum-to-maternal serum iodide concentration of 5/1 to 9/1, thus facilitating the production of fetal thyroid hormone. A similar transport mechanism is not known to exist in human placenta (Hall and Myant, 1956 and Roti et al., 1983, as cited in Fisher, 1996).

In a study by Argus (2000), female rats were dosed at 0, 0.01, 0.1, 1.0 and 30.0 mg/kg-day ammonium perchlorate in drinking water beginning 15 days before cohabitation and continuing through the day of sacrifice. All rats were sacrificed on gestation day 21, and a gross necropsy of the thoracic, abdominal, and pelvic viscera was performed. Preimplantation loss was noted at all dose levels: 12, 18, 20, 16, and 25 percent at the respective doses from 0 to 30 mg/kg-day. U.S. EPA (2002) noted that it was not clear whether these increases were statistically or biologically significant compared to control animals. OEHHA analyzed the data by the Mann-Whitney U test (since the data are not normally distributed) and found that the increase in preimplantation loss was statistically
significant in the 30 mg/kg-day group compared to controls (p<0.05). A decrease in the number of live fetuses was also reported to be statistically significant (p<0.05) at 30 mg/kg-day, although no significant decrease was noted in the lower dose groups. Ossification sites per litter for sternal centers and forelimb phalanges were significantly reduced at 30 mg/kg-day.

Immunotoxicity

Shigan (1963) administered ammonium perchlorate to rabbits and white rats in water at 190 mg/kg-day for three months. The mode of administration was not described. No effect was found on immune function as evaluated by leukocyte phagocytosis (Shigan, 1963).

A series of hematological and immunotoxicology experiments in female B6C3F1 or CBA/J Hsd mice was conducted as part of the U.S. EPA’s perchlorate testing strategy (U.S. EPA, 1998a, 2002). In these experiments mice were exposed for 14 or 90 days to ammonium perchlorate at doses between 0.02 and 50 mg/kg-day via drinking water. The mice were tested at intervals for immunotoxicological effects such as delayed type hypersensitivity and cytotoxic lymphocyte activity (Keil et al., 1998, 1999; Burleson Research Technologies).

In the hematological studies, no differences were observed between control and dosed mice in 14- or 90-day experiments for erythrocyte cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration, nor in leukocyte differential counts of neutrophils, monocytes, and lymphocytes. An increase in the percentage of reticulocytes was observed in the peripheral blood of mice exposed to 3 mg/kg-day of ammonium perchlorate in a 90-day study. No consistent alteration in the bone marrow stem cell assay was observed. An increase in the number of colony-forming units was observed in bone marrow cell cultures from mice dosed at 30 mg/kg-day in a 14-day study. However, in two other 90-day studies, this positive result was not confirmed. Upon reviewing the immunotoxicological studies, U.S. EPA (2002) found that three immune function parameters were altered by ammonium perchlorate exposure: (a) suppression of in vitro peritoneal macrophage phagocytosis of L. monocytogenes; (b) enhancement of the plaque-forming cell (PFC) assay response to sheep red blood cells (SRBCs); and (c) enhancement of the local lymph node assay (LLNA) response to 2,4-dinitrochlorobenzene (DNCB).

Decreased in vitro phagocytosis of L. monocytogenes by peritoneal macrophages obtained from mice dosed for 14 days at 1 or 30 mg/kg-day (ammonium perchlorate) was observed. In mice exposed for 90-days, phagocytosis was decreased in all dose groups (Keil et al., 1998, 1999). However, similar effects were not observed in a 90-day perchlorate exposure followed by a 30-day recovery period study. These in vitro data suggest that perchlorate suppresses the phagocytic capacity of peritoneal macrophages, but this suppression is reversed after a 30-day recovery period. It is difficult to interpret the biological significance of this data set because in vivo study results indicate ammonium perchlorate exposure did not alter the ability of mice to combat L. monocytogenes infection. It was suggested that while perchlorate may reduce the
phagocytic capacity of peritoneal macrophages, the ability of macrophages from other sites (e.g., spleen, liver) to clear \textit{L. monocytogenes} was not altered (U.S. EPA, 2002).

The PFC assay is routinely used for identifying immunosuppressive chemicals. The reason why the highest dose(s) of ammonium perchlorate, given over 90 days, enhanced this response is not known. The ELISA data for mice exposed to up to 30 mg/kg-day for 14 or 90 days do not corroborate this enhanced response to SRBCs observed in the PFC assay. The data from Burleson Research Technologies (2000) indicate that exposure to perchlorate enhances the LLNA response to DNCB. While a dose of 50 mg/kg-day for 14 days enhanced the response, the same dose for 90 days suppressed the response. Lower doses of 0.06 and 0.2 mg/kg-day also increased the response; however, interpretation of these data is made difficult by the observation that 2 mg/kg-day did not affect the response in the 14-day study. OEHHA agrees with U.S. EPA (2002) that interpretation of the results is made difficult by (a) some technical problems encountered in the studies, (b) the apparent inconsistency of the high-dose study results, and (c) the unknown biological significance of the response enhancement.

**Neurotoxicity**

By interfering with the thyroid-pituitary axis, perchlorate can interfere with development of the central nervous system. Thyroid hormone plays an essential role in the development of the corpus callosum and other brain structures. As part of the U.S. EPA’s program to evaluate the toxicity of perchlorate, neurodevelopmental tests on Sprague-Dawley rats were conducted by Argus Research Laboratories (1998a, 2001). The study design and findings have been summarized in the “Developmental and Reproductive Toxicity” section.

**Endocrine Toxicity**

Many oral and injection studies have documented the effects of perchlorate on the thyroid and pituitary hormones as well as the thyroid of the treated animals. The designs and findings of these studies are summarized in the “Subchronic Toxicity” and “Developmental and Reproductive Toxicity” sections.

Yu \textit{et al.} (2000), working with the United States Air Force and U.S. EPA, investigated the inhibitory effects of perchlorate on thyroidal iodide uptake in rats. They injected perchlorate at 0, 0.01, 0.1, 1 or 3 mg/kg to groups of male Sprague-Dawley rats (six animals per dose and time point). At two hours post dosing, the rats were challenged with $^{125}\text{I}$ with carrier (33 µg/kg) by intravenous injection and euthanized at various time points post dosing. Statistically significant thyroidal iodide uptake inhibition was found in the 1 and 3 mg/kg perchlorate dose groups at the 2, 6, and 9 hour time points. In addition, significant inhibition was also observed in the 0.1 mg/kg dose group at the 9 hour time point (Table 7).
Table 7. Percent Inhibition of Iodide Uptake in the Thyroid Gland of Male Rats (n=6) Dosed with Perchlorate (Yu et al., 2000)

<table>
<thead>
<tr>
<th>Time points</th>
<th>Perchlorate dose (mg/kg)</th>
<th>Mean iodide concentration in the thyroid (µg/g)</th>
<th>Thyroidal iodide uptake inhibition (%)(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 hours</td>
<td>Control(^b)</td>
<td>24.4</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td>21.3</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>18.6</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>7.4(^c)</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3.0(^c)</td>
<td>88</td>
</tr>
<tr>
<td>6 hours</td>
<td>Control(^b)</td>
<td>46.5</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td>36.7</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>32.0</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>19.2(^a)</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>9.1(^a)</td>
<td>80</td>
</tr>
<tr>
<td>9 hours</td>
<td>Control(^b)</td>
<td>55.0</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td>49.2</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>0.1(^c)</td>
<td>39.2</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>24.7(^c)</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>10.0(^c)</td>
<td>82</td>
</tr>
</tbody>
</table>

\(^a\)Percent inhibition = (control mean – dose mean) x 100 / (control mean)
\(^b\)Dosed with 125I with carrier only (33 µg/kg)
\(^c\)p<0.05 compared to controls.

In a follow-up study, Yu et al. (2000) exposed groups of male Sprague-Dawley rats (6 animals per dose and exposure duration) to perchlorate in drinking water with target concentrations of 0, 1, 3, and 10 mg/kg-day continually for 1, 5, or 14 days. At the end of day 1, 5, or 14, rats were challenged once with 33 µg/kg 125I with carrier and euthanized two hours later. Blood and thyroid gland were collected for analyses. A dose-related inhibition was noted in the one-day treatment group. The degree of inhibition was reduced over time and by exposure day 14, no inhibitory effect was observed in the 1 and 3 mg/kg-day groups. In a similar study, thyroid hormone profile of rats exposed to perchlorate was investigated. Male rats in groups of 8 were exposed to perchlorate in drinking water at 0, 0.1, 1, 3, and 10 mg/kg-day continually for 1, 5, or 14 days. In all treated groups, regardless of dose or exposure duration, TSH levels were increased compared to the control. The serum T4 levels were initially decreased in all dose groups except the lowest, 0.1 mg/kg-day. By 14 days, the 1 mg/kg-day dose group returned to control T4 values while T4 levels of the 3 and 10 mg/kg-day dose groups were still significantly depressed. Yu et al. (2000) suggested that the regulations of thyroidal iodide uptake and serum T4 are rapid in rats and can compensate for the anti-thyroid actions of perchlorate at low doses.
Yu et al. (2002) modeled the effects of perchlorate on the hypothalamus-pituitary-thyroid axis in the male rat. They found a high correlation between serum concentrations of perchlorate and percentage inhibition in thyroidal iodide uptake, irrespective of the route of administration. They found the hypothalamus-pituitary-thyroid axis responded quickly to perchlorate blocking effects on thyroidal iodide uptake. Serum thyroid hormone levels decreased and serum TSH levels increased in response to perchlorate. Under the influence of TSH, the thyroid was up-regulated and was able to overcome the blocking effects of perchlorate by increasing its capacity to sequester iodide and produce hormones. Yu et al. (2002) noted that this is a dose-dependent phenomenon, which was overwhelmed by the blocking effects of high serum levels of perchlorate (corresponding to above approximately 1 mg/kg-day).

In Paulus et al. (2007), perchlorate-induced inhibition of thyroidal iodide uptake was measured in normally fed female Sprague-Dawley rats and in rats made iodine-deficient by long-term restriction of iodine in the diet (n = ten rats per perchlorate-iodine group). In the iodine deficient animals, dietary iodine levels were 9-10 times lower than those in the normally fed animals. T4 levels in the iodine-deficient animals were 50 percent lower than in the normally fed animals, although TSH levels did not differ across the diet groups. Both groups were given a dose of \( ^{131} \)I via gavage, and \( ^{131} \)I uptake was measured in the thyroid. The proportion of administered \( ^{131} \)I taken up by the thyroid was greater in the iodine deficient rats than in the rats fed a normal diet.

Rats from each diet group were then given either no perchlorate or perchlorate at doses of 1.1, 5.6, or 28 mg/L, and %RAIU was re-measured. In the normally fed rats, perchlorate produced significant inhibition of iodide uptake (%RAIU) at every dose group. In the iodine-deficient rats, %RAIU was decreased at all dose levels except the lowest dose (1.1 mg/L) (Figure 4), although the %RAIU reduction in the second highest dose group was not statistically significant. These results suggest that iodide-deficient animals are resistant to the iodine-uptake inhibiting effect of perchlorate compared to animals with adequate iodine intake. Based on this, the authors concluded that if the human NIS system reacts to iodine deficiency in a manner similar to the rodents in this study, iodine-deficient individuals may not represent a sensitive subpopulation for perchlorate toxicity. Importantly, this conclusion is based on a lack of findings in only one dose group. In addition, it is currently unknown whether these results apply to humans. Finally, the degree of iodine deficiency induced in the iodine deficient rats was fairly severe (the dietary iodine levels were one tenth of what they were in the normally fed animals). It is not known whether the effects seen in with this severe degree of iodine deficiency are relevant to the more moderate iodine deficiencies that are common in human populations.
Figure 4. Dose-Response Relationship between Perchlorate and Radioactive Iodide Uptake in the Thyroid in Rats with Normal and Low Iodine Intake (Paulus et al., 2007). Gray bars are values from rats fed a normal diet, black bars are values from rats fed a low-iodine diet. Values shown are mean ± SEM.

Clewell et al. (2001, 2003, 2007) have developed and attempted to validate rat and human physiologically-based pharmacokinetic (PBPK) models for the estimation of the effect of life stage and species on perchlorate and iodide inhibition kinetics. The models have been used to estimate perchlorate distribution in the male, pregnant, fetal, lactating and neonatal rat, and predict resulting inhibitory effects on thyroidal iodide uptake. The authors conclude that the fetal rat thyroid is most vulnerable to inhibition. Clewell et al. (2007) reported that "the fetus is predicted to receive the greatest dose (per kilogram body weight) due to several factors, including placental sodium-iodide symporter (NIS) activity and reduced maternal clearance of ClO₄⁻."

Carcinogenicity

A number of animal studies have been reported that may be useful in determining the carcinogenic potential of perchlorate. However, the interpretation of the study results is hampered by the small number of animals per dose group, short exposure and observation durations, lack of multiple dose groups, and co-exposure to other cancer causing agents.

Gauss (1972) treated female NMRI mice with one percent potassium perchlorate in the diet or the control diet for 160 days. The one percent dose is equivalent to approximately 2,000 mg/kg-day based on standard assumptions. The investigator noted progressive changes in the thyroid of treated mice beginning with colloid loss, progressing to increases in size of nuclei and increased epithelial height, followed by appearance of hyperplasia and hypertrophy of the thyroid parenchyma. Later in the treatment period, hyperplastic follicles, areas of adenomatous tissue, adenoma complexes and secreting cystadenomas were observed. No progression to malignancy was observed during the study period.

Several Japanese investigators (Hiasa et al., 1987) tested potassium perchlorate for its ability to promote the carcinogenic activity of N-bis(2-hydroxypropyl)nitrosamine (DHPN). They divided the rats into four groups. Groups 1, 2, and 3 received 1000 ppm...
Groups of male Wistar rats were exposed for two years to 0 or one percent potassium perchlorate in their drinking water (Kessler and Kruskemper, 1966). Based on body weights and estimated water consumption, the one percent concentration was estimated to provide a dose of approximately 1,300 mg/kg-day. Animals were sacrificed and examined after 0, 40, 120, 220 and 730 days of exposure. Body weights of control and exposed animals were similar throughout the experiment, but thyroid weights of the exposed rats increased markedly compared to control rats at each examination interval. At 40 days, the exposed rats showed follicular cell hyperplasia, i.e., small follicles with high epithelia, large nuclei, numerous mitoses, colloid resorption and low-grade mesenchymal reaction. According to the authors, these changes are typical of thyroid glands stimulated by TSH for a relatively short time. Diffuse degenerative changes with fibrosis and increased colloid were observed after 200 days. Four of 11 rats treated with one percent potassium perchlorate for two years developed benign thyroid tumors. The twenty untreated controls had no thyroid tumors.

Pajer and Kalisnik (1991) divided 72 female BALB/c mice into 6 groups. Three groups were given 1.2 percent sodium perchlorate in drinking water, while three groups were controls. Eight or 32 weeks after the beginning of the study, one perchlorate and one control group of animals were irradiated with a total of 4 Grays of ionizing radiation (gamma rays) over a period of five days. Forty-six weeks after the beginning of the experiment, 42 animals were sacrificed, while 30 had died during the experiment. The perchlorate dose to the treated mice was about 2,100 mg/kg-day based on standard assumptions for body weight and water consumption. Perchlorate treatment alone caused hypothyroidism with hypertrophic and hyperplastic thyroid epithelial cells as well as pituitary thyrotropic cells. Perchlorate and irradiation together caused effects similar to those caused by perchlorate treatment alone. Follicular cell carcinomas of the thyroid gland were found after perchlorate treatment (5/6 mice) and after perchlorate with irradiation (14/14), both statistically significant at p<0.001 versus controls (0/22).

The data indicate perchlorate caused thyroid follicular cell carcinomas in the treated mice. The study result is limited by the small number of animals in the perchlorate-only treated group, the design of the study, and the deaths of over 40 percent of the mice before the end of the experiment.

In a two-generation reproductive toxicity study in rats (Argus Research Laboratory, 1998b), two out of 30 male Sprague-Dawley rats (P2) in the highest dose group (30 mg/kg-day) were found to have adenomas of the thyroid. No such tumors were found in the control group or the other dosed groups (0.3 mg/kg-day and 3 mg/kg-day). In the study, the male rats were exposed to ammonium perchlorate in drinking water from
conception to 19 weeks of age. As thyroid follicular cell adenomas are relatively rare in male Sprague-Dawley rats (the background incidence of this tumor reported in the literature was only 3.6-3.9 percent), U.S. EPA (2002) concluded that the increase in tumor incidence was treatment related.

In a number of subchronic perchlorate studies, increased thyroid follicular cell hypertrophy and hyperplasia were observed in some of the treated animals (Lampe et al., 1967; Caldwell et al., 1995; Springborn Laboratories, 1998; Argus Research Laboratories, 1998a, 1999, 2001; Keil et al., 1998). Summaries of these studies are provided in sections on “Subchronic Toxicity” and “Developmental and Reproductive Toxicity.” The data indicate that oral administration of perchlorate induces hyperplasia in the thyroid of rodents and if the exposures are lengthened, some of the lesions might progress to thyroid tumors.

**Toxicological Effects in Humans**

The major adverse health effects of perchlorate at low dosages are associated with disruption of thyroid hormone balance. These effects are similar to those caused by iodine deficiency. At high doses, perchlorate exposure is known to cause other adverse health effects such as blood disorders. Some of the adverse health effects of iodine deficiency are discussed in later sections.

**Acute Toxicity**

The acute lethal oral dose of perchlorate for an adult human was estimated to be 15 g, or 214 mg/kg for a 70-kg person (Von Burg, 1995).

**Subchronic Toxicity**

Potassium perchlorate has been used to treat Graves’ disease in humans, and most of the early data on perchlorate in humans are in patients with this disease. Graves’ disease is an autoimmune disorder in which patients carry immunoglobulins in their blood that bind to the TSH receptors on thyroid cells and act like TSH to stimulate DNA synthesis and cell divisions leading to a hyperthyroid state. Perchlorate inhibits the excessive synthesis and secretion of thyroid hormones by inhibiting the uptake of iodide into the thyroid and causes a discharge of accumulated iodide in the gland.

Godley and Stanbury (1954) report using potassium perchlorate to treat 24 patients with Graves’ disease. Patients were treated with 600 to 1,200 mg/day for at least 11 weeks with a few patients treated for up to 52 weeks. Two patients developed gastrointestinal problems. In one patient, these effects occurred at 600 mg/day.

Crooks and Wayne (1960) administered potassium perchlorate at 600 to 1,000 mg/day to 200 patients with Graves’ disease and observed one case of skin rash and three cases of nausea. In another group of 10 patients given 1,500 mg/day and 40 patients given 2,000 mg/day, five cases of skin rash, two cases of nausea, and one case of agranulocytosis occurred. Leukocyte counts returned to normal in the patient with the agranulocytosis when perchlorate treatment was stopped. The length of treatment was unclear but generally appears to have been less than 8 weeks.
Morgans and Trotter (1960) reported that three percent of 180 patients treated with 400 to 1,000 mg/day potassium perchlorate and 18 percent of 67 patients treated with 1,200 to 2,000 mg/day displayed a variety of adverse reactions that included skin rash, sore throat, gastrointestinal irritation, and lymphadenopathy. Based on the data reported by Crooks and Wayne (1960) and their own clinical observations, Morgans and Trotter (1960) recommended a daily dose of 800 mg/kg-day, a compromise between effectiveness and minimizing the toxic side effects of perchlorate.

Genetic Toxicity

No reports were found of studies that examined genetic endpoints (chromosomal aberrations, sister chromatid exchanges, etc.) in humans exposed to perchlorate.

Chronic Toxicity

Connell (1981) reported a case of a female Graves’ disease patient who was treated with 200 mg/day perchlorate for 22 years with good control of the disease, and no apparent adverse effects.

Developmental and Reproductive Toxicity

Introduction

Studies of the impacts of perchlorate on thyroid hormone levels in newborns or children are discussed in this section. Impacts in adults, including pregnant women, are discussed in the following section.

Several studies have assessed the association between maternal exposure to perchlorate in drinking water during pregnancy and changes in thyroid hormone levels in newborns. Most of these studies used thyroid hormone levels that were collected as part of state-mandated screening programs for congenital hypothyroidism. Although these programs typically involve measuring thyroid hormone levels at any time in the first two weeks after birth, levels collected in the first 1-2 days after birth may be particularly important. There are several reasons for this. First, studies have shown that subtle changes in thyroid hormone levels may have greater impacts on brain development if they occur in the fetal period than if they occur later (i.e. in the newborn or young child) (Pop et al., 2003; Kooistra et al., 2006). Since thyroid hormone levels generally cannot be measured in the fetus during pregnancy in humans, the best practicable way to assess any effect in the fetus caused by perchlorate exposure to the mother during pregnancy would be to measure thyroid hormone levels in the child as soon after birth as possible (e.g., within the first 1-2 days after birth). Second, most of the human studies on newborn thyroid function and maternal perchlorate exposure defined exposure based on the perchlorate concentrations in the mother’s residential drinking water during pregnancy, not on the actual perchlorate intake of the newborn after birth. Importantly, the half-lives of both perchlorate and thyroid hormones in newborns are fairly short (less than 24 hours) (Greer et al., 2002; Van den Hove et al., 1999). As such, any effect that the mother’s perchlorate exposure during pregnancy might have on the fetal thyroid might be seen soon after birth (e.g., within the first 24 hours after birth), but not necessarily at a later
time. This is because the perchlorate exposure of the child may change relatively soon after birth. For example, the newborn may be fed an infant formula with a different perchlorate concentration than that of the drinking water used by the mother during pregnancy. Perchlorate exposure may also change after birth in breast-fed infants if the mother uses water from the hospital or bottled water that has a different perchlorate concentration than the residential water used before birth. Since most of these studies based exposure status solely on the water source used by the mother, any change in exposure in the child after birth could lead to a misclassification of exposure that would bias results towards the null and could cause any true effect to appear to diminish relatively soon after birth. Since the half-life of thyroid hormone in the child is short, this bias would most likely begin to occur within 24 hours after birth and become stronger thereafter. Because of this potential bias, our evaluation of these studies adds an additional emphasis on thyroid hormone measurements collected within the first 24 hours after birth.

Clinical Studies

Crooks and Wayne (1960) administered potassium perchlorate at 600 to 1,000 mg/day to a group of pregnant women that were suffering from hyperthyroidism and observed a very slightly enlarged thyroid in 1 of the 12 infants born to the mothers. They also reported that the enlarged thyroid returned to normal size in six weeks, and no other abnormalities were observed. Several key parameters were not provided in the paper: detailed dosage information, time of perchlorate treatment in relation to the gestation period, thyroid function of the newborns, and the neurological as well as behavioral development of the offspring. Furthermore, interpretation of the result is made difficult by the fact that the women were suffering from thyrotoxicosis (excess quantities of thyroid hormones).

Epidemiologic Studies

DHS, 1997. A preliminary health review of a potentially perchlorate-exposed area of Rancho Cordova, CA by the California Department of Health Services (DHS, 1997) included an analysis of several state databases for possible perchlorate-related adverse health effects. Analysis of newborn thyroid hormone data for the period 1985 through 1996 did not indicate a positive correlation between residence in potentially perchlorate-exposed areas and neonatal hypothyroidism. The TSH levels of neonates with initially low T4 levels in the potentially exposed areas were found to be statistically lower than those in the control areas, contrary to what was expected.

Kelsh et al., 2003. This investigation used the California Newborn Screening database to study the thyroid health of newborns whose mothers resided in the city of Redlands, California during the years 1983 through 1997. Perchlorate at variable levels has been detected in groundwater wells in this city. The outcomes assessed were neonatal primary congenital hypothyroidism (PCH) and elevated neonatal serum levels of TSH (> 25 μU/mL). PCH is a severe condition, usually caused by a missing or partially missing thyroid gland in the child. It is generally associated with very large increases in TSH (e.g. > 25 μU/mL) and often requires treatment with thyroid hormone to prevent severe neurologic and physical growth deficits. TSH measurements were only collected when
T4 levels were low (typically below 9 μg/dL or in the lowest five percent of the remaining daily tray samples). PCH was defined as an elevated TSH plus a physician’s confirmatory diagnosis. Newborns of San Bernardino and Riverside counties, excluding newborns from Redlands and other communities where perchlorate has been detected, were used as the comparison group. The Colorado River is one of the water sources of Riverside County, so the water serving some of the “unexposed” comparison group may have been contaminated with perchlorate. There is little information about the perchlorate levels in the drinking water in this area during the study period since the detection limit of perchlorate in water before 1997 was about 400 ppb. In the 2001 and 2002 Consumer Confidence Reports, the City of Redlands reported that the concentrations of perchlorate in its water system ranged from non-detect to 9 ppb, with an average concentration below 1 ppb. However, in data from the California Department of Health, reported perchlorate levels in Redlands wells in 1997 ranged from 130 ppb to 4 ppb, although it is unknown how much water from the high exposure wells was used for drinking.

Kelsh et al. (2003) found no increase in the prevalence of PCH in Redlands newborns over the 15-year study period, although there were only two cases of PCH reported in Redlands during this time. Because there is a normal transient surge in neonatal TSH levels immediately after birth, measuring TSH levels within the first few hours of birth can lead to a high rate of false positives in screening programs for PCH. Because of this, the researchers did further analyses, which excluded subjects who had TSH measurements collected within the first 18 hours of birth. However, as discussed above, measurements collected in the first day after birth may actually be the most relevant, and as discussed below, the post-natal surge in TSH does not necessarily limit the ability of a study to identify associations between perchlorate and neonatal thyroid hormone levels.

The odds ratio for an elevated TSH for Redlands compared to San Bernardino/Riverside Counties for all subjects (regardless of the age at measurement), and for only those subjects with TSH measurements collected at ≥ 18 hours of age reported by Kelsh et al. (2003) were 1.24 (95% CI, 0.89-1.68) and 0.69 (95% CI, 0.27-1.45), respectively. The prevalence ratio for PCH standardized by ethnicity, sex, birth weight, and birth year for Redlands compared to San Bernardino/Riverside Counties was 0.45 (95% CI, 0.06-1.64). The researchers found that Hispanic ethnicity, low and high birth weight, and female sex were risk factors for PCH.

Kelsh et al. (2003) did not calculate the odds ratio for having a low T4, although this can be estimated using the data in their tables. The odds ratio for having a low T4 in Redlands compared to San Bernardino/Riverside Counties was 1.18 (95% CI, 1.13-1.24; p < 0.0001). This odds ratio is unadjusted. However, it is unlikely that adjusting for age at collection, ethnicity, sex, birth weight, or birth year would have any major impact on this odds ratio since adjusting for these factors had little impact on the TSH odds ratios provided by the authors.

Kelsh et al. (2003) also did not report specific results for neonates who had serum TSH measurements collected before 18 hours of age. However, data provided in the tables of Kelsh et al. (2003) can be used to estimate the odds ratio for having a high TSH level in subjects who had their TSH levels measured during this time. This odds ratio, comparing
Redlands to all of San Bernardino/Riverside Counties, was 1.57 (95% CI, 1.14-2.16; p < 0.0001). The data used in these calculations are shown in Table 8.

The major strength of the Kelsh et al. (2003) study is its large sample size. However, it is limited by the small number of cases of PCH in Redlands, and like most other ecological studies, it was limited by the lack of detailed information on individual exposure (discussed below).

Table 8. Estimated Odds Ratio Calculations For a High Neonatal TSH Level in Subjects With Blood Collected < 18 Hours of Birth (Kelsh et al., 2003)

<table>
<thead>
<tr>
<th>Area (Perchlorate)</th>
<th>TSH levels</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Elevated</td>
<td>Not elevated</td>
<td>Totals</td>
<td></td>
</tr>
<tr>
<td>Redlands (High)</td>
<td>38</td>
<td>4,808</td>
<td>4,846</td>
<td></td>
</tr>
<tr>
<td>San Bernardino &amp; Riverside (Low)</td>
<td>1,175</td>
<td>232,990</td>
<td>234,165</td>
<td></td>
</tr>
<tr>
<td>Totals</td>
<td>1,213</td>
<td>237,798</td>
<td>239,011</td>
<td></td>
</tr>
</tbody>
</table>

Odds ratio = \((38/4,808) / (1,175/232,990)\) = 1.57 (95% CI, 1.14-2.16)

Crump et al., 2000. These investigators studied 162 school-age children (age 6-8 years old) and 9,784 newborns in three cities in northern Chile that had different concentrations of perchlorate in their drinking water: Taltal (perchlorate concentration, 100 to 120 µg/L), Chañaral (5-7 µg/L), and Antofagasta (non-detectable: <4 µg/L). Approximately 25 separate water sources were sampled in each city. Water samples were taken from water faucets at participating schools, homes of students, and public buildings located near the schools.

The unadjusted mean levels of TSH, T4, fT4, and T3 of the school-age children were very similar across the three cities. Among all the school-age children, there was a small, non-significant increased risk of goiter in Chañaral (26.5 percent) and Taltal (23.3 percent) compared with Antofagasta (17 percent), although this was not seen in analyses confined to life-long residents. The reason for the high prevalence of goiter in the unexposed city of Antofagasta is unknown.

Overall, neonatal TSH levels were similar across the three cities. Adjusted for sex and age, linear regression comparisons of the logarithm (log) of TSH of the newborns by city showed that average logTSH in Taltal was significantly lower than the averages of the other two cities. However, TSH levels in those neonates with TSH measured on day 1-2 after birth were higher in Taltal (4.2 µU/mL ± 1.2) than in Antofagasta (3.2 µU/mL ± 3.5) or Chañaral (3.2 µU/mL ± 3.5), although the sample size was small (n = 62).

It should be noted that the iodine levels measured in the schoolchildren in all three study cities were very high. Mean urine iodine levels were 766 µg/L, 614 µg/L, and 756 µg/L for Taltal, Chañaral, and Antofagasta, respectively. These levels are much higher than those in the NHANES III database, where a mean urinary iodine level of 305 µg/L was found for 6-11 year old children in the U.S. The high urinary iodine levels and high
prevalence of goiter in this study make it difficult to interpret the relevance of its findings to children in California, where rates of goiter are much less and moderate iodine deficiency (a potential susceptibility factor) is likely much more common.

Crump et al. (2000) found that schoolchildren with lifelong residence in Taltal were five times more likely to have a family history of thyroid disease than schoolchildren with lifelong residence in Antofagasta. These results were adjusted for age, sex, and urinary iodine (Table 9). Chañaral children had no increased prevalence of self-reported family history of thyroid disease. Families of 19 out of 61 (31 percent) children in Taltal were reported to have some history of thyroid disease. Twelve of these families reported having a single relative (usually a mother or grandmother) with goiter, hypothyroidism, or unspecified thyroid disease; and seven reported having two or more relatives with thyroid disease. The reasons why there was evidence of perchlorate-related thyroid effects in older relatives, but not in the children themselves, is unknown. However, the authors speculated that this might be related to the major changes in average iodine intakes that have occurred in Chile over the last several decades. Iodinized salt was introduced to this region in the late 1970's, and average urinary iodine levels in Chile have risen dramatically since that time. For example, according to the International Council for Control of Iodine Deficiency Disorders, average urinary iodine levels in Chile rose from 109 ug/gm creatinine in 1982 to 1191 ug/gm creatinine in 2001 (ICCIDD, 2009). It is possible that the elevated odds ratio for a family history of thyroid disease reflects effects that occurred several decades ago when intakes of iodine were low and this low iodine caused some people to be especially susceptible to perchlorate. It is also possible that now that iodine levels are much higher, these high levels are protective, and the children and other members of this community are now much less susceptible to perchlorate.

Table 9. Odds Ratios for the Association between Self-Reported Family History of Thyroid Diseasea Among Schoolchildren and City of Residenceb (Crump et al., 2000)

<table>
<thead>
<tr>
<th>City</th>
<th>Schoolchildren with less than lifelong residence (n=162)</th>
<th>Schoolchildren with lifelong residence (n=127)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antofagasta</td>
<td>0.89, 0.25-3.19</td>
<td>1.04, 0.21-5.09</td>
</tr>
<tr>
<td>Chañaral</td>
<td>3.35, 1.19-9.38</td>
<td>4.97, 1.29-19.17</td>
</tr>
</tbody>
</table>

*aDirect relative (parent, sibling, grandparent, great-grandparent, aunt, uncle, or cousin) with history of goiter, hypothyroidism, or subtotal thyroidectomy.

*bAdjusted for age, sex, and urinary iodine; excluded one child with autoimmune hypothyroidism.

Assuming the level of perchlorate contamination of the city of Taltal has not changed significantly in the last few decades, a LOAEL of 100 µg/L for familial thyroid problems can be identified from Crump et al. (2000). Applying the default values of 2 L/day for drinking water consumption and 70 kg for an adult body weight, the LOAEL is equivalent to an intake of 3 µg/kg-day from drinking water alone.
Lamm and Doemland, 1999. These authors identified six counties in California (Los Angeles, Orange, Riverside, Sacramento, San Bernardino, and San Diego) and one county in Nevada (Clark) that have had detectable levels of perchlorate (4 to 16 µg/L) in at least some of their drinking water sources. They then compared the rates of primary congenital hypothyroidism (PCH) in these seven counties with overall state rates. All infants were screened by their serum T4 levels, and those with a low T4 (i.e., less than the 10th percentile) were further screened for high TSH levels. An infant was considered to be potentially congenitally hypothyroid if the serum TSH was > 25 µU/mL. Infants with these high TSH values were then evaluated by a physician to confirm whether or not they had PCH.

County- and ethnicity-specific data for the two states were obtained for the years 1996 and 1997. Within the seven counties, nearly 700,000 newborns were screened. In all, 249 cases of PCH were identified, where 243 were expected based on the state incidence rate, for an overall risk ratio of 1.0 (95% CI, 0.9-1.2). The risk ratios for the individual counties ranged between 0.6 and 1.1. Out of the 36,016 newborns screened in Clark County (Nevada) between 1996 and 1997, seven cases were observed and 8.3 cases were expected. The risk ratio was 0.8 (95% CI, 0.34-1.74). Based on these results, Lamm and Doemland (1999) concluded that the study did not indicate an increase in the incidence of PCH in those counties with detectable perchlorate levels. Results were not adjusted for several important variables. In addition, although Clark County of Nevada obtains nearly all its water from Lake Mead, which is known to be contaminated with perchlorate, the six California counties obtain their water from multiple sources, many of which are not contaminated with perchlorate. Because of this, there was likely significant misclassification of exposure for the California counties. Finally, PCH is a very serious disease, usually requiring treatment with thyroid hormone, and it is generally associated with large increases in TSH. As discussed in subsequent sections, much smaller changes in thyroid hormone levels may also be associated with significant health outcomes, and these more subtle effects would probably be missed in a study that solely focused on physician-diagnosed cases of PCH.

Li et al., 2000a. In a related study, Li et al. (2000a) compared serum T4 levels of newborns (collected 1 to 4 days after birth) from the city of Las Vegas, Clark County, Nevada, which has perchlorate in its drinking water, to those from the city of Reno, Nevada, which does not (detection limit, 4 µg/L). A total of 17,308 newborns from Las Vegas and 5,882 newborns from Reno born from April 1998 through June 1999 were included in the study. During the study period, monthly drinking water perchlorate levels for Las Vegas ranged from non-detectable to 15 µg/L. Perchlorate was not detected in the Las Vegas water supply in 8 of the 15 months covered by the study.

Overall, Li et al. (2000a) reported no differences in mean T4 levels (approximately 17 µg/dL) between the two cities (p =0.41). Specific analyses stratified by age at the time T4 was measured were not presented in detail but are shown in Figure 3 of their paper. Based on this figure it appears that among infants who had their T4 levels collected on day one after birth, the mean T4 level in Las Vegas was about 4 µg/mL (about 22 percent) lower than the mean T4 in Reno.

Li et al. (2000a) used the monthly perchlorate measurements in Las Vegas drinking water to estimate the cumulative perchlorate exposure for each newborn during the first three
months pregnancy and for all nine months of pregnancy. Cumulative exposures in Las Vegas ranged from 9 ppb-months to 83 ppb-months; the Reno newborns during this period were presumed to have had no drinking water-related prenatal exposure. In linear regression analyses, no association was found between cumulative perchlorate exposure and mean neonatal T4 levels (slope = -0.0003; R² = 0.002).

**Li et al., 2000b.** Li et al. (2000b) studied neonatal blood TSH levels sampled between December 1998 and October 1999 in Las Vegas (up to 15 ppb perchlorate in drinking water) and Reno (perchlorate below the detection level of 4 ppb). Serum TSH levels were measured in all neonates who had T4 measurements below the 10th percentile in each daily batch of T4 samples. TSH measurements collected on the first day after birth were excluded. (As discussed above, associations between maternal perchlorate exposures and neonatal thyroid hormone levels are probably best evaluated using TSH measurements collected within the first 24 hours after birth). In addition, only neonates with birth weights of 2.5 – 4.5 kg were included. The authors found that neonatal TSH levels were not significantly different between Reno and Las Vegas (p=0.97). Several factors might have affected the validity of these results including the lack of control of birth weight and ethnic origin, the use of broad categories to control for age at TSH collection (2-7 and 8-30 days), the small sample size, and perhaps most importantly, the exclusion of subjects who had TSH measurements at age < 24 hours.

**Brechner et al., 2000.** This study identified an association between low-level perchlorate exposure in maternal drinking water and serum TSH levels in newborns. As in the studies discussed above, T4 was measured in all newborns, but TSH was only measured in newborns who had low T4 levels. The investigators compared serum TSH levels in newborns from Yuma, a city that obtains its public drinking water entirely from the Colorado River below Lake Mead, with TSH levels in newborns from Flagstaff, a city that obtains none of its public drinking water from the Colorado River below Lake Mead. Although Lake Mead was known to have perchlorate contamination, no useful water monitoring data were available for Yuma and Flagstaff during the study period (between 1994 and 1997), because the detection limit of perchlorate in water was 400 ppb during that time. In March 1997, the detection limit of perchlorate was improved to approximately 4 ppb. In August 1999, U.S. EPA reported that perchlorate levels in Yuma were about 6 ppb in both raw water and finished drinking water.

In unadjusted analyses, Brechner et al. (2000) found that median newborn TSL levels in Yuma were significantly higher than in Flagstaff (19.9 vs. 13.4 mU/L). In addition, the odds ratio for having a low T4 comparing Yuma to Flagstaff was elevated (1.18; 95 percent CI, 1.05-1.33; p = 0.006). Four cases of congenital hypothyroidism were reported in Yuma but none in Flagstaff. Because of a normal surge in TSH that occurs soon after birth, a major factor influencing newborn TSH levels is the time (after birth) at which the TSH blood samples are collected. This time was significantly earlier in Yuma than in Flagstaff, and this may have caused some of the increase in TSH levels seen in Yuma compared to Flagstaff. However, according to the authors, the difference in mean TSH levels between Yuma and Flagstaff remained after adjusting for age in days at measurement, gender, and race/ethnicity (p = 0.009) (Brechner et al., 2001). Although the effect size of the adjusted results was not reported, median TSL levels in the two cities stratified by age at measurement are presented. Using the data provided in Table 2
of their article, it can be seen that median TSH levels are greater in Yuma than in Flagstaff on most days of age, with the greatest difference seen on days 0-2 of age (shown in Table 10). The interpretation of this study is complicated by the fact that TSH levels were only measured in samples with low T4 measurements (discussed below). In addition, this study did not adjust for birth weight or gestational age. The difference in altitude between the two cities has also been cited as a possible bias but it is not clear that this potential confounder would be strong enough to cause the results observed.

### Table 10. Median TSH Levels in Yuma and Flagstaff Stratified by Day of Blood Collection (Brechner et al., 2000)

<table>
<thead>
<tr>
<th>Days</th>
<th>Flagstaff</th>
<th>Yuma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>0</td>
<td>14</td>
<td>3.2%</td>
</tr>
<tr>
<td>1</td>
<td>122</td>
<td>27.5%</td>
</tr>
<tr>
<td>2</td>
<td>25</td>
<td>5.6%</td>
</tr>
<tr>
<td>3</td>
<td>24</td>
<td>5.4%</td>
</tr>
<tr>
<td>4</td>
<td>15</td>
<td>3.4%</td>
</tr>
<tr>
<td>5</td>
<td>243</td>
<td>54.9%</td>
</tr>
<tr>
<td>Total</td>
<td>443</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

<sup>a</sup>Median TSH in Yuma minus median TSH in Flagstaff.

**Buffler et al., 2006.** This study was an ecologic analysis comparing neonatal TSH levels in California communities with perchlorate concentrations above 5 µg/L to those in communities with no known drinking water perchlorate measurements above 5 µg/L. Perchlorate levels in community water sources were obtained for the years 1997 and 1998 from the California Drinking Water Program and used to estimate weighted average perchlorate concentrations in community water. TSH levels among 342,257 California newborns screened in 1998 were obtained from the California Department of Health Services. The major outcomes assessed in this study were primary congenital hypothyroidism (PCH) and the elevations in TSH typically used to screen for this disorder (i.e. a TSH > 25 μU/mL collected after the first 24 hours after birth). As discussed for the Kelsh et al. (2003) study above, PCH was defined as a TSH > 25 μU/mL and a physicians confirmatory diagnosis. Subjects who were screened before 24 hours of age were excluded from the analyses because the normal physiologic post-natal surge of TSH that occurs during this period can increase the rate of false positives when screening for PCH.

Overall, Buffler et al. (2006) reported an adjusted odds ratio for having a TSH > 25 μU/mL of 0.73 (95 percent CI, 0.40-1.23) comparing the high to low perchlorate communities. The corresponding odds ratio for PCH was 0.71 (95 percent CI, 0.40-1.19).
As discussed above, although TSH measurements collected within the first 24 hours of birth may not be the most appropriate for screening for PCH, levels collected during this time may be the most relevant for assessing associations between maternal drinking water perchlorate concentrations and changes in neonatal thyroid hormone levels that are less severe than those typically seen with PCH. The odds ratio for all subjects (those with TSH measured < 24 hours of age combined with those with TSH measurements at ≥ 24 hours of age) were not reported but can be estimated from the data given in Table 1 of their paper. The OR for a high TSH comparing communities with perchlorate concentrations above and below 5 µg/L in all subjects regardless of the age of measurement was 1.59 (95 percent CI, 1.33-1.91). The data used in these calculations are presented in Table 11.

Table 11. Data for Estimated Odds Ratio Calculations for All Subjects in Buffler et al. (2006)

<table>
<thead>
<tr>
<th>Perchlorate</th>
<th>Elevated</th>
<th>Normal</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 5 µg/L</td>
<td>147</td>
<td>50,179</td>
<td>50,326</td>
</tr>
<tr>
<td>&lt; 5 µg/L</td>
<td>537</td>
<td>291,394</td>
<td>291,931</td>
</tr>
<tr>
<td>Totals</td>
<td>684</td>
<td>341,573</td>
<td>342,257</td>
</tr>
</tbody>
</table>

Odds ratio = (147/50,179) / (537/291,394) = 1.59 (95% CI, 1.33-1.91)

Given the normal TSH surge that occurs in the first 24 hours after birth, we evaluated the possibility that this elevated odds ratio could be due to earlier TSH testing in the communities with perchlorate > 5 µg/L. An estimate of the percentage of neonates with TSH measurements before and after 24 hours can be obtained by subtracting the number of TSH levels measured at ≥ 24 hours (given in their Table 4) from the total number of TSH measurements (at any age) (given in their Table 1). These data are shown in our Table 12. (These are estimates since their Table 1 appears to include all subjects whereas their Table 4 appears to only include subjects who have all of the data on the co-variates used in their adjusted analyses).
Table 12. Subjects with TSH Measurements Before and After 24 Hours of Birth (Buffler et al., 2006)

<table>
<thead>
<tr>
<th></th>
<th>Perchlorate</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≤ 5 µg/L</td>
<td>&gt; 5 µg/L</td>
<td></td>
</tr>
<tr>
<td>Total subjects (Table 1)</td>
<td>291931</td>
<td>50326</td>
<td></td>
</tr>
<tr>
<td>High TSH (Table 1)</td>
<td>537</td>
<td>147</td>
<td></td>
</tr>
<tr>
<td>Total &gt; 24 hours (Table 4)</td>
<td>185528</td>
<td>29114</td>
<td></td>
</tr>
<tr>
<td>Percent</td>
<td>63.6%</td>
<td>57.9%</td>
<td></td>
</tr>
<tr>
<td>High TSH (Table 3)</td>
<td>124</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Percent with high TSH</td>
<td>0.067%</td>
<td>0.052%</td>
<td></td>
</tr>
<tr>
<td>Total &lt; 24 hours (calculated)</td>
<td>106403</td>
<td>21212</td>
<td></td>
</tr>
<tr>
<td>Percent</td>
<td>36.4%</td>
<td>42.1%</td>
<td></td>
</tr>
<tr>
<td>High TSH (Table 3)</td>
<td>413</td>
<td>132</td>
<td></td>
</tr>
<tr>
<td>Percent with high TSH</td>
<td>0.39%</td>
<td>0.62%</td>
<td></td>
</tr>
</tbody>
</table>

Based on these numbers, the percentage of all neonates with TSH measurements collected within the first 24 hours of birth was greater in the high perchlorate communities than in the low perchlorate communities (42.1 versus 36.4 percent). Importantly though, when analyses are confined to only those subjects with TSH measurements collected at < 24 hours of age, the odds ratio for a high TSH comparing communities with and without perchlorate > 5 µg/L remained high (OR = 1.60; 95 percent CI, 1.32-1.94). If age at measurement was an important confounder, we would have expected the odds ratio to be near 1.0 after stratifying by age. It seems unlikely that the entire 60 percent increase in risk would go away with an even more detailed stratification or adjustment by age of sample collection.

Steinmaus et al., 2010. In a very recent publication, the individual data were obtained from the Buffler et al. (2006) study, and analysis of these confirmed the elevated odds ratios discussed above. For example, the odds ratio for a TSH > 25 µU/mL in the first 24 hours of birth was 1.53 (p < 0.0001). For TSH levels collected after 24 hours of birth, the odds ratio for a TSH > 25 µU/mL was similar to that reported in Buffler et al. However, a TSH of 25 µU/mL was the 99.99th percentile of all TSH levels in this age strata and there were very few exposed cases (n = 13). Because significant neurologic effects have been seen with smaller changes in thyroid hormones (Pop et al., 1999, 2003; Haddow et al., 1999; Klein et al., 2001; Kooistra et al., 2006; Vermiglio et al., 2004), lower TSH cut-off points were also used to define a “high” TSH in this paper. When this was done, elevated odds ratios were seen both before and after 24 hours of age. For example, the odds ratio for having a TSH above the 95th percentile in samples collected after 24 hours of age comparing perchlorate exposed and unexposed communities was 1.27 (p < 0.0001). These analyses adjusted for age of sample collection, gender, mother’s age, per capita income, race/ethnicity, birth weight, and feeding type (breast vs. formula).

Li et al., 2001. This study was an ecologic analysis of various thyroid diseases comparing two counties in Nevada: Clark County, where average water perchlorate levels of around 0-14 ppb were reported, and Washoe County which has not had detectable
levels of perchlorate in its major drinking water supplies. The largest city in Washoe County is Reno and the largest city in Clark County is Las Vegas. Relative risks for 6 of the 8 diseases assessed comparing Clark County to Washoe County were above 1.0 (although none were statistically significant) including goiter (RR = 1.24), nodular goiter (RR =1.45), thyroiditis (RR=1.69), and other thyroid conditions (RR=1.89). Relative risks for congenital and acquired hypothyroidism were 0.60 and 1.01 respectively. Disease rates were based on Medicaid records which could be a very insensitive marker of the true rates of these diseases since only a fraction of the people in these counties are on Medicaid rolls.

Chang et al., 2003. In a similar study comparing Clark County (known to have elevated perchlorate levels in its drinking water) to the rest of Nevada, no differences were seen in the rates of pediatric neurobehavioral diseases including autism and attention deficit hyperactivity disorder assessed using Medicaid records. No difference was also seen in comparisons of 4th grade performance results, although the methods used in this study to assess both exposure and outcome are likely too inaccurate to identify subtle or even moderate effects.

Téllez Téllez et al., 2005. Neonatal and maternal thyroid function was assessed in subjects from the same three cities in northern Chile used in Crump et al. (2000). These cities (and their mean perchlorate levels in drinking water) were Taltal (100 to 120 µg/L), Chañaral (5-7 µg/L), and Antofagasta (non-detectable: <4 µg/L). No clear difference was seen in maternal thyroid hormone levels between the three cities (discussed in a subsequent section). In addition, no differences were seen across cities in mean neonatal cord blood fT4 (fT4) or TSH. Interestingly, 72.7 percent of the births in the high exposure city were males (compared to 49 percent in the low exposure city), and 57 percent of the births from the high exposure city were done by Caesarian section (compared to 39 percent in the low exposure city). The reasons for the unusually high proportion of males and the unusually high rate of Cesarean-sections in Taltal are unknown.

Mean concentrations of perchlorate in breast milk were similar in the high and low exposure cities (95.6 µg/L versus 81.6 µg/L), although these were highly variable within a city and the median levels were markedly different across cities (< 4 in Antofagasta and 104 µg/L in Taltal). No association was seen between breast milk iodine and perchlorate concentrations. Mean urinary iodine levels in the women were greater than 300 µg/L in all three cities, suggesting that very few women had low iodine intakes. As discussed below, relatively high iodine intakes may help prevent the thyroidal effects of perchlorate. The mean number of cigarettes smoked per week (0.52 for the 62 women in Taltal) suggested that few if any women were moderate or heavy smokers. In addition, differences in urinary levels of perchlorate were not as great as might be expected based on the perchlorate concentrations reported for the drinking water of each city. For example, maternal urine perchlorate concentrations measured during the post-partum visit for the low, medium, and high exposure cities were 22.3, 17.5, and 49.1 µg/L, respectively, although these measurements were only done in a fraction of the women in the study. A graphical display of the urinary perchlorate levels from all three cities shows a marked overlap across cities. Part of this may have been due to the fact that a large percentage of the women (45 percent) from the high exposure city of Taltal went to
the low exposure city of Antofagasta to give birth. Taltal (population about 10,000) is fairly remote and is about 200 miles away from the much larger city of Antofagasta (population about 250,000). Part of it may have been due to exposure from foods or some other unknown source in Antofagasta. Regardless of the cause, the lack of a large contrast in exposure between the subjects from each of the cities probably decreased the likelihood that true associations, if present, could be found.

Amatai et al., 2007. T4 values were measured in newborns in the neighboring cities of Ramat Hasharon and Hertzlia, Israel, whose mothers resided in areas where drinking water had perchlorate concentrations that were very high (340 µg/L, n = 97), high (42-94 µg/L, n = 216), and low (< 3 µg/L, n = 843). The high perchlorate concentrations were found in wells near a military plant. Heel-stick T4 values were measured in all newborns in these communities as part of the national screening program, and were done at 36-48 hours after birth in >90 percent of all newborns. Mothers also completed a questionnaire asking whether they had drunk tap water, filtered water, or bottled water during their pregnancy.

The mean T4 values in the very high, high, and low perchlorate areas (in µg/dL) were 13.93 (± 3.8), 13.91 (± 3.4), and 13.98 (± 3.5), showing no differences between the exposure areas. It is unclear if these means were adjusted for other factors associated with neonatal T4 levels including gender or the age of the child when the heel stick was taken. No association was seen with neonatal T4 and maternal age, birth weight, gestational age, or sex. No difference was seen in mean T4 values in the analysis confined to only the children of exposed women who reportedly drank tap water during pregnancy, although this included less than 30 percent (n = 93) of the women from the very high and high exposure areas.

Serum perchlorate levels were reported in this study on a small number of people who lived in the study areas and who were proxy donors (i.e., blood bank donors who were not involved in the actual study). Mean serum levels (in µg/L) in the very high, high, and low perchlorate areas in these subjects were 5.99 (± 3.89, n = 4), 1.19 (± 1.37, n = 19), and 0.44 (± 0.55, n = 14). As seen in Figure 3 of this paper, and in the reported standard deviations, there was considerable overlap in serum perchlorate among the three exposure categories. Serum iodine levels were also measured in the proxy donors. Serum iodine levels were higher in proxy subjects from the very high/high exposure areas compared to the low exposure area (3.10 µg/L ± 1.25 versus 2.24 µg/L ± 0.85; p = 0.031).

The strengths of this study are its collection of at least some individual data on exposure (i.e., the source of drinking water during pregnancy) and the presumably large contrast in perchlorate exposure. Urinary perchlorate levels would have likely provided a better indication of true exposure but were not measured. Other weaknesses are the lack of information on adjustments for potential confounders, the lack of individual data on smoking and iodine, and the relatively small number of women from the exposed areas who drank tap water during pregnancy. In addition, the authors reported that >90 percent of infants in these areas had their blood sampling at 36-48 hours after birth, suggesting that very few (probably < 4) of the highly exposed study infants had thyroid hormone measurements within the first 24 hours of birth. As discussed above, since the half-life of perchlorate and thyroid hormones is relatively short, this may have limited the ability of
this study to find an association between maternal perchlorate exposure during pregnancy and neonatal thyroid hormone levels.

**Summary of Studies of Perchlorate and Infant Thyroid Hormone Levels**

Table 13 summarizes the results of the most relevant studies of perchlorate exposure and newborn thyroid hormone levels. The Li et al. (2000) and Amatai et al. (2007) studies are excluded from this table because they did not include a substantial portion of subjects who had thyroid hormone levels measured within the first 24-36 hours after birth. As discussed above, this period is likely the most relevant time frame for assessing the effects related to maternal exposures during pregnancy. Téllez-Téllez et al. (2005) is excluded from the table because 45 percent of the newborns from the exposed city were born in the unexposed city and therefore were probably not exposed at the time of birth. The Téllez-Téllez et al. (2005) study is also inconsistent with the other studies in Table 13 because the very high iodine levels in this population may have protected the infants in this study from the effects of perchlorate.

As seen, every study in Table 13 found either a perchlorate-associated decrease in T4, an increase in TSH, or both. Several aspects of these findings provide evidence that they represent real effects. First, despite major differences in study populations, study designs, time periods, funding sources, and research groups, these results are markedly consistent across studies. This type of consistency across different studies is one of the major tenets of causal inference (Rothman and Greenland, 1998b). Second, several of these results have very low p-values, which means that they are probably not due to chance. Third, these findings are consistent with the known biologic mechanism of perchlorate. That is, these results show that perchlorate may decrease T4 and increase TSH, both of which are effects that are in the direction expected based on the known mechanism of action of perchlorate.

Several additional issues potentially affect the interpretation of these results.

**Ecologic assessment of perchlorate exposure:** Most of these studies used average perchlorate concentrations in large community drinking water supplies as a surrogate for exposure to the individuals in that community. In all of these studies, the reported perchlorate concentrations were based on a relatively small number of samples. Average perchlorate concentrations were then assigned to individuals without knowledge of whether or not they drank the tap water, how much they drank, or for how long they drank it. Importantly though, most of these studies were designed to collect information on perchlorate exposure using methods that were independent of the outcome of interest (i.e., thyroid hormone levels). This non-differential misclassification of exposure will generally bias results towards the null. That is, if an association truly exists, non-differential exposure misclassification will cause the magnitude of the observed association to be less than the magnitude of the true association. It will not cause a false association and will not strengthen an association that is truly weak. There are some rare exceptions to this rule, but these exceptions are not likely applicable to the studies in Table 13 (Rothman and Greenland, 1998a).

Despite this misclassification bias, which was likely present to some degree in every one of the studies we evaluated, each one of the studies in Table 13 still found evidence of an
association. If non-differential misclassification of exposure could somehow be corrected for in these studies, the effects found would likely be even greater than those reported.

Table 13. Studies of Maternal Perchlorate Exposure in Pregnancy and Thyroid Hormone Levels in Early Newborns

<table>
<thead>
<tr>
<th>Location and source of dataa</th>
<th>Exposed</th>
<th>Unexposed</th>
<th>Results: Exposed compared to the unexposed group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>T4</td>
</tr>
<tr>
<td>Redlands (Kelsh et al., 2003)</td>
<td>Redlands (9 ppb)</td>
<td>San Bernardino &amp; Riverside Co.</td>
<td>OR for low T4 = 1.18 (p &lt; 0.0001)</td>
</tr>
<tr>
<td>California (Steinmaus et al., 2010)</td>
<td>Exposed communities (&gt; 5 ppb)</td>
<td>Unexposed communities (&lt; 5 ppb)</td>
<td>No data</td>
</tr>
<tr>
<td>Arizona (Brechner et al., 2000)</td>
<td>Yuma (4-6 ppb)</td>
<td>Flagstaff</td>
<td>OR for low T4 = 1.18 (p = 0.006)</td>
</tr>
<tr>
<td>Nevada (Li et al., 2000a)</td>
<td>Las Vegas (0-9 ppb)</td>
<td>Reno</td>
<td>Mean T4 ≈ 22% lower</td>
</tr>
<tr>
<td>Chile (Crump et al., 2000)</td>
<td>Taltal (100 ppb)</td>
<td>Antofagasta and Chañaral (0-5 ppb)</td>
<td>No data</td>
</tr>
</tbody>
</table>

Excluded studies

<table>
<thead>
<tr>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Téllez Téllez et al., 2005</td>
</tr>
<tr>
<td>Li et al., 2000b</td>
</tr>
<tr>
<td>Amatai et al., 2007</td>
</tr>
</tbody>
</table>

*aSome the findings presented in this table were not reported in the original articles but were calculated by OEHHA based on the data provided.

Confounding: Another potential problem with several of these studies is that some potential confounding factors were either not controlled for or were only partially controlled for. For example, in the analyses of thyroid hormone levels in Las Vegas and Reno newborns (Li et al., 2000b), ethnic differences were not accounted for. In studies reported by DHS (1997), Lamm and Doemland (1999), and Li et al. (2000b), control for age after birth was either not done or may have been inadequate. Since serum T4 and
TSH levels are known to change significantly during the first 24 hours after birth, knowing the age at sampling (in hours) could be very important in this type of study.

Several studies did adjust for some potentially important confounders and found that these adjustments generally had little effect. Other variables such as polychlorinated biphenyls (PCBs) or anti-thyroid antibodies can affect thyroid hormone levels and were not adjusted for in these studies (Charnley, 2008). However, in order to cause important confounding, a variable must be relatively strongly related to both the outcome (e.g., T4 level) and the exposure (perchlorate) (Axelson, 1978). Since there is no evidence or biologic rationale linking these variables to perchlorate exposure, the likelihood that they caused major confounding is small. It is also possible that factors like PCBs and anti-thyroid antibodies were not confounders but were effect modifiers like iodine or thiocyanate. If this is the case, infants with these factors would be even more susceptible to perchlorate than indicated by the findings in Table 13.

**Study size:** Several of these studies involved a very large number of study subjects [Kelsh *et al.* (2003), Brechner *et al.* (2000), and Buffler *et al.* (2006)], and the p-values are less than 0.001. This means that the probability that these findings are due to chance is less than one in one thousand. In Brechner *et al.* (2000), although the odds ratio for a low T4 was somewhat small (OR = 1.18), the p-value was 0.006, which means that the probability that this finding was due to chance is about 6 in 1000.

A lack of statistical power may have affected some of the smaller studies. If relative risks are expected to be fairly low (e.g., less than 2.0), large sample sizes are needed to detect statistically significant associations. The small sample sizes and relatively low prevalence rates of the outcomes of interest of some studies might have limited their ability to identify true effects.

**Subject selection:** There is a concern about the way the neonate blood samples were selected for TSH determination in the studies reported by Brechner *et al.* (2000), Kelsh *et al.* (2003), and Li *et al.* (2000b). In these studies, TSH levels were only measured in newborns who had low T4 levels. The TSH findings of these studies are still important, however, because they indicate that the risk of having both a low T4 and a corresponding high TSH is greater in newborns from perchlorate-exposed areas than in newborns from unexposed areas. This is important since people with both a low T4 and a high TSH are more likely to have real thyroid effects than people with just a high TSH. For example, a high TSH reading in a person who does not have a correspondingly low T4 could just reflect normal intra- or inter-individual variability, or laboratory or collection error. Regardless, in each of these studies, T4 was measured in all subjects and at least some evidence was seen in each study that perchlorate was associated with a decreased T4. Given the known relationship between T4 and TSH, these decreases in T4 levels are biologically consistent with the reciprocal increases in TSH that were reported. This consistency provides evidence that the associations identified between perchlorate and increased TSH are real effects and are not solely due to bias from selective TSH sampling.

**Other susceptibility factors not accounted for:** Another important issue in these studies is the overall lack of data on co-variates that might interact with perchlorate to impact thyroid function. None of these studies specifically investigated potentially susceptible
subpopulations such as people who have low iodine intakes, smokers, people with anti-thyroid antibodies, or people with high intakes of nitrate or thiocyanate from foods. Risks of thyroid-related effects may be greater in these groups than in the general population samples that were used in the studies in Table 13.

The TSH surge: For the reasons discussed above, the first 24 hours after birth may be the most relevant period for assessing associations between maternal perchlorate exposure during pregnancy and newborn thyroid hormone levels. One potential complicating factor of measurements collected during this time is the normal physiologic surge in TSH that occurs soon after birth. The exact causes of this surge are unknown, but mechanisms related to cold exposure, the shock of birth, or an acute drop in maternal T4 have been proposed. As shown in Figure 5, TSH levels surge right after birth, typically peak at 30 minutes, then gradually fall to normal levels in the next 24-48 hours (Fisher and Klein, 1981). Several authors have warned against measuring TSH levels during this period because it can lead to an increased rate of false positives when screening for congenital hypothyroidism. In other words, many children who have TSH reading above 25 µU/mL (the traditional cut-off point for this diagnosis) during the first 24 hours, may have normal TSH readings a few days later and not require treatment for congenital hypothyroidism.

However, a clinical diagnosis of congenital hypothyroidism is not the only outcome that should be assessed when looking at the possible impacts of perchlorate. This diagnosis is generally associated with very large changes in thyroid hormone levels and severe effects if untreated. As discussed above, much more subtle changes in thyroid hormones have been associated with cognitive effects in children in several studies (Pop et al., 1999, 2003; Haddow et al., 1999; Klein et al., 2001; Kooistra et al., 2006; Vermiglio et al., 2004). That is, small changes in thyroid hormone levels that are within normal reference ranges have been associated with significant decreases in IQ in children that were not clinically hypothyroid and showed no other evidence of thyroid problems. If researchers only focus on the more severe effect levels that are associated with most cases of congenital hypothyroidism, these more subtle effects will be missed. For this reason, researchers should not only evaluate whether perchlorate is associated with clinically treatable congenital hypothyroidism (and the large TSH changes associated with this diagnosis), but should also investigate whether perchlorate is associated with even smaller changes in thyroid hormone levels. In this regard, while the studies in Table 13 provide little evidence that perchlorate increases the rate of clinical congenital hypothyroidism, they do provide evidence that perchlorate is associated with more subtle changes in newborn thyroid hormone levels.

Health consequences are unknown: The long-term health consequences of the effects seen in Table 13 are unknown. As discussed below, subtle changes in maternal thyroid hormone levels during pregnancy have been linked to cognitive effects in the offspring. This suggests that the fetus is highly sensitive to any changes in thyroid hormone levels during pregnancy. It is unknown whether the neonate is similarly sensitive.

It is possible that the effects seen in Table 13 are also occurring in the fetus. This possibility is consistent with the well-established mechanism of perchlorate, by which a long-term continuous exposure would be expected to cause continuous effects on the thyroid. That is, if the mother is consuming drinking water contaminated with
perchlorate during pregnancy, it would be expected that the fetus would be exposed to perchlorate during pregnancy and that some perchlorate would be present in the newborn immediately after birth. If this perchlorate exposure can lead to altered thyroid hormone levels in the newborn (as shown in Table 13), it seems likely that it is also doing so in the fetus. If perchlorate does impact thyroid hormone levels in the fetus, it may cause the same cognitive developmental impacts seen in the studies of maternal thyroid hormone changes during pregnancy (Pop et al., 1999, 2003; Haddow et al., 1999; Klein et al., 2001; Kooistra et al., 2006; Vermiglio et al., 2004). Whether or not this is the case is currently unknown, and further research is needed to determine if the effects seen in Table 13 are truly associated with long-term health outcomes.

It is possible that the effects reported in Table 13 are simply temporary effects that occur in the day-old newborn and do not occur in the fetus or older child. For example, it is possible that perchlorate somehow only affects the TSH surge, and either does not affect the thyroid at all (i.e., an extra-thyroidal mechanism), or does not affect the thyroid before or after the surge. There are several reasons to believe that this is not the case. First, the data in Table 13 are not consistent with an extra-thyroidal mechanism. If perchlorate were simply causing an increase in TSH by some extra-thyroidal process (that is, without first causing a low T4), then this increase in TSH would be expected to cause an increase in T4 levels. This was not seen. Instead, a perchlorate-associated decrease in T4 levels was seen in several studies. This suggests that the TSH effects are due to a perchlorate-associated inhibition of T4 production and a direct action on the thyroid gland. Second, TSH peaks about 30 minutes after birth (Figure 5), and the effects reported in Table 13 mostly involve measurements taken after the major part of this peak. For example, in Buffler et al. (2006), of all the newborns who had TSH levels measured in the first 24 hours after birth, less than one percent had measurements within the first three hours of birth. This small fraction suggests that any measurements collected during the highest points of the TSH peak had little impact on the Table 13 results. Finally, as discussed above, the hypothesis that the results seen in Table 13 simply represent a short-term temporary effect that occurs only in the day-old newborn (and not in the fetus) is inconsistent with the well-established mechanism in which a continuous dose of perchlorate is known to cause a continuous suppression of iodide uptake and a continuous suppression of thyroid hormone production. Given the abundance of data supporting this mechanism, it seems somewhat implausible that some new and completely unknown mechanism, with no evidence to support it, would be causing these effects.

In summary, the data in Table 13 provide a consistent body of evidence linking perchlorate exposure during pregnancy with changes in thyroid hormone levels in the newborn. Currently, the long-term health implications of these effects are unknown. However, given the known mechanism of perchlorate, these effects may represent effects that are also occurring during the fetal period, which is a critical period of thyroid-hormone-dependent brain development.
Figure 5. Changes in Serum Neonatal T4 and TSH Levels by Hour after Birth (Abuid et al., 1973; Cavallo et al., 1980; Fisher and Odell 1969; Sack et al., 1976) [Data are compiled from averaged individual thyroid hormone measurements from the cited studies from infants with blood collected at different times].

Endocrine Toxicity

Clinical Dosing Studies

Stanbury and Wyngaarden, 1952. These investigators studied the effect of perchlorate on the discharge and uptake of iodide by the thyroid in Graves’ disease patients. To study the effect of perchlorate on the discharge of accumulated iodine, they gave 30 mg of 1-methyl-2-mercaptoimidazole orally to eight patients. A dose of 200 mg of propylthiouracil was given to a ninth patient. One hour later, a tracer of I^{131} was given. The accumulation of this isotope in the neck was recorded at frequent intervals until it leveled off. At this point, potassium perchlorate doses varying from 3 to 500 mg were given orally in small volumes of water. In each patient except the one treated with propylthiouracil there was a sharp fall in the counting rate within a few minutes after the ingestion. This always occurred within 30 minutes. With smaller doses the discharge of the I^{131} was incomplete, but doses of 100 mg caused a fall in counting rates nearly equal to the counting rates recorded from the thigh (background). The investigators also reported that a single oral dose of 10 mg perchlorate caused about a 50 percent release of accumulated iodine. Potassium perchlorate doses as low as 3 mg (equivalent to 2.2 mg perchlorate) caused detectable, but incomplete, release of iodide from the thyroid. Assuming an adult body weight of 70 kg, this is equivalent to an oral dose of 31 µg/kg.

A LOAEL is not identified for this experiment because: (a) the number of patients per dose group is not known; (b) it is an acute exposure; (c) the patients suffered from a thyroid disease which might have affected iodide uptake; and (d) the patients were pretreated with drugs (either 1-methyl-2-mercaptoimidazole or propylthiouracil) that may
enhance the release of iodide in the thyroid gland by preventing the oxidation of iodide ion to iodine and thyroid hormone synthesis.

To study the effect of perchlorate on the uptake of iodide in the unblocked gland, Stanbury and Wyngaarden (1952) gave 100 mg of potassium perchlorate to three patients and an hour later, tracers of I\textsuperscript{131}. No thyroid hormone-disrupting drugs were given. Several days later each patient received a control tracer without previous perchlorate. In two cases, the studies were continued for 48 hours, but in the third, an observation period of only five hours was possible after the tracer. For the two patients with the long observation time, the control uptake was about 70 percent of the administered dose at 24 and 48 hours. When the patients were pretreated with potassium perchlorate, the uptakes were approximately 12 percent and 21 percent of the administered dose at 24 and 48 hours following the administration of the tracer.

The duration of the inhibition of iodide uptake after the oral administration of 100 mg of potassium perchlorate (71.8 mg of perchlorate) appeared to be about six hours. Beyond six hours, accumulation of I\textsuperscript{131} commenced. Durand (1938; as cited in Stanbury and Wyngaarden, 1952) found that at this time approximately half the administered dose of perchlorate has been excreted in the urine.

A LOAEL is not identified for this experiment because: (a) there were only two subjects that completed the experiment; (b) acute exposure; and (c) the patients suffered from a thyroid disease which might have affected iodide uptake by the thyroid.

**Godley and Stanbury, 1954.** This study reported using potassium perchlorate to treat 24 patients with Graves’ disease. Patients were treated with 600 to 1,200 mg/day for at least 11 weeks with a few as long as 52 weeks. Thirteen patients had determinations of the uptake of radioactive iodine by the thyroid both before beginning perchlorate therapy and within two weeks after medication had begun. The mean control uptake was 77.5 percent, with a range from 60.7 to 108 percent. The mean uptake during perchlorate therapy was 15.9 percent, with a range from 3.4 to 38.8 percent.

**Bürgi et al., 1974.** This investigation studied the effects of perchlorate treatment on the release of endogenous iodine from the thyroid glands of five normal healthy volunteers (three females and two males). The volunteers were given I\textsuperscript{125}-labeled iodide and I\textsuperscript{131}-labeled T\textsubscript{4} for seventeen days, followed by 3 x 200 mg/day (9.7 mg/kg-day) perchlorate for eight days. Analysis for the two tracers in the urine and serum of the subjects showed that this dose was sufficient to totally block iodide uptake by the thyroid. Additionally, the perchlorate treatment caused an increase in excretion of non-thyroxine iodine of 65 percent above background.

**Brabant et al., 1992.** In this study five healthy male volunteers were pretreated with 200 µg/day iodine for four weeks before perchlorate exposure. Iodine exposure was discontinued, and the volunteers were given 3 x 300 mg/day of perchlorate for another four weeks. Serum levels of T\textsubscript{3} and T\textsubscript{4} were measured at the end of the four-week perchlorate-dosing period. Perchlorate treatment had no effect on serum T\textsubscript{3} or T\textsubscript{4} levels or on thyroid gland volume. However, serum fT\textsubscript{4} and TSH levels were significantly diminished by treatment, and thyroglobulin serum levels were almost doubled, indicating the stress of the treatment on the thyroid hormone balance. The perchlorate treatment also reduced intrathyroidal iodine levels.
In a follow-up study, Brabant et al. (1994, as cited in U.S. EPA, 2002) repeated the earlier studies with perchlorate treatment lasting longer than 4 weeks. As a result of the longer treatment, thyroid volumes increased in all subjects, although TSH levels did not increase.

**Lawrence et al., 2000.** The investigators administered perchlorate to nine healthy male volunteers and monitored the impact on thyroid function. Each subject ingested 10 mg of perchlorate (as potassium perchlorate) dissolved in a liter of spring water for 14 days. Baseline serum TSH, total T4, total T3, 24-hour thyroid $^{123}$I uptakes, serum and 24-hour urine perchlorate, and 24-hour urine iodine were determined. All blood and urine tests were repeated on days 7 and 14 of perchlorate administration, and 24-hour thyroid $^{123}$I uptakes on day 14 of perchlorate administration. All tests were repeated 14 days after perchlorate exposure was discontinued. No effect of perchlorate was observed on serum T4, T3 and TSH (Table 14). It should be noted that the dietary iodine intake levels of the subjects were rather high, as indicated by the high urine iodine values (Table 15).

Because iodide and perchlorate compete for the same receptor site on the sodium-iodide symporter (Wolff, 1998), a high dietary iodide intake may reduce the impact of perchlorate on the thyroid. There was no statistically significant difference in serum perchlorate levels after 7 days and 14 days of exposure, indicating no apparent accumulation of perchlorate in the systemic circulation over that period.

### Table 14. The Effect of Perchlorate Administration (10 mg/day, about 0.14 mg/kg-day) for 7 and 14 Days on Thyroid Function Tests (Lawrence et al., 2000)

<table>
<thead>
<tr>
<th>Time</th>
<th>$T_4$ (µg/dL)</th>
<th>$T_3$ (ng/dL)</th>
<th>TSH (µU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>6.6 ± 0.4</td>
<td>136 ± 6</td>
<td>1.05 ± 0.14</td>
</tr>
<tr>
<td>Day 7 of perchlorate</td>
<td>6.7 ± 0.4</td>
<td>140 ± 8</td>
<td>1.00 ± 0.17</td>
</tr>
<tr>
<td>Day 14 of perchlorate</td>
<td>6.6 ± 0.5</td>
<td>151 ± 6</td>
<td>0.96 ± 0.12</td>
</tr>
<tr>
<td>14 days after perchlorate</td>
<td>6.5 ± 0.5</td>
<td>157 ± 9</td>
<td>1.23 ± 0.17</td>
</tr>
</tbody>
</table>

Values are mean ± standard error.

### Table 15. Urine and Serum Perchlorate and Iodine Values Before, During, and After Ingestion of 10 mg Perchlorate (about 0.14 mg/kg-day) for 14 Days (Lawrence et al., 2000)

<table>
<thead>
<tr>
<th>Time</th>
<th>Urine perchlorate (mg/24 hr)</th>
<th>Serum perchlorate (µg/mL)</th>
<th>Urine iodine (µg/24 hr)</th>
<th>Serum iodine (µg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>&lt;0.5</td>
<td>0</td>
<td>254 ± 69</td>
<td>6.5 ± 0.42</td>
</tr>
<tr>
<td>Day 7 of perchlorate</td>
<td>7.7 ± 0.8</td>
<td>0.61 ± 0.02</td>
<td>233 ± 49</td>
<td>6.2 ± 0.34</td>
</tr>
<tr>
<td>Day 14 of perchlorate</td>
<td>7.5 ± 1.0</td>
<td>0.59 ± 0.02</td>
<td>385 ± 123</td>
<td>6.4 ± 0.37</td>
</tr>
<tr>
<td>14 days after perchlorate</td>
<td>&lt;0.5</td>
<td>0</td>
<td>208 ± 42</td>
<td>6.3 ± 0.57</td>
</tr>
</tbody>
</table>

Values are mean ± standard error.
Lawrence et al. (2000) also reported that during perchlorate ingestion, there was a highly significant decrease in the thyroid $^{123}$I uptakes at all three time points. In each instance, 150 µCi $^{123}$I was administered to a subject and thyroid iodide uptake was measured at 4, 8, and 24 hours. The average decrease below baseline values over all three time points was 38 percent. Two weeks after perchlorate was discontinued, the 24-hour thyroid $^{123}$I uptakes were significantly higher than baseline at 4, 8, and 24 hours (Table 16).

Table 16. Thyroid $^{123}$I Uptakes Before, During, and After Ingestion of 10 mg Perchlorate (about 0.14 mg/kg-day) Daily for 14 Days (Lawrence et al., 2000)

<table>
<thead>
<tr>
<th>Time</th>
<th>Thyroid $^{123}$I uptake–baseline (% of dose)</th>
<th>Thyroid $^{123}$I uptake 14 days on perchlorate (% of dose)</th>
<th>Thyroid $^{123}$I uptake 14 days after perchlorate was discontinued (% of dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 hours</td>
<td>12.5 ± 1.3</td>
<td>8.2 ± 0.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16.6 ± 2.4&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>8 hours</td>
<td>17.3 ± 1.9</td>
<td>10.6 ± 1.0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>21.9 ± 2.8&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>24 hours</td>
<td>23.6 ± 2.6</td>
<td>14.0 ± 1.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>27.1 ± 3.3&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>p < 0.01 vs. baseline and after perchlorate treatment was discontinued  
<sup>b</sup>p < 0.01 vs. baseline  
<sup>c</sup>p < 0.05 vs. baseline  
Values are mean ± standard error

Lawrence et al., 2001. In a follow-up study, Lawrence et al. (2001) administered a daily oral dose of 3 mg to a group of eight healthy male volunteers for 14 days. They reported that the mean 8-hour thyroid radioactive iodine uptake decreased from 13.1 percent to 11.8 percent during perchlorate ingestion. Similarly, the 24-hour thyroid radioactive iodine uptake decreased from 16.1 percent to 14.5 percent, a 10 percent decrease that was not statistically significant. Assuming a default body weight of 70 kg, the dose used in this study is estimated to be 0.043 mg/kg-day.

Greer et al., 2002. Daily oral doses of perchlorate ($\text{ClO}_4^-$) dissolved in 400 mL of water were given to groups of euthyroid human volunteers for 14 days. Subjects (4 male and 4 female; 18-57 years old) of each dose group were exposed to a daily dose of 0.02, 0.1, or 0.5 mg/kg of perchlorate (approximately 1.4, 7, or 35 mg, assuming 70 kg body weight). In a follow-up study, one additional subject of each sex received perchlorate at 0.02, 0.1, or 0.5 mg/kg-day, while six women and one man received a dose of 0.007 mg/kg-day. Subjects drank 100 mL of the perchlorate solution at 4 set times throughout each day. Measurement of 8- and 24-hour $^{123}$I thyroid uptakes was performed prior to perchlorate exposure (baseline), on exposure days 2 and 14, and on post-exposure day 15. There was a strong correlation between the 8- and 24-hr uptakes over all dose groups and measurement days. There was no difference between exposure days 2 and 14 in the inhibition of uptake produced by a given perchlorate dose. There was no sex difference. Uptakes measured on post-exposure day 15 were not significantly different from baseline. Table 17 provides the 24-hour thyroid radioiodine uptake data by dose. The researchers measured total T4, fT4, total T3, and TSH in blood sampled throughout the study, and found them to be in the normal range for all subjects. One woman in the lowest dose group had abnormally high TSH on both the screening visit and on exposure day 14. Because of the limited data in the follow-up study, analysis of treatment effects
on hormonal levels was confined to the 24 volunteers in the first study. Greer et al. (2002) reported no association between perchlorate dose and thyroid hormone levels except a marginally statistically significant association of TSH in the 0.5 mg/kg-day dose group.

Table 17. Descriptive Statistics for the 24-hour Thyroid Radioiodine Uptake Data from Greer et al., 2002

<table>
<thead>
<tr>
<th>Dose group</th>
<th>Time</th>
<th>Number of subjects in dose group</th>
<th>24-hr uptake (mean ± standard error)</th>
<th>Raw (%)</th>
<th>% of baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.007 mg/kg-day</td>
<td>Baseline visit</td>
<td>7</td>
<td>18.1 ± 3.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.007 mg/kg-day</td>
<td>Exposure day 14</td>
<td>7</td>
<td>16.5 ± 1.6</td>
<td>98.2 ± 8.3</td>
<td></td>
</tr>
<tr>
<td>0.02 mg/kg-day</td>
<td>Baseline visit</td>
<td>10</td>
<td>18.4 ± 1.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.02 mg/kg-day</td>
<td>Exposure day 14</td>
<td>10</td>
<td>15.2 ± 1.1</td>
<td>83.6 ± 4.1</td>
<td></td>
</tr>
<tr>
<td>0.1 mg/kg-day</td>
<td>Baseline visit</td>
<td>10</td>
<td>19.9 ± 2.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1 mg/kg-day</td>
<td>Exposure day 14</td>
<td>10</td>
<td>11.0 ± 1.6</td>
<td>55.3 ± 3.9</td>
<td></td>
</tr>
<tr>
<td>0.5 mg/kg-day</td>
<td>Baseline visit</td>
<td>10</td>
<td>21.6 ± 2.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5 mg/kg-day</td>
<td>Exposure day 14</td>
<td>10</td>
<td>6.9 ± 0.9</td>
<td>32.9 ± 3.8</td>
<td></td>
</tr>
</tbody>
</table>

Braverman et al., 2006. This investigation was a double blinded, randomized clinical dosing study in which 14 healthy volunteers received either placebo, or 0.5 mg, 1 mg, or 3.0 mg of potassium perchlorate once per day for six months. Nine of the subjects were women. Serum thyroid hormone and perchlorate levels, and urine perchlorate, iodine, and creatinine levels were measured monthly. Twenty four hour radioactive iodine uptake (RAIU) was measured at baseline, and at 3 and 6 months of perchlorate ingestion, and one month after dosing was discontinued.

The mean urinary perchlorate level in the five subjects who received 0.5 mg/day was 332.7 µg (± 66.1) per 24 hours. The corresponding amount in the four subjects who received 3 mg/day of perchlorate was 2079 µg (± 430) per 24 hours. Only one subject receiving the 1 mg dose completed the study and data on this subject was not reported. There were no significant changes in RAIU, T4, FTI, or TSH during or after the dosing period. The mean urinary iodine level in the 3 mg group was very high before the dosing started (322 µg/g creatinine; SD ± 357). This dropped to 192.8 µg/g (SD ± 110.1) one month after the dosing period. The large standard deviation suggests that this could be due to one outlying value, although the individual data on iodine were not shown.

The reason why this study did not find impacts on RAIU similar to other studies is unknown, although the authors note that this could be due to the small number of subjects, differences in dosing regimens (once daily versus semi-continuous), or the up-regulation of the NIS as an adaptive response to long-term exposure.

Occupational Studies
**Gibbs et al., 1998.** This study monitored triiodothyronine resin uptake (T3U), total serum T4, free T4 index (FTI) and TSH levels in 18 workers occupationally exposed to ammonium perchlorate in air before and after a work shift. They also similarly monitored 83 workers who were not exposed. Based on the thyroid function test results collected, the authors concluded that exposure to a mean of 36 µg/kg-day ammonium perchlorate (ranging from 0.2 to 436 µg/kg-day) was not a significant predictor of the cross-shift change in any of the thyroid parameters. Given the relatively long serum half-life of T4 in adult humans (5-9 days) (U.S. EPA, 1998b), it would be very unlikely that serum T4 levels would exhibit a change over a single work shift.

Gibbs et al. (1998) also evaluated the thyroid function test results of workers exposed to ammonium perchlorate based on their working-lifetime dose estimates. They reviewed personnel records and employees were interviewed to determine the number of years worked in each of the seven exposure groups. An average of 2,000 hours worked yearly was assumed. Each subject’s working-lifetime cumulative dose was then estimated as:

\[ \sum [\text{mean group exposure}] \times [\text{years in exposure group}] \times 2,000 \]

No significant correlations with estimated lifetime cumulative perchlorate dose were detected with any of the thyroid function measures (T3U, T4, FTI, and TSH levels). However, the tenure of the workers ranged from 1 to 27 years, while thyroid hormone levels are most likely to be affected by relatively recent perchlorate exposures (probably in the range of 1-3 months). Because of this, cumulative dose over a long period of time may not be the best metric for characterizing the effect of perchlorate exposure on thyroid hormone levels.

**Lamm et al., 1999.** This is a cross-sectional study of two similar worker populations from the same industrial complex: ammonium perchlorate production workers and sodium azide production workers. A total of 37 workers were exposed to airborne ammonium perchlorate, 35 males and two females. Twenty-one workers from the azide production plant served as the control group. Perchlorate exposure was measured using full-shift breathing zone personal air samplers for total as well as respirable perchlorate particles. Urinary perchlorate concentration was assessed at the beginning and end of the 12-hour shift in which the perchlorate exposure was measured. Post shift serum samples were collected for measurements of T4, T3, TSH, and anti-thyroid antibodies. The authors reported that there were no differences in thyroid function tests between workers in the azide and perchlorate plants or between the azide workers and any of the three perchlorate-exposure groups (Table 18). Based on these data, a NOAEL of 0.48 mg/kg-day (33.6 mg/day divided by 70 kg) can be estimated. However, this data set has several limitations: (a) small sample size, (b) high dietary iodine intake among the workers, and (c) given the short biological half-life of perchlorate (approximately 8 hour), the exposed workers might recover from the effects of perchlorate during off-shift hours. Using the medical examination and questionnaire findings, Lamm et al. (1999) reported that worker exposures to perchlorate in the plant were not found to be associated with thyroid abnormalities.
Table 18. Perchlorate Exposures and Thyroid-Function Parameters, by Plant and Exposure Groups (Adapted from Lamm et al., 1999)

<table>
<thead>
<tr>
<th>Group</th>
<th>Total airborne perchlorate (mg/day)</th>
<th>Respirable airborne perchlorate (mg/day)</th>
<th>Absorbed dose (mg/shift)*</th>
<th>T4 (µg/dL)</th>
<th>T3 (ng/dL)</th>
<th>TSH (µU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal range</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azide worker</td>
<td>0.014±0.012 (n=4)</td>
<td>0.021±0.014 (n=6)</td>
<td>0.88±1.17 (n=21)</td>
<td>6.73±1.48 (n=21)</td>
<td>142.5±17.5 (n=21)</td>
<td>3.14±1.87 (n=21)</td>
</tr>
<tr>
<td>Perchlorate worker A</td>
<td>0.337±0.187 (n=6)</td>
<td>0.091±0.095 (n=11)</td>
<td>3.98±2.69 (n=14)</td>
<td>7.13±1.58 (n=13)</td>
<td>148.4±25.2 (n=13)</td>
<td>2.68±1.14 (n=12)</td>
</tr>
<tr>
<td>Perchlorate worker B</td>
<td>6.57±7.14 (n=2)</td>
<td>0.601±0.671 (n=7)</td>
<td>10.9±8.7 (n=8)</td>
<td>7.34±1.12 (n=8)</td>
<td>152.1±23.2 (n=8)</td>
<td>2.41±1.27 (n=8)</td>
</tr>
<tr>
<td>Perchlorate worker C</td>
<td>59.4±53.6 (n=12)</td>
<td>8.59±9.39 (n=14)</td>
<td>33.6±14.5 (n=14)</td>
<td>7.03±1.30 (n=15)</td>
<td>152.1±20.4 (n=15)</td>
<td>3.33±2.34 (n=15)</td>
</tr>
</tbody>
</table>

*Derived from urinary perchlorate concentration
Values are mean ± standard deviation

**Braverman et al., 2005.** This was an investigation of RAIU and thyroid hormone levels in 29 workers employed in the same perchlorate production facility used in Lamm et al. (1999) and in 12 volunteers who did not work at the plant. All subjects were Caucasian males, and eight workers and two controls were smokers. The normal schedule for employees at the plant was to work three 12 hours shifts on three consecutive days and then have three days off work. Serum levels of perchlorate, thiocyanate, nitrite, T3, T4, FTI, and TSH and urine concentrations of perchlorate and iodine were measured just before (pre-shift) and just after (post-shift) the three day shift. Mean serum perchlorate levels in the workers increased from 2 µg/L to 838 µg/L from pre-shift to post-shift. RAIU decreased from 21.5 percent pre-shift to 13.5 percent post-shift (p-value for the difference < 0.01). The authors estimated perchlorate intakes based on differences in pre- and post-shift serum levels and used these estimates to plot dose-response relationships with RAIU. Figure 4 of their paper shows that perchlorate and RAIU relationship in this study was similar to that reported in Greer et al. (2002) and Lawrence et al. (2000, 2001). Interestingly, the RAIU levels in the non-worker control subjects (14.4 percent) was significantly lower than the pre-shift level of the workers (p < 0.01) and very similar to that of the post-shift level of the workers. The reason for this is unknown, although the authors note that this might be consistent with an apparent rebound increase in RAIU that has been noted in other studies. Post-shift workers had a slight but statistically significant increase in T3, T4, and FTI. The reason for this is unknown, although the authors hypothesize it may be due to a decreased iodine concentration in the thyroid enhancing the thyroid’s response to TSH.

Although serum levels of thiocyanate and nitrate and urinary levels of iodine were measured, no data were presented on possible interactions between these variables and perchlorate on RAIU or thyroid hormone levels. The authors reported that exposure caused no statistically significant change in serum thiocyanate and nitrate levels but was
associated with a statistically significant increase in urinary iodine:creatinine ratio. The pre-shift vs. just-after-shift means were 148 µg/g and 230 µg/g, respectively (p = 0.02). The mean urinary iodine:creatinine ratio in controls was 296 µg/g. The authors hypothesize that the increase in urinary iodine might have been a result of less dietary iodine being concentrated in the thyroid with perchlorate exposure.

Environmental Studies

Téllez Téllez et al., 2005. Neonatal and maternal thyroid function was assessed in subjects from the following three cities (mean perchlorate levels in drinking water) in northern Chile: Taltal (100 to 120 µg/L), Chañaral (5-7 µg/L), and Antofagasta (non-detectable: <4 µg/L). The neonatal results are discussed in a preceding section. Serum fT4 and TSH measurements were collected from 184 women at two prenatal visits and one post-partum visit. No difference in mean fT4 or TSH was seen across the three cities at any of the three visits. For example, on the first prenatal visit (a mean of about 16 weeks gestation), the mean fT4 (in ng/dl) in the low, medium, and high perchlorate cities were 0.97 (SD ± 0.15), 0.95 (± 0.13), and 0.99 (± 0.13) (Kruskal-Wallis p = 0.19). Regression analyses showed no association between urinary perchlorate excretion and levels of fT4, TSH, and T3, although details of this analysis, such as whether urine concentrations were adjusted for urine dilution, or whether perchlorate concentrations were log transformed, were not reported. Maternal goiter was seen in all cities and increased from the first prenatal visit to the post-partum visit in both Taltal and Antofagasta, although the increase was greater in Taltal (from 9.4 percent to 22.5 percent) than in Antofagasta (from 8.7 percent to 11.1 percent).

As discussed in the section reviewing the neonatal findings of this study, maternal iodine levels were very high and it is possible that this may have protected the infants and the mothers from the impacts of perchlorate. Other factors that were also discussed above include: 1) similarity of the urinary perchlorate concentrations across the unexposed, low, and high exposure cities; 2) Cesarean-section rates were markedly different across cities. (Cesarean section rates may impact chemical-thyroid hormone associations (Herbstman et al., 2008)) ; 3) 45 percent of women from the exposed city gave birth in the unexposed city; and 4) there were few smokers (a common source of thiocyanate) and no data on thiocyanate levels. As discussed below, iodine, thiocyanate, and smoking may be important susceptibility factors in perchlorate-exposed women.

Gibbs and Landingham, 2008. This study involved a re-analysis of the data collected in the Téllez Téllez et al. (2005) study. In the previous paper, a regression analysis was done but very few results and details were provided. Most of the results presented in the previous paper were comparisons of mean thyroid hormone levels in each of the three cities. This may have diminished the ability of the study to identify a true effect since there was substantial overlap in urinary perchlorate concentrations across the cities. In the 2008 paper, Gibbs and Landingham used individual data on urine perchlorate, urine iodine, serum fT4 and TSH, and an interaction term for iodine and perchlorate in a linear regression analysis involving 150 women from the previous study. fT4 was entered into the model as fT4 unchanged or as 1/fT4². The latter was used in order to achieve a normal distribution of the residuals, which is an assumption of the linear regression model. No associations were identified between urine perchlorate and fT4 or TSH. In
addition, no associations were found in analyses restricted to subjects with urinary iodine levels below 100 µg/L, although this included only 16 subjects. Interestingly, in the analysis using the normalized fT4 variable (i.e., $1/\text{fT4}^{1/2}$), a statistically significant positive interaction was seen for iodine and perchlorate ($b$ for the urinary iodide-perchlorate interaction $= 6.26 \times 10^{-7}; p < 0.0001$). The authors note that the coefficient for perchlorate itself was not significant in this analysis; however, the inclusion of an interaction term which includes perchlorate invalidates the use of the perchlorate regression coefficient for assessing any association with the dependent variable (Greenland, 1998). If these findings truly represent a perchlorate-iodine interaction, they would support the findings seen in Blount et al. (2006) described in the next section.

**Blount et al., 2006 and Steinmaus et al., 2007.** These are two studies which used data from the same cross-sectional investigation of urinary perchlorate levels and serum levels of thyroid hormones in 2,299 men and women ≥ age 12 years who took part in the 2001-2002 National Health and Nutrition Examination Survey (NHANES). NHANES is conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention (CDC) and is designed to assess the health and nutrition status of the non-institutionalized population of the U.S. This survey involves a complex multistage sampling design with some over-sampling in certain areas and among certain subgroups, but is designed to provide results that are nationally representative. Information that is collected as part of this survey includes questionnaire data on demographic information, smoking, health history, and medication use. A single serum measurement of T4 and TSH and a single measurement of urinary perchlorate and iodine concentration were also collected. Other information collected included urinary creatinine, thiocyanate, and nitrate; and serum levels of albumin, cotinine, and c-reactive protein. Blount et al. (2006) assessed the relationship between serum thyroid hormone levels and urine perchlorate concentrations using a linear regression analysis adjusted for potential confounding variables and co-variates including age, urinary creatinine, estrogen use, c-reactive protein, cotinine, ethnicity, menopause, premenarche, pregnancy, fasting time, body mass index, and kilocalorie intake. Several factors including urinary perchlorate and creatinine and serum TSH were log-transformed to normalize their distributions. Exclusions included subjects with missing data on co-variates, a history of thyroid disease, current use of thyroid medications, extreme values of T4 or TSH ($n = 3$), and subjects missing perchlorate measurements. No association was found between T4 or TSH and perchlorate in men. In women, separate analyses were done for women with urinary iodine levels above and below 100 µg/L. This level was chosen since it is used by the World Health Organization to define iodine deficiency in a population. Thirty-seven percent of the women in this study had urinary iodine levels below 100 µg/L. The results of the analyses in women are shown in Table 19. A statistically significant association was seen between TSH and perchlorate in women with iodine levels below and below 100 µg/L. A statistically significant association was also seen between T4 and perchlorate in women with urinary iodine levels below 100 µg/L, but not in women with iodine levels above 100 µg/L.
Table 19. Associations between Thyroid Hormone Levels and the Logarithm of Urinary Perchlorate in Women with High and Low Levels of Urinary Iodine (Blount et al., 2006)

<table>
<thead>
<tr>
<th></th>
<th>Number of Subjects</th>
<th>Regression Coefficient (b)</th>
<th>Standard Error of b</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine iodine &lt; 100 µg/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>348</td>
<td>-0.8917</td>
<td>0.1811</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Logarithm of TSH</td>
<td>356</td>
<td>0.1230</td>
<td>0.0373</td>
<td>0.0010</td>
</tr>
<tr>
<td>Urine iodine ≥ 100 µg/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>724</td>
<td>0.2203</td>
<td>0.3687</td>
<td>0.5503</td>
</tr>
<tr>
<td>Logarithm of TSH</td>
<td>697</td>
<td>0.1137</td>
<td>0.0506</td>
<td>0.0249</td>
</tr>
</tbody>
</table>

Differences in the numbers of subjects with an iodine category are due to differences in the number of subjects missing data on co-variates in each analysis. Except for perchlorate and creatinine, only co-variates with p-values < 0.10 were retained in each model.

Steinmaus et al., 2007 used the same NHANES database and assessed whether other NIS inhibitors such as thiocyanate and nitrate might interact with perchlorate and iodine to affect thyroid hormone levels. Associations assessed by linear regression between thyroid hormones and urinary perchlorate were stratified by categories of nitrate, thiocyanate, smoking, and cotinine. Smoking and cotinine were evaluated since smoking is a major source of thiocyanate in many people and serum cotinine has been used in past studies as a biomarker for smoking intensity. The results of these analyses are shown in Table 20. In analyses of women with urinary iodine levels below 100 µg/L, regression coefficients between T4 and urinary perchlorate were greater in smokers, those with high cotinine, and those with high thiocyanate levels than in non-smokers, those with low cotinine, and those with low thiocyanate, respectively. These findings provide evidence that thiocyanate interacts with perchlorate and low iodine levels to decrease T4 production. The fact that similar effects are seen with all three methods used to categorize thiocyanate exposure (urine thiocyanate, serum cotinine, and smoking history) provides strong evidence that these findings are not due to chance. Interactions with TSH were seen in some analyses but not all and were not as clear as those seen for T4.
Table 20. Association between the Logarithm of Urinary Perchlorate (μg/L) and Serum T4 (μg/dL) and the Logarithm of TSH (μg/dL) in Women with Urinary Iodine < 100 μg/L, 2001-2002 NHANES (Steinmaus et al., 2007)

<table>
<thead>
<tr>
<th></th>
<th>T4&lt;sup&gt;a&lt;/sup&gt;</th>
<th>logTSH&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>B</td>
</tr>
<tr>
<td>All</td>
<td>362</td>
<td>-0.73</td>
</tr>
<tr>
<td>Smoking&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>63</td>
<td>-1.66</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>245</td>
<td>-0.54</td>
</tr>
<tr>
<td>Cotinine (serum)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High (&gt;10 ng/mL)</td>
<td>64</td>
<td>-1.47</td>
</tr>
<tr>
<td>Medium&lt;sup&gt;d&lt;/sup&gt;</td>
<td>185</td>
<td>-0.57</td>
</tr>
<tr>
<td>Low (ND)</td>
<td>101</td>
<td>-0.16</td>
</tr>
<tr>
<td>Thiocyanate (urine)&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High (&gt;1800 μg/L)</td>
<td>78</td>
<td>-1.67</td>
</tr>
<tr>
<td>Medium</td>
<td>107</td>
<td>-0.68</td>
</tr>
<tr>
<td>Low (&lt;751 μg/L)</td>
<td>176</td>
<td>-0.49</td>
</tr>
</tbody>
</table>

Abbreviations: b, regression slope; ND, non-detectable; SE, standard error.

<sup>a</sup>T4 models were adjusted for fasting time, kcal, body mass index, c-reactive protein, nitrate, race, estrogen use, and pregnancy. T4 model with cotinine was also adjusted for menopause status.

<sup>b</sup>LogTSH models adjusted for age, fasting time, body mass index, race, premenarche, and lactation. LogTSH model with smoking status also adjusted for menopause status.

<sup>c</sup>Smoking data not available on all women and recent former smokers are excluded.

<sup>d</sup>Medium category includes all subjects with serum cotinine levels between 10 ng/mL and non-detectable.

<sup>e</sup>Thiocyanate categories based on tertiles in all women age 12 or older.

Analysis of Blount et al. (2006) and Steinmaus et al. (2007)

Blount et al. (2006) and Steinmaus et al. (2007) are key studies supporting two of the potential susceptibility groups identified by OEHHA (women with low iodine and women with high thiocyanate) and thus were evaluated in further detail. These studies have several strengths. First, they are based on individual rather than ecological data on perchlorate exposure and thyroid hormone levels. Second, information on a variety of potential confounders was collected and could be controlled for. Third, the studies involved a fairly large sample size, so the researchers could assess certain important susceptibility factors, like iodine status, sex, and thiocyanate intake that were not assessed in other studies. Some occupational and clinical studies, although they involved higher perchlorate exposure levels, may have missed the effects seen in Blount et al. (2006) and Steinmaus et al. (2007) because they did not specifically investigate susceptible groups. Fourth, the p-values for the associations identified were well below 0.05, signifying that the probability these findings were due to chance is fairly low. Finally, the findings are biologically plausible in that they are consistent with the mechanism and direction by which perchlorate, iodine, and thiocyanate are all known to affect T4 and TSH levels.
There are also several potential concerns regarding these data. First, the studies are based on cross-sectional data and single measurements of urinary perchlorate, urinary iodine, and serum thyroid hormones. This could lead to some misclassification of true long-term exposure and thyroid hormone status. However, the half life of perchlorate is short (about 8 hours in Greer et al., 2002), and perchlorate seems to affect the thyroid fairly rapidly (less than one day in rats in Yu et al., 2000). Because of this, more short-term measures of perchlorate and thyroid status are probably better for assessing true associations than more long-term measures. Also, since specimens were collected similarly in all subjects, any error resulting from not using the most relevant measure of perchlorate and thyroid hormone status would most likely cause a non-differential misclassification and bias towards the null, not towards the positive effects identified. The use of total T4 rather than free T4 (the physiologically available form) may also cause some misclassification, but again this would be expected to be non-differential and towards the null.

Urinary iodine levels for an individual can vary throughout the day and from day to day. Because of this fluctuation, it has been argued that measuring a single spot urinary iodine level is a poor reflection of an individual’s overall, long-term iodine status. However, studies show that moderate to fairly strong correlations exist between single spot fasting urinary iodine concentrations and 24-hour urinary iodine concentrations, the recommended method for evaluating iodine deficiency in an individual (see Table 21). The fact that these correlations are not near zero suggests that while spot urinary iodine measurements may be associated with some misclassification, they still do provide at least some indication of true long-term iodine status in most people.

Table 21. Correlation Coefficients (R) of 24-hour Urinary Iodine Levels with Single Spot Urinary Iodine Concentrations (µg/L) and Urine Iodine/Creatinine (I/Cr) Ratios

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Location</th>
<th>N</th>
<th>R (for µg/L)</th>
<th>R (for I/Cr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Konno et al., 1993</td>
<td>Japan</td>
<td>22</td>
<td>0.83 (p &lt; 0.001) (unknown)</td>
<td>0.699</td>
</tr>
<tr>
<td>Thomson et al., 1997</td>
<td>New Zealand</td>
<td>333</td>
<td>0.49 (p &lt; 0.0001) (log converted)</td>
<td>0.587</td>
</tr>
<tr>
<td>Knudsen et al., 2000</td>
<td>Denmark</td>
<td>31</td>
<td>0.37a (Pearson)</td>
<td>0.61a</td>
</tr>
<tr>
<td>Rasmussen et al., 1999</td>
<td>Denmark</td>
<td>21</td>
<td>0.61 (p = 0.004) (Spearman)</td>
<td>0.70</td>
</tr>
</tbody>
</table>

*Pearson correlation coefficient involves an assumption that the data are normally distributed; distortions of the true correlation can occur if they are not.

Urinary creatinine levels are commonly used to adjust urinary levels of other chemicals for urine dilution. Lamm et al. (2007) analyzed the NHANES 2001-2 data using the iodine:creatinine (I/Cr) ratio rather than iodine concentration and found no association between T4 and perchlorate in women with low I/Cr values. However, there are some concerns about the validity of using I/Cr ratios. The first is whether or not dividing a urinary analyte concentration by urine creatinine concentration actually increases the accuracy of classifying true long-term exposure to that analyte, either in an individual or in a group. Increasing evidence suggests that it does not (at least for some chemicals).
As seen in Table 21, several studies show that correlations between I/Cr ratios and 24-hour iodine levels are no better than those seen with unadjusted urine iodine concentrations. Studies of other chemicals in urine have also shown that creatinine adjustment does not improve correlations with 24-hour urine levels or with biomarkers of effect (Hinwood et al., 2002; Biggs et al., 1997). One study presented in Table 21 did find an increased correlation coefficient after creatinine adjustment (Knudsen et al., 2000). However, unlike the other studies in this table, this one presented Pearson correlation coefficients. These assume that variables are normally distributed (which many times urinary iodine levels are not) and can give highly distorted results if this assumption is not met.

As discussed above, the most likely bias from misclassifying true long-term iodine status would be bias towards finding no effect. The fact that the perchlorate-T4 association goes away in analyses stratified by I/Cr ratios suggests that the use of I/Cr leads to much more, not less, misclassification of true iodine status. One possible reason for this is that the concentration of creatinine in urine depends on many factors other than urine dilution. Dividing urine iodine concentration by urine creatinine concentration creates a variable with two components: iodine and creatinine. Between-person differences in I/Cr will depend on both the variability in iodine and the variability in creatinine. Thus, I/Cr is not only dependent of iodine excretion and iodine status, but is also dependent on creatinine excretion and all of its determinants. Studies have shown that while urine dilution may be a major determinant of urinary creatinine levels within an individual, factors such as age, sex, genetics, physical activity, muscle mass, and diet are major determinants of differences in creatinine excretion between individuals and may play an even greater role than urine dilution in determining inter-individual variation in urine creatinine levels (Barr et al., 2005). People who have very high or very low levels of urine creatinine because of factors other than urine dilution will have their true iodine status misclassified if I/Cr ratios are used. Because urine creatinine concentration is dependent on all of these factors, using it to adjust for urine dilution may introduce a degree of misclassification of true iodine status which could overwhelm any improved accuracy that results from correcting for urine dilution. Based on these factors, several authors have concluded that I/Cr ratios should not be used for assessing iodine status (Bourdoux, 1993; Furnee et al., 1994; Thomson et al., 1996, 1997; Rasmussen et al., 1999).

In summary, most evidence suggests that the findings in Blount et al. (2006) are not due to misclassification of exposure or outcome, and are not due to the cross-sectional nature of the study design. In fact, given that the most likely direction of the bias caused by these factors is towards finding no effect, if any misclassification of perchlorate, iodine, T4, and TSH could be corrected, the associations identified in these studies are likely to be even stronger than those reported.

Another potential problem with cross-sectional data is that one cannot be assured of the appropriate temporality; that is, that the exposure came before and caused the outcome, rather than the outcome coming before and causing the exposure. However, given the abundance of data showing that perchlorate can lead to a decrease in thyroid hormone levels, and no evidence for the opposite effect, it seems highly unlikely that the Blount et al. (2006) and Steinmaus et al. (2007) results represent an effect of thyroid hormones on urinary perchlorate levels.
Another potential concern in Blount et al. (2006) and Steinmaus et al. (2007) is the possibility of confounding. Although analyses included a number of potential confounding variables, some factors associated with thyroid hormone levels were not adjusted for. Importantly though, in order for a variable to cause confounding it must be associated with the exposure and the outcome of interest. If it is not associated with both, it cannot be a confounder. In addition, confounding should not be viewed as a qualitative issue, but rather as a quantitative problem. As stated in Rothman and Greenland (1998a), “It is the amount of confounding rather than the mere presence or absence that is important....” In order for a variable to cause important confounding, it must be strongly (not weakly) related to the exposure or outcome. If a variable is only moderately or weakly associated with the exposure and outcome it will likely cause little confounding and have only minimal impacts on results and overall conclusions (Axelson, 1978). It would be wrong to suggest that a variable that is unassociated with, or only weakly associated with, T4 or urinary perchlorate likely caused the relatively strong association between T4 and perchlorate identified by Blount et al. (2006).

In both the Blount et al. (2006) and Steinmaus et al. (2007) studies, the fully adjusted regression coefficients between T4 and perchlorate were very similar to the unadjusted coefficients. This suggests that although the potential confounders included in the models may have been related to the exposure, or to the outcome, or to both, none were related strongly enough to cause significant confounding. The impact of these variables at causing confounding can be assessed by looking at the effect of each one individually. Table 22 presents the results of the perchlorate-T4 linear regression analysis before and after each potential confounder is removed from either the unadjusted or fully adjusted model. As can be seen, removing any of the individual co-variates had less than a 20 percent effect on the magnitude of the perchlorate-T4 regression coefficient.

Some factors that might be related to thyroid hormone levels were not adjusted for in the NHANES studies (e.g., anti-thyroid hormone antibodies, PCBs, physical activity, menstruation disturbances). However, we are not aware of any evidence that these factors are strongly enough associated with perchlorate exposure that they would cause important confounding.

Nitrate has also been shown to be an NIS inhibitor. However, analyses of the NHANES 2001-2 urinary concentration data showed no evidence of an interaction of nitrate with perchlorate and iodine. The reasons for this are unknown, although some possible explanations are:

- Urine nitrate may not be an adequate reflection of serum nitrate or the concentration of nitrate reaching the thyroid gland and NIS.
- Variability in nitrate levels may be greater than variability in perchlorate and thiocyanate. Increased variability would decrease the statistical power of the study to find true associations.
- The in vitro studies in human cell lines which have assessed the relative potencies of iodine, perchlorate, thiocyanate, and nitrate may not be relevant to in vivo exposures.
- The nitrate exposures in NHANES may not have been high enough to affect thyroid function. In a clinical trial, a nitrate dose of 15 mg/kg-day for 28 days did not
decrease thyroidal iodide uptake or impact thyroid hormone levels in 10 healthy volunteers (Lambers et al., 2000). This intake level is 5-20 times or more higher than average nitrate intakes reported in several populations in Europe and the U.S. (OEHHA, 2000).

As a whole, although some of the details of the findings of Blount et al. (2006) and Steinmaus et al. (2007) remain unexplained, a thorough analysis of the major tenets of causal inference show that the overall results are generally consistent with known mechanisms and not likely are due to chance, confounding, or other bias.

Table 22. Impact of Each Potential Confounding Variable on the Perchlorate-T4 Regression Coefficient in Steinmaus et al. (2007)a

<table>
<thead>
<tr>
<th>Variable</th>
<th>Remove one variable at a time from the fully adjusted model</th>
<th>Add a single variable to the unadjusted modelb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B</td>
<td>p-value</td>
</tr>
<tr>
<td>None</td>
<td>0.81</td>
<td>0.001</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.81</td>
<td>0.002</td>
</tr>
<tr>
<td>Age</td>
<td>0.85</td>
<td>0.0003</td>
</tr>
<tr>
<td>Fasting time</td>
<td>0.81</td>
<td>0.001</td>
</tr>
<tr>
<td>Albumin</td>
<td>0.83</td>
<td>0.001</td>
</tr>
<tr>
<td>Kcals</td>
<td>0.80</td>
<td>0.0004</td>
</tr>
<tr>
<td>BMI</td>
<td>0.88</td>
<td>0.001</td>
</tr>
<tr>
<td>C-reactive</td>
<td>0.83</td>
<td>0.001</td>
</tr>
<tr>
<td>Nitrate</td>
<td>0.66</td>
<td>0.001</td>
</tr>
<tr>
<td>Race</td>
<td>0.81</td>
<td>0.002</td>
</tr>
<tr>
<td>Estrogen</td>
<td>0.78</td>
<td>0.002</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>0.84</td>
<td>0.001</td>
</tr>
<tr>
<td>Menopause</td>
<td>0.79</td>
<td>0.0006</td>
</tr>
<tr>
<td>Pregnant</td>
<td>0.80</td>
<td>0.0009</td>
</tr>
<tr>
<td>Premenarche</td>
<td>0.80</td>
<td>0.001</td>
</tr>
<tr>
<td>Lactate</td>
<td>0.80</td>
<td>0.001</td>
</tr>
</tbody>
</table>

a All of the available potential confounders were entered into the model presented here. In Steinmaus et al. (2007) only those with p-values < 0.20 were added to and retained in the model. All analyses include the NHANES sample weights.
b The independent variables in the unadjusted model are the logarithm of perchlorate and the logarithm of creatinine. This is the coefficient with creatinine removed.

Pearce et al., 2010. Urinary perchlorate and iodine concentrations and serum thyroid hormone levels were measured during the first trimester of pregnancy in 480 euthyroid women from Cardiff, Wales and 526 euthyroid women from Turin, Italy. Median urinary iodine levels were 117 µg/L in Cardiff and 50 µg/L in Turin. Median perchlorate levels were 2.6 µg/L (range, 0.3-49) in Cardiff and 5.2 µg/L (range, 0.2-168) in Turin. No correlation was found between urinary perchlorate concentrations and maternal T4 or
TSH in either city. Analyses restricted to the large subset of women with urinary iodine levels below 100 µg/L gave similar results. It is unknown if perchlorate levels were adjusted for creatinine, which is commonly used to adjust for urine dilution. Failure to adjust for urine dilution can potentially cause misclassification of exposure and bias results towards the null. Urine thiocyanate levels were low, much lower than those commonly found in the U.S. The median urine thiocyanate levels in Cardiff and Turin were 470.5 and 372.5 µg/L, respectively. In the NHANES study discussed above (Steinmaus et al., 2007), the strongest perchlorate-thyroid hormone associations were found with thiocyanate levels in the upper tertile (i.e., above 1800 µg/L), and clear associations were not found with thiocyanate levels below 751 µg/L. In this regard, the Pearce et al. (2010) findings are consistent with those of Steinmaus et al. (2007).

Immunotoxicity

Weetman et al., 1984. The authors investigated the effect of perchlorate on human T and B cell responses to mitogen in vitro. Perchlorate at concentrations of 0, 0.01, 0.1, 1.0 and 10 mmol/L (1.17 g/L) were tested in cultures “designed to assess B and T cell responses.” Supernatant IgG and IgM were measured by enzyme-linked immunoassays after culture of cells for 10 days with pokeweed mitogen. The investigators found that perchlorate at 0.1 to 10 mmol/L inhibited IgG production and at 10 mmol/L inhibited IgM production. They concluded that perchlorate has significant immunosuppressive activity at pharmacologically relevant concentrations that is not due to simple cytotoxicity (assessed by ethidium bromide/acridine orange fluorescence). However, the perchlorate concentrations in this study are in fact very high. A later study in CHO cells expressing the human sodium-iodide symporter (Ajian et al., 1998) showed perchlorate inhibition of iodide uptake evident at 0.01 micromolar, progressing to complete inhibition at 20 micromolar (0.02 mmol/L), which is much lower than the doses used in Weetman et al. Thus the immune effects of the high concentrations used in the study of Weetman et al. (1984) appear of doubtful relevance.

Hematological Effects

Graves’ disease patients treated with perchlorate doses in the range of 6 to 14 mg/kg-day for three to eight months occasionally developed fatal aplastic anemia (Fawcett and Clarke, 1961; Hobson, 1961; Johnson and Moore, 1961). The mechanism of this blood disorder is not known. The use of perchlorate to treat Graves' disease was discontinued because of these cases. Nonfatal agranulocytosis was reported in patients treated with 14 mg/kg-day perchlorate for 12 days (Southwell and Randall, 1960) or three months (Sunar, 1963). Barzilai and Sheinfeld (1966) reported that 8 of 76 patients treated with 14 mg/kg-day perchlorate for at least two months developed leukopenia or other side effects. There was also one case of fatal aplastic anemia and one of fatal agranulocytosis within this group of 76 patients (Barzilai and Sheinfeld, 1966). As similar adverse hematological effects were not observed in rodents exposed to 30 mg/kg-day or 100 mg/kg-day, humans may be more sensitive than rodents for this endpoint.
Carcinogenicity

Morgan and Cassady, 2002. Morgan and Cassady (2002) assessed observed and expected numbers of new invasive cancer cases for all sites combined and 16 cancer types among residents of the greater Redlands area between 1988 and 1998. The community is known to have drinking water contaminated with perchlorate and trichloroethylene (0.09-97 ppb measured in 1980). They reported no significant differences between observed and expected numbers for all cancers, thyroid cancer, or 11 other cancer types. Significantly fewer cases were observed than expected for cancer of the lung and bronchus and the colon and rectum. More cases were observed for uterine cancer (standardized incidence ratio = 1.35; 99 percent CI = 1.06 to 1.70) and skin melanoma (standardized incidence ratio = 1.42; 99 percent CI = 1.13 to 1.77).

Li et al., 2001. These authors compared the prevalence of thyroid cancer in Clark County (Las Vegas) which had measurable perchlorate concentrations in public water supplies to Washoe County, which did not. The relative risk was 0.75 (95% CI, 0.35-1.59).

Adverse Health Effects Associated with Iodide and Thyroid Deficiency

The most important and early effect of perchlorate exposure is its effect on reducing iodide uptake by the thyroid. Significant reduction in iodine uptake can lead to decreased thyroid hormone production. For this reason, we reviewed studies of the adverse health effects of iodide deficiency and decreased levels of thyroid hormone.

Thyroid Problems in Pregnant Women with Low Iodide Intake

A number of human studies have shown that pregnancy stresses the thyroid (Crooks et al., 1967; Glinoer et al., 1990, 1992, 1995; Smyth et al., 1997; Caron et al., 1997; Brent, 1999; Kung et al., 2000). In areas of iodine deficiency (e.g. intake level <100 µg/day), there is an increased risk of abnormally low serum T3 and T4 levels, and thyroid enlargement and goiter in pregnant women. The nature and severity of changes in thyroid function are related to the severity of the iodine deficiency. In an epidemiologic survey reported by Delange and Ermans (1991; as cited in Delange, 1994), the investigators found the prevalence of goiter in an area with severe iodine deficiency is influenced by age and sex, with maximal frequency in females during puberty and childbearing age (Figure 6).
Figure 6. Changes in the Prevalence of Goiter as a Function of Age and Sex in Severe Endemic Goiter (Idjwi Island, Zaire) (Delange, 1994)

Crooks et al., 1967. Crooks et al. (1967) studied enlargement of the thyroid gland in pregnant and non-pregnant women in Aberdeen, Scotland and Reykjavik, Iceland. In the Scotland study, they found that the thyroid gland was visible and palpable in 70 percent of pregnant women but in only 37 percent of non-pregnant women in the reproductive age group. By contrast, in the Iceland study, the frequency of thyroid enlargement was about the same in pregnant (23 percent) and non-pregnant women (19 percent). The authors (1967) suggested that the results can be explained by the fact that Icelandic diet is based on fish and contains high levels of iodine. This hypothesis is supported by the significantly higher mean plasma inorganic iodine concentration measured in non-pregnant Icelandic women (0.691 µg/dL) compared to the mean of 0.420 µg/dL found in Scottish non-pregnant women (p<0.001).

Glinoer et al., 1990. Glinoer et al. (1990) suggested that in conditions of marginally low iodide intake, pregnancy constituted a goitrogenic stimulus. They followed a group of 606 healthy pregnant women in Brussels, Belgium, an area of marginally low iodide intake (50-70 µg/day), and monitored their T3, T4, TSH, and human chorionic gonadotropin (hCG) levels in serum during the first, second, and third trimesters. All subjects were evaluated clinically and determined to be without detectable thyroid abnormality at the beginning of the study. The authors found that a normal thyroid is faced with a triple challenge during pregnancy. First, there is a significant increase in circulating levels of the major T4 transport protein, thyroglobulin, in response to high estrogen levels. As a result, the thyroid has to increase its T4 output in order to maintain a stable T4/thyroglobulin ratio of 37-40 percent.

Second, several thyroidal stimulating factors of placental origin (mainly hCG) are produced in excess. This contributes to a decrease of serum TSH (mainly in the first half of gestation) and an increase in thyroid volume (Table 23). They found that during pregnancy thyroid volume increased by an average of 18 percent. This increase was
statistically significant and thyroid size increased in a majority of women (73 percent). Goiter, defined as thyroid volume greater than 23 mL, was found in nine percent of the cohort at delivery.

Table 23. Changes in Mean Thyroid Volume in Healthy Women During Pregnancy (from Glinoer et al., 1990)

<table>
<thead>
<tr>
<th>Stage of Pregnancy</th>
<th>N</th>
<th>Total volume (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First trimester</td>
<td>168</td>
<td>12.1 ± 4.5</td>
</tr>
<tr>
<td>Second trimester</td>
<td>172</td>
<td>12.8 ± 4.5</td>
</tr>
<tr>
<td>Third trimester</td>
<td>33</td>
<td>13.9 ± 4.8&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Delivery</td>
<td>179</td>
<td>15.0 ± 6.8&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>p < 0.03 vs. beginning of pregnancy.
<sup>b</sup>p < 0.001 vs. beginning of pregnancy.

Third, pregnancy is accompanied by a decrease in the availability of iodide for the maternal thyroid, due to increased renal clearance (Aboul-Khair et al., 1964; as cited in Glinoer et al., 1990) and losses to the feto-placental complex during late gestation, resulting in a relative iodine deficiency state.

**Glinoer et al., 1992.** In a related study, Glinoer et al. (1992) monitored the thyroid condition of pregnant women in an area without overt iodine deficiency, but with a marginal iodide supply (less than 100 µg/day in 80 percent of women). They found that maternal thyroid function at delivery was characterized by a relative hypothyroxinemia; increased T3/T4 ratios, indicating preferential T3 secretion; slightly increased TSH levels within the normal range in 97 percent of women; increased serum thyroglobulin values, which were above normal in 60 percent of women; and goiter formation in almost 10 percent of women. In the newborns, they found fT4 levels were significantly higher than in the respective mothers. However, mean neonatal TSH and Tg levels were significantly higher than maternal values. Furthermore, these values were highly correlated with maternal data, suggesting the limited availability of iodine was the common link.

In a review paper, Glinoer (2001) again stressed the profound alterations in the thyroid economy associated with pregnancy. In healthy iodine-sufficient pregnant women, this leads to a physiological adaptation of the thyroid and an increased production of thyroid hormones. When gestation takes place in conditions with iodine restriction or deficiency, pregnancy may lead to pathological alterations affecting both thyroid function and the anatomical integrity of the thyroid gland. The more severe the iodine deficiency, the more obvious, frequent, and profound the potential maternal and fetal repercussions.

**Smyth et al., 1997.** Supportive results were reported in two other studies, one in Ireland and the other in France. Smyth et al. (1997) evaluated ultrasound-measured thyroid volume of 115 pregnant women during one of the three trimesters. These women (Group A) were enrolled based on availability, and each trimester’s study group comprised different individuals. Control values for thyroid volume were obtained from 95 pre-menopausal females. All subjects were from Dublin, Ireland, an area of moderately low dietary iodide intake (median urinary iodine was 82 µg/day). All pregnant women
studied delivered live-born, normally formed, singleton infants and received no iodide-containing supplements during their pregnancy. The authors reported that the mean thyroid volume of 13.9 ± 0.8 mL, observed in the first trimester, was significantly greater than the control value (11.3 ± 0.5 mL; p < 0.05) and reached a maximum of 16.0 ± 0.7 mL, a 47 percent increase (p<0.01), in the third trimester.

In a related study, Smyth et al. (1997) studied a group of 38 pregnant women (Group B), prospectively. Casual urine samples were collected sequentially during the 3 trimesters of pregnancy and at approximately 6 weeks postpartum. Of those 38 subjects, 20 had thyroid ultrasound scans during each trimester of pregnancy and at 6 weeks postpartum. Thyroid volumes greater than 18.0 mL were defined as enlarged. The number of enlarged thyroids increased from the non-pregnant control value of 6.3 percent, through 19.5 percent in the first trimester, to reach a plateau of approximately 32 percent in the second and the third trimesters, which was maintained up to 40 days postpartum.

Urinary iodine of the women in Group A and Group B were also measured. Urinary iodine measurements collected from 1063 premenopausal women over a one-year period were used for comparison. The researchers found that urinary iodine levels measured throughout the pregnancies of the women in Group A and Group B (Table 24) were higher than in the controls (median 70 µg/L). They suggested that in an area of moderately low dietary iodide intake, urinary loss during pregnancy may result in maternal thyroid enlargement.

### Table 24. Median Urinary Iodine Excretion (µg/L) in Pregnancy (Smyth et al., 1997)*

<table>
<thead>
<tr>
<th></th>
<th>First Trimester</th>
<th>Second Trimester</th>
<th>Third trimester</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>135</td>
<td>122</td>
<td>122</td>
</tr>
<tr>
<td>Group B</td>
<td>155</td>
<td>122</td>
<td>115</td>
</tr>
</tbody>
</table>

*Some of the values were estimated from a graph.

**Caron et al., 1997.** In a prospective study, Caron et al. (1997) evaluated the thyroid condition of 347 pregnant women living in the southwest of France (with an estimated urinary iodine excretion value of 50 µg/day). Iodine concentration in urine samples and serum thyroid hormone measurements were taken at initial presentation (before 12 weeks of gestation), and during the nine months of pregnancy. Mean urinary iodine levels were low during the first trimester (6.9 ± 0.4 µg/dL), as well as during the ninth months of pregnancy (8.6 ± 0.6 µg/dL). A thyroid ultrasound was performed one to five days after delivery in 246 mothers. During pregnancy fT4 and T3 concentrations decreased (p<0.001), and TSH and Tg concentrations increased (p<0.001). Thyroid hypertrophy (thyroid volume greater than 18 mL) was present in 29 percent of the mothers. The percentage of thyroid hypertrophy at delivery was associated with urinary iodine concentration during the first trimester of gestation: 15.4 percent (urinary iodine < 5 µg/dL), 9.2 percent (urinary iodine 5-10 µg/dL), and 3.5 percent (urinary iodine > 10 µg/dL) (Figure 7). Goiter (thyroid volume greater than 22 mL) was present in 11 percent of the mothers. The researchers concluded that in areas with a marginally low iodide supply, pregnancy constitutes a goitrogenic stimulus.
Kung et al., 2000. In another prospective study, Kung et al. (2000) studied 230 pregnant women living in a borderline iodine sufficient area (Hong Kong). The median urine iodine concentration in healthy adults was 0.77 µmol/L (9.8 µg/dL) in Hong Kong, which was close to the World Health Organization cut-off value of 0.79 µmol/L (or 10 µg/dL) for iodine sufficiency. When recruited into the study, all pregnant women were in their first trimester; subjects with a history of thyroid dysfunction were excluded. These women were prospectively studied at approximately 12-14 weeks, 20-24 weeks, and 36 weeks of gestation, as well as 6 weeks and 3 months postpartum for thyroid function, thyroid volume by ultrasound examination, and urine iodine concentration. Study results are presented in Table 25. The investigators showed that in an area of borderline low dietary iodine intake, pregnancy was an important stress to the maternal thyroid axis. Pregnancy caused an average 30 percent increase (range, 3 – 230 percent) in thyroid volume, with some subjects having a more than two-fold increase. This thyroid enlargement persisted and failed to revert completely even 3 months after delivery.

The researchers also reported that 14 women with excessive thyroidal stimulation in the second trimester had lower urine iodine concentrations and larger thyroid volumes throughout pregnancy. Furthermore, their neonates had higher cord TSH, Tg, and slightly higher thyroid volumes than the neonates of 216 pregnant women without evidence of thyroid stimulation. Seven neonates (50 percent) born to these women had subnormal fT4 levels at birth.

![Figure 7. Percentage of Maternal Thyroid Hypertrophy in Relation to Urinary Iodine Concentration During the First Trimester of Pregnancy (Caron et al., 1997)](image-url)
Table 25. Change of Thyroid Function Tests, Thyroidal Volume, and Urinary Iodine Level of Women During and After Pregnancy (Kung et al., 2000)

<table>
<thead>
<tr>
<th></th>
<th>First trimester</th>
<th>Second trimester</th>
<th>Third trimester</th>
<th>Postpartum 6 weeks</th>
<th>Postpartum 3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total T4 (nmol/L)</td>
<td>154 (132-176)</td>
<td>126 (110-143)</td>
<td>125 (106-142)</td>
<td>89 (81-98)</td>
<td>92 (82-101)</td>
</tr>
<tr>
<td>Free T3 (pmol/L)</td>
<td>3.9 (3.6-4.3)</td>
<td>3.4 (3.1-3.7)</td>
<td>3.3 (3.0-3.7)</td>
<td>4.0 (3.7-4.4)</td>
<td>4.3 (4.1-4.6)</td>
</tr>
<tr>
<td>TSH (mIU/L)</td>
<td>0.49 (0.12-1.00)</td>
<td>0.96 (0.62-1.28)</td>
<td>0.95 (0.60-1.36)</td>
<td>1.15 (0.74-1.58)</td>
<td>1.14 (0.81-1.61)</td>
</tr>
<tr>
<td>Urine iodine (µmol/L)</td>
<td>0.84 (0.60-1.09)</td>
<td>0.91 (0.65-1.14)</td>
<td>0.98 (0.72-1.24)</td>
<td>0.83 (0.56-1.08)</td>
<td>0.79 (0.51-1.14)</td>
</tr>
<tr>
<td>Thyroid volume (mL)</td>
<td>9.5 (7.2-12.3)</td>
<td>10.3 (7.7-13.6)</td>
<td>11.2 (8.9-13.8)</td>
<td>11.0 (8.3-14.2)</td>
<td>10.6 (8.6-13.7)</td>
</tr>
</tbody>
</table>

Results are medians

\[ ^{a}p < 0.05 \text{ vs. first trimester} \]
\[ ^{b}p < 0.01 \text{ vs. first trimester} \]

Another source of data supporting the concept that normal pregnancy requires increased thyroid hormone production comes from the observation that women previously diagnosed with hypothyroidism on adequate T4 replacement doses often require an increase in their T4 doses during pregnancy (Table 26).

Table 26. Thyroid Hormone Requirement in Pregnancy (Brent, 1999)

<table>
<thead>
<tr>
<th>Study</th>
<th>Mean daily dose (µg)</th>
<th>Fraction of women requiring an increased dose</th>
<th>Mean dose increase for those who had an adjustment (µg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pekonen et al. (1984)</td>
<td>141</td>
<td>7/34 (21%)</td>
<td>62</td>
</tr>
<tr>
<td>Mandel et al. (1990)</td>
<td>148</td>
<td>9/12 (75%)</td>
<td>46</td>
</tr>
<tr>
<td>Tamaki et al. (1990)</td>
<td>-</td>
<td>4/4 (100%)</td>
<td>-</td>
</tr>
<tr>
<td>Girling and de Swiet (1992)</td>
<td>142</td>
<td>9/32 (28%)</td>
<td>68</td>
</tr>
<tr>
<td>Kaplan (1992)</td>
<td>154</td>
<td>27/42 (64%)</td>
<td>42</td>
</tr>
<tr>
<td>Pooled data</td>
<td>146</td>
<td>56/124 (45%)</td>
<td>46</td>
</tr>
</tbody>
</table>

Romano et al., 1991; Pedersen et al., 1993; Glinoer et al., 1995. These are three prospective studies showing that in an area with marginal or moderate iodide deficiency, iodide supplementation often can reduce the stress on the thyroid during pregnancy. The first study was carried out in L’Aquila, Italy, an area with moderate iodine deficiency.
There were 35 pregnant women in the study, all of whom had a normal pregnancy and no history of thyroid disease. They had a mean age of 27.1 years (±3.8) and a mean body weight of 61.6 kg (± 4.9) at the first examination during the first trimester. Pregnant women were randomly assigned into group A (n=17) or group B (n=18). Immediately after the first examination, iodide salt equivalent to a daily intake of about 120 to 180 µg iodide was prescribed to all the women in group A. Each trimester all pregnant women in both groups were subjected to three ultrasonographic evaluations of thyroid volume and to measurement of body weight. During each examination, 24-hour urine samples were also taken to determine the iodine urinary excretion. Romano et al. (1991) reported that TSH levels of all the subjects were within the normal range and TSH levels measured in group A did not statistically differ from those measured in group B. The effect of iodide supplement was confirmed by urinary iodine measurements. A significant increase in urinary iodine excretion was found at the second and third examination (p<0.0001 and p<0.01, respectively, Table 27) only in group A, treated with iodide salt.

Table 27. Iodine Excretion (µg/24 hours) in Both Groups at Each Trimester (mean± standard deviation) (from Romano et al., 1991)

<table>
<thead>
<tr>
<th></th>
<th>First trimester</th>
<th>Second trimester</th>
<th>Third trimester</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>37.0±36.0</td>
<td>154.0±59.0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>100.0±39.0&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Group B</td>
<td>30.5±42.0</td>
<td>55.0±35.0</td>
<td>50.0±37.0</td>
</tr>
</tbody>
</table>

<sup>a</sup>p<0.0001  
<sup>b</sup>p<0.01 vs. first trimester

Thyroid volume did not change throughout pregnancy in the group treated with iodide salt. However, in the control group (Group B) there was a statistically significant increase in thyroid volume from the first to the third trimester (mean increase = 1.6 ± 0.6 mL; p<0.0001). Romano et al. (1991) concluded that an adequate dietary iodide intake is necessary to prevent the development of gestational goiter, and iodine deficiency is the main causative factor of thyroid enlargement during pregnancy.

A similar study was also carried out in East Jutland, Denmark, an area with a median daily urinary iodine excretion around 50 µg (Pedersen et al., 1993). The researchers selected 54 normal pregnant women and randomly divided them into iodine-treated (28 subjects) and untreated groups (26 subjects). Before iodine supplementation was initiated, the measured variables were nearly identical in the two groups. Treated subjects received 200 µg iodide/day starting from weeks 17-18 of pregnancy until 12 months after delivery. All women were followed at regular intervals during pregnancy. In the control group, serum TSH, serum Tg, and thyroid size showed significant increases during pregnancy. These variations were less in the iodide supplementation group (Figures 8, 9, and 10).

Iodine did not induce significant variations in serum T4, T3 or free T4 in this study. Pedersen et al. (1993) concluded that a relatively low iodide intake during pregnancy leads to thyroid stress, with increases in Tg release and thyroid size. It is important to note that even in the iodide-supplement group, there was a significant increase in thyroid...
volume during pregnancy. Notably, the size of the thyroid returned to initial values one year after delivery independent of iodide supplementation. Pedersen et al. (1993) were concerned that thyroidal stress during pregnancy in an area of iodine deficiency can lead to goiter, which is primarily reversible, as was shown in the study. However, at some point iodine deficiency triggers, by an unknown mechanism, irreversible changes in the thyroid with autonomous growth and function and may lead to high incidence of multinodular toxic goiter in elderly subjects. It was suggested that iodine deficiency during pregnancy or even during fetal life could be an important factor for the late development of thyroid autonomy.

Figure 8. Serum Tg and TSH During Pregnancy and for 52 Weeks Postpartum in Women Receiving Iodide Supplementation and Control Women, as a Percentage of the Initial Values (from Pedersen et al., 1993). Median values are shown. The increase in serum Tg during pregnancy in the control group was statistically significant (p<0.01), but the first value obtained during pregnancy and the values obtained one year after delivery were not different. Tg values from the two groups were significantly different at all periods, except before initiation of iodide supplementation. The increase in serum TSH in the control group during pregnancy was statistically significant (p<0.01), whereas no differences between values were found in the iodine supplemented group (p=0.29, by Friedman’s test). During the postpartum period, no significant TSH differences between the groups were found.
Figure 9. Median Thyroid Volume During Pregnancy and 52 Weeks Postpartum in Women Receiving Iodide Supplementation and Control Women, as Percent of Initial Values (from Pedersen et al., 1993). In both groups, statistically significant increases during pregnancy and decreases during the postpartum period were found (p<0.05). The increase during pregnancy in controls was higher than that in the iodide-supplemented group (p<0.05).

Figure 10. Iodine Concentration in Spot Urine Samples During Pregnancy and for 52 Weeks Postpartum in Women Receiving Iodide Supplementation and Control Women (Pedersen et al., 1993). The last sample was obtained after iodide supplementation was stopped.
Glinoer et al. (1995) studied a group of euthyroid pregnant women with mild to moderate iodine deficiency and found pregnancy-related stresses on the thyroid could be prevented by the administration of potassium iodine or potassium iodine plus L-T4. They selected 180 pregnant women at the end of the first trimester on the basis of biochemical criteria of excessive thyroid stimulation, defined as serum thyroglobin > 20 µg/L associated with a low normal fT4 index (<1.23) and/or an increased T3/T4 ratio (>25x10^{-3}). The subjects were randomized in a double-blind protocol into three groups and treated until term with either placebo (Group A), potassium iodine (100 µg/day) (Group B), or potassium iodine (100 µg/day) plus L-T4 (100 µg/day) (Group C). At the beginning of the study, all the subjects were mildly or moderately iodine deficient as indicated by a median urinary iodine concentration of 36 µg/L. Only 10 percent of women had urinary iodine above 80 µg/L. After therapy was instituted, the urinary iodine concentrations in Groups B and C rose to approximately 75-130 µg/L in the second and third trimesters; while urinary iodine of Group A remained low during gestation and at delivery.

Study results showed that total T4 levels of all groups increased during the second and third trimesters compared to those measured during the first trimester. However, the increases observed in Group A (4 percent and 7 percent for the second and third trimesters, respectively) were much smaller than those observed in Group B (9 percent and 11 percent) and Group C (19 percent and 15 percent). Glinoer et al. (1995) also reported that in Groups A and B, the ratios of T3/T4 were higher than normal at the start of the therapy and remained elevated during gestation. However, in Group C the ratios decreased rapidly toward normal and were maintained at a level of approximately 22 x 10^{-3}. These results indicated that thyroid stimulation associated with pregnancy and leading to preferential T3 secretion by the thyroid was suppressed after potassium iodide plus L-T4 administration. Glinoer et al. (1995) found an average increase of 30 percent in thyroid volume in Group A. Sixteen percent of the women in this group developed a goiter during gestation, with thyroid volumes up to 34 mL at delivery. The increment in thyroid volume was much less in Group B (mean increase of 15 percent) and in Group C (mean increase of 8 percent). Furthermore, goiter formation in Groups B (10 percent) and C (3 percent) was less frequent than that in Group A. In the same study, Glinoer et al. (1995) also evaluated the thyroid status of the newborns, 3-6 days after delivery. They found that the mean thyroid volume of newborns in Group A (1.05 ± 0.05 mL) was significantly larger than those in Groups B (0.76 ± 0.05 mL) and Group C (0.75 ± 0.05 mL). Furthermore, glandular hyperplasia (thyroid volume >1.4 mL) was found in 10 percent of newborns in Group A (range 1.5-2.2 mL) compared to none in Groups B and C (p=0.01, by χ^2 test). Glinoer et al. (1995) found the study results in agreement with other investigations on goitrogenesis during pregnancy in areas with less than adequate iodine supply.

Rotondi et al., 2000. This study found an association between thyroid size and the number of their previous pregnancies in an area with moderate iodine deficiency. The researchers studied the size of thyroids of 208 non-goitrous healthy females by ultrasound examination. All subjects lived in a region (Naples, Italy) that is known to have moderate iodine deficiency, with usual urinary levels ranging from 40-100 µg/day. All subjects had serum free T3, fT4, and TSH measurements, as well as thyroglobulin antibody and thyroid peroxidase antibody detection. All subjects were clinically and biochemically euthyroid and had no detectable thyroid autoantibodies. The subjects were
divided into five groups, according to the number of completed pregnancies (0, 1, 2, 3, 4 or more term pregnancies). The researchers found mean thyroid volume increased progressively among the groups; group 0 (14.8±0.7 mL); group I (16.0±0.9 mL); group II (17.1±0.6 mL); group III (18.2±0.6 mL); group IV (20.3±0.9 mL). The difference in the increases in thyroid volume was statistically significant between group 0 and groups III (p<0.01) and IV (p<0.001), and also between group I and group IV (p<0.05). No independent effect of body weight and age on thyroid volume was seen. Based on the results, Rotondi et al. (2000) suggested that, in an area with moderate iodine deficiency, there is a cumulative goitrogenic effect of successive pregnancies and the goitrogenic effect of pregnancy is not fully reversible.

As shown above, several studies have identified associations between pregnancy and increased thyroid size. However, as we review in the following paragraphs, this effect has not been seen in all studies.

**Gerghourt et al., 1994.** These researchers studied 10 healthy women before and during a normal pregnancy in an iodine replete area of Amsterdam, the Netherlands. They found no change in thyroid volume during pregnancy (data given before pregnancy and during first, second, and third trimesters, respectively: 10.3 ± 5.1, 10.6 ± 4.4, 9.6 ± 3.8, and 9.4 ± 3.0 mL. Urinary iodine levels or dietary iodine intakes were not reported.

**Long et al., 1985.** These researchers studied a group of pregnant teenagers and found the frequency of goiter in this group was not higher than that in non-pregnant teenagers. They studied 309 consecutive pregnant adolescent girls who were admitted to a medical center in San Diego, California from August 1978 through December 1982. A group of 600 adolescent girls was used as controls to establish the prevalence of goiter in non-pregnant adolescents. The mean gestational age for the first visit was 22 weeks. A thyroid gland was defined as enlarged if it was visible and/or palpable and had a transverse span of ≥ 6 cm. Eighteen goiters (6 percent) were identified in the pregnant teenagers versus 27 goiters (5 percent) in the control group. It should be noted that the detection method used in the study is not as sensitive and reliable as the ultrasound detection used in the more recent studies. Long et al. (1985) concluded that abnormalities of size and function of the thyroid gland were not more prevalent during the stress of reproduction at a young age.

**Levy et al., 1980.** This study examined the thyroid glands of 49 matched pairs of women in Ohio, one pregnant and one non-pregnant woman per pair. All pregnant women were at least 20 weeks into the pregnancy and had no personal history of thyroid abnormality. The subjects were paired by race and age (within 5 years) and examined by multiple observers. Observers independently graded each thyroid as “not palpable,” “palpable but not enlarged,” or “enlarged”. They also compared the size of the two glands relative to one another for every pair of subjects. Levy et al. (1980) found that in 22 pairs the pregnant woman had the larger thyroid, whereas in 20 pairs the opposite was true. In six pairs the thyroid glands were not palpable, and in one pair the thyroid glands were of equal size. Five pregnant and three nonpregnant women had clinically significant goiters. None of the differences was statistically significant. These results are consistent with the study of Crooks et al. (1967) conducted in Reykjavik, Iceland, which showed that pregnancy did not impact the thyroid gland when iodide intake was adequate.
Liberman et al., 1998. This investigation studied the serum T4, TSH, and serum and urinary inorganic iodine levels during the first, second, and third trimesters and after delivery of 16 women. They reported significantly higher levels of mean serum T4 during the pregnancy than after delivery. Similar levels of serum TSH, serum inorganic iodine, and urinary iodine were measured during pregnancy and after delivery. The daily iodide intakes of the subjects were high, as indicated by the relatively high average urinary iodine levels (459 – 786 µg/day). Liberman et al. suggested that pregnancy does not have an important influence on serum inorganic iodine or thyroid status in iodine-sufficient regions.

Adverse Neurological Development in Infants Born to Mothers with Iodine Deficiency or Low Thyroid Hormone Levels

The changes in thyroid function associated with pregnancy are related to increased hormone requirements. The need can only be met by a proportional increase in hormone production and is dependent upon the availability of iodine in the diet (Glinoer, 2001). The National Academy of Sciences has recommended an Estimated Average Requirement of 160 µg/day and a Recommended Dietary Allowance of 220 µg/day for pregnant women (NAS, 2001). These values are higher than the Estimated Average Requirement of 95 µg/day and the Recommended Dietary Allowance of 150 µg/day for non-pregnant adults (age 19 years and older).

Iodine deficiency disorders range from endemic cretinism to endemic goiter and less severe forms of brain abnormalities. The impact of iodine deficiency differs depending on the age and life stage of the affected individual, as well as the degree of iodine deficiency. The most severe problems caused by iodine deficiency are among fetuses, neonates, and infants because of the irreversible changes that can occur during this period of rapid structural and behavioral development. Cognitive impairment is the most common finding seen with iodine deficiency, and thyroid disorders during pregnancy have been shown to increase the risk of neurologic damage in offspring (Hetzel and Maberly, 1986; as cited in Hollowell and Hannon, 1997). It was considered a paradox that in areas of iodine deficiency, children with cretinism, but with functioning thyroid glands, had more severe central nervous system damage than some children who were missing a thyroid gland. For prevention of central nervous system damage, iodide has to be supplied before conception or early in the first trimester, a time in development before the fetal thyroid is known to be functional (Hollowell and Hannon, 1997). The finding that maternal T4 reaches the fetus (Vulisma et al., 1989) made it understandable that maternal thyroid hormones are necessary for brain development during early fetal development, and severe central nervous system damage can occur as a result of maternal thyroid deficiency.

This theory is supported by the results of a number of animal and human studies.

Animal Studies

Obregon et al., 1984 and Woods et al., 1984 and others. Obregon et al. (1984) and Woods et al. (1984) showed that fetal rat tissues, including brain, contained T4 and T3 before fetal thyroid hormone was produced. Several researchers also reported that nuclear T3 receptors in brain tissues obtained from rat and human fetuses early in
gestation (before the development of the fetal thyroid) were relatively saturated with T3 (Bernal and Pekonen, 1984; Perez Castillo et al., 1985; Ferreiro et al., 1988; as cited in Burrow et al., 1994). The presence of occupied T3 nuclear receptors in brain tissues early in fetal development supports a role for maternal thyroid hormones in the maturation of the brain.

**Argus Research Laboratories, 1998a and 2001.** In two animal developmental studies (discussed in an earlier section), ammonium perchlorate was administered to female Sprague-Dawley rats via drinking water at target doses between 0.01 and 30 mg/kg-day. Morphometric analysis of the pups revealed significant changes in sizes of a number of brain regions (e.g., corpus callosum), although a simple dose-response relationship is not observed for any of the changes (Figure 3).

**Potter et al., 1982 and Hetzel et al., 1987.** Severe iodine deficiency has been shown to cause abnormal fetal brain development in a number of animal species. Potter et al. (1982) reported that severe iodine deficiency in sheep caused reduction in fetal brain weights and in brain DNA and protein from 70 days of gestation to parturition. They also found unusual morphological changes in both the cerebral hemispheres and the cerebellum of the fetal brains. Hetzel et al. (1987) reported that severe iodine deficiency caused abnormal fetal brain development in rat, marmoset, and sheep. The abnormalities included reduced brain weight, change in cell density in the cerebral hemispheres, reduced synaptic counts in the visual cortex, and reductions of brain DNA and brain protein.

**Lavado-Autric et al., 2003.** In this study, the investigators evaluated the effects of a low iodine diet (LID) with (LID-2) or without (LID-1) 1 percent potassium perchlorate in pregnant rats. The potassium perchlorate was used to produce hypothyroxinemia in the pregnant rats. Cell migration and cytoarchitecture in the somatosensory cortex and hippocampus of the 40-day-old offspring were examined (n = 5-7 pups per group). The number of dams per group was not provided. According to the authors, the reproductive performance of the LID-2 animals and the post-natal growth of their pups was normal (although no details are provided). Serum T4 levels were 90 percent lower in both the LID-1 and LID-2 dams than in controls. Levels of serum T3 (the hormonally active form of thyroid hormone) in the LID-1 and control dams were similar. The mean T3 in the LID-2 dams was lower than controls, although the difference was much less than that seen for T4 (mean serum T3 (in ng/mL) in controls: 0.73 ± 0.02 (standard error); in LID-1 animals: 0.65 ± 0.15; in LID-2 animals: 0.37 ± 0.06). Litter size, body weight or postnatal growth measures were not affected.

Using BrdU labeling of cells at specific time points of development, the authors took advantage of the normal migration patterns of cortical neuronal cells to investigate the impacts of thyroid deficiencies on normal structural brain development. Normally, cells born later migrate past cells born earlier and occupy more superficial layers of the cortex. When BrdU was administered on gestational days 14-16, there was a decrease in the proportion of BrdU-labeled cells in the deeper cortical layers and an increase in the subcortical white matter in the LID-1 and -2 offspring compared to controls. The researchers noted that gestational days 14-16 are before the fetal thyroid begins producing thyroid hormone (which usually starts around day 17.5-18). As such, these effects are likely due to deficiencies in maternal thyroid hormones rather than any
deficiency of the fetal thyroid. When BrdU was administered on gestational days 17-19, 
there was a decrease in labeled cells in the superficial layers and an increase in the deeper 
layers of the cortex. The researchers used single- and double-label immunostaining to 
find that the BrdU-labeled cells were neurons, not glia.

Overall, these findings provide evidence that the normal pattern of neuronal cell 
migration in the cortex during fetal development can be disrupted by maternal 
hypothroxinemia. In addition, since these effects were assessed in the offspring at 
postnatal day 40, these findings likely represent permanent rather than temporary 
alterations to the cortical cytoarchitecture (Zoeller, 2003). This study was different from 
earlier studies because the level of maternal hypothyroidism introduced was relatively 
mild and treated pups or dams could not be distinguished from controls by their weight, 
growth, reproductive performance, or physical appearance. In previous studies, severe 
hypothyroidism was introduced in the dams of pups by surgical thyroidectomy or strong 
goitrogens such as high dose methimazole.

The results of this study could potentially provide some mechanistic explanation for the 
findings in human studies which have linked decreases in maternal thyroid hormone 
during pregnancy to subsequent altered neurological development in the offspring (e.g. 
Pop et al., 1999, 2003; Haddow et al. 1999). Migration defects in the brain have been 
associated with neurological deficits in humans (Sun et al., 2002). However, it is not 
currently known how the particular effects seen in this study might impact long-term 
neurological function or whether these results apply to humans.

Auso et al., 2004. Normal rat dams were given the goitrogens 2-mercapto-1-
methylimidazole on gestation days 12 through 15. Maternal thyroid hormone levels 
decreased transiently by about 30 percent compared to normal values. There were no 
clinical signs of hypothyroidism. Mean T4 (± SEM) in the treated and control dams was 
11.60 ± 0.67 and 15.90 ± 1.89, respectively. BrdU was injected from gestation day 14-16 
or 17-19 and pups were tested for audiogenic seizure susceptibility 39 days after birth. 
The cytoarchitecture and radial distribution of the BrdU-labeled neurons on postnatal day 
40 was affected in 83 percent of the pups from the treated mothers. Infusion of T4 at 
gestation days 13-15, but not during days 15-18 avoided these alterations. An increase in 
seizures and wild runs in response to acoustic stimulus was seen in the pups from treated 
dams versus controls. These data provide evidence that transient and relatively mild 
decreases in maternal T4 during early pregnancy can lead to permanent architectural 
changes in the brain.

van Wijk et al., 2008. This report describes how a lack of thyroid hormone during early 
development can result in multiple morphological and functional alterations in the 
developing brain of Wistar (HsdCpb:WU) rats. The behavioral effects of perinatal and 
chronic hypothyroidism during development in offspring (male and female) of 
hypothyroid rats were assessed. Twelve dams (starting 2 weeks prior to mating) and 
offspring (one litter per dam, eight pups per litter) were fed an iodide-poor diet and 
drinking water with 0.75 percent sodium perchlorate. This continued either until weaning 
(perinatal hypothyroidism) or until the day of killing (chronic hypothyroidism). The pups 
were tested for neuromotor competence, locomotor activity and cognitive function until 
postnatal day 71, comparing them to age-matched control rats. Early neuromotor 
competence, as assessed in the grip test and balance beam test, was impaired in both
chronic and perinatal hypothyroidism groups. The open field test, assessing locomotor activity, revealed hyperactive locomotor behavioral patterns only in the chronic hypothyroid animals. The Morris water maze test assessed cognitive performance and showed that chronic hypothyroidism affected spatial memory in a negative manner, with perinatal hypothyroidism impairing spatial memory in female rats only. Overall, the effects of chronic hypothyroidism appeared to be more pronounced than the effects of perinatal hypothyroidism. This suggests that the early effects of hypothyroidism on functional alterations of the developing brain depend on the timing of the thyroid hormone deficiency during development and the impacts may be decreased, but not eliminated, if the deficiency is improved.

*Gilbert and Sui, 2008.* These investigators exposed 106 pregnant Long-Evans rats to 0, 30, 300, or 1,000 ppm perchlorate in drinking water (equivalent to 0, 4.5, 44.2, or 140.3 mg/kg-day) from gestational day 6 until weaning (PND 30). Adult male offspring from an unstated number of litters/group were studied with a series of behavioral tasks. These included motor activity as a general test of neurotoxicity (8-11/group), the Morris maze as a spatial learning test (11-17/group), and fear conditioning as a reflection of the integrity of the hippocampus (N unstated). The authors also utilized neurophysiologic measures of synaptic function in the hippocampus including long-term potentiation (LTP), a well established model of synaptic plasticity (14-17/group). There was no positive control. In the dams, T4 was reduced relative to controls by 16 percent, 28 percent, and 60 percent in the 30, 300, and 1,000 ppm dose groups, respectively. Little change was seen in T3 across dose groups and TSH levels were only increased in the highest dose group (1,000 ppm). Perchlorate dose was not associated with body weight in the dam or pups, or with pup eye opening, brain or hippocampal weights.

In the pups, small decreases (i.e., 10-20 percent) in serum T3 and T4 were seen in the two higher dose groups compared to controls on postnatal day 21. However, all serum hormone levels returned to control levels in adulthood. Perchlorate exposure did not affect motor activity, spatial learning, or fear conditioning in the male offspring at ages 3-13 months. Significant reductions in baseline synaptic transmission were observed in hippocampal field potentials at all dose levels. This included reductions in synaptic transmission at the perchlorate dose that only marginally reduced (about 16 percent) circulating levels of thyroid hormone in dams (30 ppm, 4.5 mg/kg/day).

The Morris water maze failed to uncover spatial learning deficits in perchlorate-treated animals despite the observations of altered hippocampal synaptic transmission coupled with spatial learning impairments after thyroid hormone disruption induced by PTU or methimazole noted in this report and in contemporary studies in perchlorate treated animals. Perhaps these differences are related to sex. This study examined only male offspring, while in the van Wilk et al. (2008) study discussed above, spatial memory effects were only seen in females. It may also be related to differences in the mechanism of toxicity or dosimetry compared to PTU and methimazole.

The lack of behavioral effects in the specific tasks used by Gilbert and Sui (2008) may also be a function of dose, degree of hormonal disruption, or the duration of prenatal exposure. Given the cognitive demands and sensitivity of the behavioral tasks, such outcomes are understandable. The failure of perchlorate to detrimentally impact hippocampal LTP is consistent with a lack of effect on behavioral plasticity and it is
possible that the augmentation of PS LTP is a reflection of an adaptive or compensatory response in cell physiology that aids in the reversal of learning deficits. Also, many other brain regions are engaged in the performance of simple learning tasks, and significant behavioral compensation may mask underlying behavioral deficits apparent earlier in development or revealed with more demanding cognitive tasks. Despite the lack of behavioral effects in the specific tasks used, the changes seen in synaptic transmission in adult offspring nevertheless provide evidence in a rodent model that modest degrees of thyroid hormone reduction induced by perchlorate result in persistent alterations in brain function.

**Human Studies**

Many human studies have been published that demonstrate maternal thyroid deficiency during pregnancy affects neuropsychological development of the child. Some of the studies have shown that these effects may occur at thyroid hormone levels that have been traditionally considered to be within normal ranges.

**Man and Jones, 1969.** Man and Jones first reported that maternal hypothyroidism was associated with lower intelligence quotient scores (IQs) in 8-month-old infants. Hypothyroidism was defined in this study by two low serum butanol-extractable iodine test values during pregnancy or by one low serum butanol-extractable iodine value with clinical hypothyroidism. They found that 81 percent of 26 infants of women given thyroid replacement therapy after two low serum iodine tests were classified “normal,” approximately the same percentage as for infants of euthyroid women. In contrast, only 48 percent of the 56 infants of women with two low serum iodine values who were not given adequate thyroid replacement therapy were “normal.”

**Glorieux et al., 1985.** These authors reported that children with significantly retarded skeletal maturation at the time of diagnosis, signifying hypothyroidism in utero, obtained lower global IQs than did children whose skeletal maturity was within normal limits.

**Glorieux et al., 1988.** In a later study, Glorieux et al. studied 43 infants with congenital hypothyroidism and found that low T4 (<2 µg/dL) and retarded bone surface (<0.05 cm²) measurements taken before therapy initiation were strongly correlated with mental development at 3, 5, and 7 years of age (Table 28).

<table>
<thead>
<tr>
<th>Table 28. Mental Outcome in Infants with Congenital Hypothyroidism Relative to Newborn Risk Criteria (Glorieux et al., 1988)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age in years</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>7</td>
</tr>
</tbody>
</table>

<sup>a</sup>p < 0.01
<sup>b</sup>p < 0.001
Rovet et al., 1987. Similar findings have been reported by Rovet et al., who studied intellectual and behavioral characteristics at 1, 2, 3, 4, and 5 years of age of 23 boys and 57 girls with congenital hypothyroidism. The children were assigned to two groups based on degree of skeletal maturity at the time of diagnosis. Forty-five children with bone age <36 weeks were assigned to the delayed group; 35 with bone age 37 to term were assigned to the nondelayed group. Both groups were treated for congenital hypothyroidism and the initial starting dosages of L-thyroxine for the delayed and nondelayed were similar, 8.1 mg/kg and 7.8 mg/kg, respectively. Although most children with athyrosis were found in the delayed group, the group did not differ in birth weight, hormone levels, or family background. Hormone levels at diagnosis of both groups are shown in Table 29. Tests showed that although children in the delayed group performed within the normal range, their scores were significantly lower than those of the nondelayed group from age 2 years on. Perceptual-motor, visuospatial, and language areas were most affected.

| Table 29. Hormone Levels at Diagnosis in Children with Delayed and Nondelayed Skeletal Maturity (Rovet et al., 1987) |
|-------------------------------------------------|--------------------------------------------------|
| **Delayed (n = 45)** | **Nondelayed (n = 35)** |
| TSH (U/dL) | |
| Screening | 136.1 ± 128.8 | 130.6 ± 78.6 |
| Confirmation | 112.5 ± 119.2 | 131.9 ± 100.5 |
| Thyroxine (T4) (µg/dL) | |
| Confirmation | 5.1 ± 4.7 | 5.5 ± 3.9 |
| 1 month | 11.0 ± 5.3 | 10.3 ± 5.7 |
| 3 months | 12.0 ± 4.5 | 13.5 ± 3.9 |
| 6 months | 13.6 ± 2.8 | 12.6 ± 3.2 |
| 9 months | 12.4 ± 3.5 | 14.1 ± 5.3 |
| 12 months | 12.7 ± 2.7 | 13.5 ± 2.3 |

Values represent mean ± standard deviation.

Vermiglio et al., 1990. This study demonstrated that normal euthyroid children born to mothers from severe (area A) and less severe (area B) iodine deficiency regions in northeastern Sicily have a defective visual perceptual integrative motor ability. They studied 719 primary schoolchildren (366 males and 353 females) from these areas ranging from ages 6 to 12 years old (conceived and born between 1975 and 1981). A control group consisted of 370 age-matched schoolchildren from an iodine-sufficient area where rates of goiter were lower (area C). The prevalence of goiter in the schoolchildren of these areas and the daily urinary iodine excretion in the general population between 1976 and 1984 are given in Table 30.

<table>
<thead>
<tr>
<th>Study area</th>
<th>Total population</th>
<th>Prevalence of goiter in the schoolchildren (%)</th>
<th>Daily urinary iodine excretion (µg/day)(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area A (with endemic cretinism)</td>
<td>7,432</td>
<td>70.3 (708)</td>
<td>24.3 ± 16.4 (55)</td>
</tr>
<tr>
<td>Area B (without endemic cretinism)</td>
<td>10,992</td>
<td>45.9 (763)</td>
<td>31.3 ± 18.7 (150)</td>
</tr>
<tr>
<td>Area C (control area)</td>
<td>9,730</td>
<td>8.9 (370)</td>
<td>82.4 ± 43.0 (30)</td>
</tr>
</tbody>
</table>

\(^a\)Mean ± standard deviation; the number of observations is given in parentheses.

Variable degrees of thyroid enlargement were found in 205 of the 719 (28.5 percent) children included in the study from areas A and B (area A: 30.4 percent, visible goiter 15.2 percent; area B: 26.5 percent, visible goiter 16.3 percent). Furthermore, defective visual perceptual integrative motor ability (the Bender Gestalt test) was significantly higher in children from area A (14.4 percent) and area B (13.1 percent) than in those from area C (3.5 percent) (Table 31).

Table 31. Number of Defective, Borderline, and Nondefective Schoolchildren as Assessed by the Bender Gestalt Test (Vermiglio et al., 1990)

<table>
<thead>
<tr>
<th>Performance on Bender(^a)</th>
<th>Area A</th>
<th>Area B</th>
<th>Area A+B</th>
<th>Area C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defective</td>
<td>53 (14.4)</td>
<td>46 (13.1)</td>
<td>99 (13.8)</td>
<td>13 (3.5)</td>
</tr>
<tr>
<td>Borderline</td>
<td>57 (15.5)</td>
<td>67 (19.1)</td>
<td>124 (17.2)</td>
<td>14 (3.8)</td>
</tr>
<tr>
<td>Nondefective</td>
<td>258 (70.1)</td>
<td>238 (67.8)</td>
<td>496 (69.0)</td>
<td>343 (92.7)</td>
</tr>
<tr>
<td>Total</td>
<td>368 (100)</td>
<td>351 (100)</td>
<td>719 (100)</td>
<td>370 (100)</td>
</tr>
</tbody>
</table>

\(^a\)Performance scores: Defective = below -1 standard deviation from average score of normal children of the same age; Borderline = –1 standard deviation from average score; Nondefective = higher than –1 standard deviation from average score.

The statistical comparisons for the Bender Gestalt Test scores across the different areas were as follows:

Defective:

Area A vs. area B: \(\chi^2 = 2.75; p=0.87\) (NS);

Areas A+B vs. area C: \(\chi^2 = 36.25; p<0.000001\)

Borderline:

Area A vs. area B: \(\chi^2 = 1.22; p=0.27\) (NS);

Areas A+B vs. area C: \(\chi^2 = 77.55; p<0.000001\)
Vermiglio et al. (1990) also reported higher frequency of neuromuscular and neurosensorial abnormalities among children from areas A and B (a combined overall prevalence of 18.9 percent) compared to those from area C. The Terman Merrill test of general intellectual aptitude was administered to 96 of the 99 “defective” children and 62 of the 124 borderline children from both areas A and B (Table 31). Ninety-one of the 96 “defective” children (94.8 percent) had IQs lower than 90, as did 35 of the 62 borderline (56.4 percent) children (Table 32).

Table 32. Performance on the Terman Merrill Test of General Intellectual Aptitude Administered to Schoolchildren with Defective or Borderline Performance Scores on the Bender Gestalt Test (Vermiglio et al., 1990)

<table>
<thead>
<tr>
<th>Performance on Bender test</th>
<th>Intelligence quotient score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; 90</td>
</tr>
<tr>
<td>Defective (n = 96)</td>
<td>91</td>
</tr>
<tr>
<td>Borderline (n = 62)</td>
<td>35</td>
</tr>
<tr>
<td>Nondefective (n = 12)</td>
<td>0</td>
</tr>
</tbody>
</table>

Statistical analysis: $\chi^2=52.1; p<0.0000005$.

Despite the adverse effects described above, the serum T3 and T4 levels of the children from area A and area B were within the normal range. This suggests that serum T3 and T4 are not completely accurate indicators of the neurological damages that may be caused by iodine deficiency.

Tillotson et al., 1994. These authors reported the results of a prospective study of psychological outcomes of 361 children with congenital hypothyroidism after five years of treatment and follow-up. They also selected 315 children as controls, matched for school attended, sex, age (within three months), language spoken at home, and social class defined by occupation of the family breadwinner. The severity of the hypothyroidism was assessed using T4 measurements collected at the time of diagnosis (median age 17 days; range 0-114). The study showed that among children with congenital hypothyroidism and given early treatment, those with plasma T4 concentrations of less than 42.8 nmol/L (3.3 µg/dL) at the time of diagnosis had a global deficit in mean IQ of 10 points, while those with higher T4 levels at the time of diagnosis had no deficit.

Bleichrodt and Born, 1994. These authors performed a meta-analysis on 18 studies of iodine deficiency and mental development. Studies included those with information on the general cognitive functioning of children and adults living in iodine-deficient areas and provided the necessary statistical data. Three studies were excluded from the analysis because the composition of the groups studied was different (they were composed exclusively of school children). In the meta-analysis of the effects of iodine deficiency on cognitive development, a large effect size was found with a d-value of 0.90. This means that the mean scores for the two groups (the iodine-deficient group and the non-iodine-deficient group) were 0.90 of a standard deviation (or 13.5 IQ points) apart.
**Pop et al., 1999.** Pop et al. (1999) reported that low maternal fT4 concentrations in apparently healthy women during early gestation are associated with an increased risk of impaired neurodevelopment in the infant. They studied a group of 291 pregnant women in an iodine-sufficient area (in and around the city of Veldhoven, Netherlands) between January and November, 1994. No women in the study group were receiving antithyroid drugs or thyroid hormones. Maternal fT4, TSH, and thyroid peroxidase antibodies were assessed at 12 and 32 weeks’ gestation, and neurodevelopment of 220 healthy children was assessed at 10 months of age. The authors found that children of women with fT4 levels below the 5th (<9.8 pmol/L, n=11) and 10th (<10.4 pmol/L, n=22) percentiles at 12 weeks’ gestation had significantly lower scores on the Bayley Psychomotor Developmental Index (PDI) scale at 10 months of age than children of mothers with higher fT4 values. These findings are shown in Table 33. The mean of PDI scores in all subjects was 100, so the decreases seen here represent about a 7-14 percent decrease. The unadjusted odds ratio for impaired psychomotor development (defined as a one standard deviation decrease from the mean) for a fT4 in the lower 10th percentile was 3.6 (95 percent CI, 1.1-12.1). This rose to 5.8 (95 percent CI, 1.3-12.6) following adjustment for alcohol use, anti-thyroid antibodies, depression, education and other factors.

Although the mean fT4 value for subjects in the lower 10th percentile of fT4 is not given (only the percentile cut-off points are provided), they can be estimated from Table 1 and Figure 2 of the paper. The mean fT4 for subjects in the lower 10th percentile is approximately 9.8 pmol/l compared to a mean fT4 of a little over 13.1 in the remaining subjects. This represents a difference of about 25 percent. Thus, a 25 percent lower maternal fT4 was associated with about a 7 percent decrease in PDI scores in children.

Evidence of a linear association between maternal fT4 and child PDI scores was seen in those children with maternal fT4 levels in the lower 10th percentile (r = 0.46, p = 0.03). No correlation was found between maternal thyroid hormone levels at 32 weeks’ gestation and PDI scores. All children had normal T4 and TSH values. Six of the 22 women with fT4 values in the lower 10th percentile had high levels of anti-thyroid antibodies.

Table 33. Maternal fT4 Levels at 12 Weeks Gestation and PDI Scores in Children at 10 Months of Age (Pop et al., 1999)

<table>
<thead>
<tr>
<th>Low Maternal fT4 Groupa</th>
<th>Difference in PDI scores</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower 5th percentile (n = 11)</td>
<td>14.1</td>
<td>5.9-22</td>
</tr>
<tr>
<td>Lower 10th percentile (n = 11)</td>
<td>7.4</td>
<td>1.1-13.9</td>
</tr>
</tbody>
</table>

These groups were compared to all the children with higher maternal fT4 levels.

**Haddow et al., 1999.** This study involved measurements of TSH, fT4, and T4 in 25,216 pregnant women in Maine at 17 weeks of gestation. Three subgroups of women were selected from this large cohort: 47 women with TSH levels in the upper 99.7th percentile, 15 women with TSH levels in the upper 98th to 99.6th percentile, and 124 women with TSH levels below the upper 98th percentile (the “controls”). Measurements of thyroid function of the women in the study are shown in Table 34. Notably, the fT4 and T4
values of many of the women in the high TSH groups are within normal reference ranges. The researchers then administered 15 neuropsychological tests to the children of these women at ages seven to nine years old. The tests included assessment of intelligence, attention, language, reading ability, school performance, and visual-motor performance. The staff giving the tests did not know whether the children’s mothers were women with hypothyroidism or control women. They found that the children of the 62 women with high serum TSH concentrations (all those above the 98th percentile) performed less well on all 15 tests. Mean IQ scores, as measured by the Wechsler Intelligence Scale for Children, were 4 points lower in the children of women with high TSH levels compared to the children of the control mothers (103 versus 107, p = 0.06). Of the 62 women with elevated TSH levels during pregnancy, 48 were not treated for the condition during the pregnancy. The full-scale IQ scores of their children averaged 7 points lower than those of the 124 matched control children (100 versus 107, p = 0.005). Results were controlled for education, maternal age, sampling time, sample storage time, and gender. The effect size seen in this study is similar in magnitude to that seen in Pop et al. (1999). That is, a difference in maternal T4 or fT4 of about 25 percent was associated with about a 4-7 percent decrease in IQ.

Sixty-four percent of the women with high TSH levels during pregnancy went on to be diagnosed with clinical hypothyroidism over the next 10 years. None of the children were diagnosed as hypothyroid as newborns. Haddow et al. (1999) concluded that even mild and probably asymptomatic hypothyroidism in pregnant women can adversely affect their children’s subsequent performance on neuropsychological tests.

Table 34. Measurements of Thyroid Function in the Study Women During Pregnancy (Haddow et al., 1999)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hypothyroidism (n = 62)</th>
<th>Controls (n = 124)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum TSH (mU/L)</td>
<td>13.2 ± 0.3b</td>
<td>1.4 ± 0.2</td>
</tr>
<tr>
<td>Serum T4 (µg/dL)</td>
<td>7.4 ± 0.1b</td>
<td>10.6 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>(95.2 nmol/L)</td>
<td>(136.4 nmol/L)</td>
</tr>
<tr>
<td>Serum fT4 level (ng/dL)</td>
<td>0.71 ± 0.1b</td>
<td>0.97 ± 0.07</td>
</tr>
<tr>
<td></td>
<td>(9.1 pmol/L)</td>
<td>(12.5 pmol/L)</td>
</tr>
</tbody>
</table>

Values are geometric means ± the logarithmic standard deviation.
bp<0.001 for the comparison with the control women.

Pop et al., 2003. In another study, Pop et al. (2003) reported that a low maternal fT4 during early pregnancy was associated with a delay in infant neurodevelopment. In this study, the researchers followed 115 children and their mothers for two years. Maternal levels of fT4 and TSH were assessed at 12, 24, and 32 weeks of gestation. “Cases” (n = 57) were defined as children of mothers who had fT4 levels in the lower 10th percentile at 12 weeks of gestation and “controls” (n = 58) were defined as children of mothers who had fT4 levels in the upper 50th to 90th percentiles at 12 weeks gestation. Mothers of cases and controls were matched on parity and gravidity. Cases and control families were similar with respect to education, breast feeding, smoking, alcohol use, and income. Mothers with thyroid disease, depression, and TSH levels outside of normal ranges were
excluded. Child mental and motor function was assessed using the Bayley Scales of Infant Development at ages 1 and 2. The results are shown in Table 35. Case children scored 8-10 points lower on the mental and motor scales than control children.

Table 35. Mental and Motor Scale Scores (± Standard Deviation) in Children of Mothers with Low (Cases) and High (Controls) Levels of fT4 at 12 Weeks of Gestation (Pop et al., 2003)

<table>
<thead>
<tr>
<th>Age</th>
<th>Cases</th>
<th>Controls</th>
<th>Difference (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>One year</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental score</td>
<td>95 ± 15</td>
<td>105 ± 14</td>
<td>10 (4-16)</td>
<td>0.004</td>
</tr>
<tr>
<td>Motor score</td>
<td>91 ± 15</td>
<td>99 ± 14</td>
<td>8 (3-12)</td>
<td>0.02</td>
</tr>
<tr>
<td>Two years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental score</td>
<td>98 ± 15</td>
<td>106 ± 14</td>
<td>8 (4-12)</td>
<td>0.02</td>
</tr>
<tr>
<td>Motor score</td>
<td>92 ± 16</td>
<td>102 ± 16</td>
<td>10 (6-16)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

All children had normal Apgar scores at birth and normal screening results for congenital hypothyroidism on the seventh postpartum day. Pop et al. observed that children of women who had low fT4 levels during early gestation and who exhibited a further decrease of fT4 during gestation had the lowest mental and motor scores. In contrast, children whose mothers had a low fT4 at 12 weeks gestation, but whose fT4 levels increased during later gestation, did not show any delay in development. Maternal fT4 levels at 24 and 32 weeks gestation were not associated with decreases in childhood motor or mental scores.

The mean fT4 levels at 12 weeks of gestation was 11.5 pmol/l in the case mothers and 17.0 pmol/l in the control mothers (estimated from Figure 2 in their paper), about a 32 percent difference. Thus, a 32 percent difference in fT4 was associated with an 8-10 drop in mental and motor scores. This is about the same magnitude of effect as seen in Pop et al. (1999) and Haddow et al. (1999). Importantly, the cut-off point used to define cases (the 10th percentile) is above the level traditionally used to define low fT4 levels (the 2.5th or 5th percentiles), thus many of the cases had maternal values of fT4 that would traditionally be defined as normal. Figure 3 of the paper presents a scatter plot of maternal fT4 values and childhood mental and motor scores in the case children at 2 years of age. Evidence of a linear relationship is present for both mental scores ($r^2 = 0.13$, $p = 0.006$) and psychomotor scores ($r^2 = 0.23$, $p = 0.001$). These $r^2$ values suggest that maternal fT4 accounts for a statistically significant fraction of the total variance in these scores.

Klein et al., 2001. In a follow-up investigation, Klein et al. (2001) studied serum TSH concentrations of pregnant mothers at a mean of 17 weeks gestation and the standard neuropsychological testing results of their offspring at a mean age of 8 years. They found an inverse correlation between the severity of maternal hypothyroidism and IQs in the offspring. The researchers divided the mothers and their offspring into three groups: group 1, 124 control mothers with TSH concentrations <98th percentile; group 2, 28
mothers with TSH concentrations between the 98th and 99.85th percentile; group 3, 20 mothers with TSH concentrations ≥99.85th percentile. Mothers treated for hypothyroidism during pregnancy were excluded from the study. The mean neuropsychological test score (± standard deviation) for the children of the 124 control mothers was 107 (± 12). Means (and standard deviations) for the children in groups 2 and 3 were 102 (± 15, p > 0.05 compared to group 1) and 97 (± 14, p = 0.003 compared to group 1), respectively. The incidences of IQs greater than one standard deviation below the control mean were 15 percent, 21 percent, and 50 percent for the children in group 1, group 2, and group 3, respectively. In a related study, the same authors also reported spontaneous abortions and intra-uterine fetal deaths were more than five times as common in the mothers with TSH concentrations above the 98th percentile than in control mothers with TSH concentrations below the 98th percentile.

Kooistra et al., 2006. This study involved the children of 108 pregnant women who had fT4 values below the 10th percentile at 12 weeks gestation (“cases”) and 96 pregnant women who had fT4 values in the 50th to 90th percentiles at 12 weeks gestation (“controls”). People with clinical disease were excluded. Case and control mothers were matched on parity and gravidity. Newborn development was assessed at 3 weeks of age using the Neonatal Behavioral Assessment Scale. Mean thyroid hormone levels in the cases and controls are shown in Table 36.

Table 36. Mean (± Standard Deviation) Maternal fT4 and TSH, and the Proportion with Anti-thyroid Antibodies at 12 Weeks Gestation (Kooistra et al., 2006)

<table>
<thead>
<tr>
<th></th>
<th>Cases</th>
<th>Controls</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>fT4 (pmol/L)</td>
<td>11.4 ± 1.0</td>
<td>17.0 ± 0.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>TSH (mIU/L)</td>
<td>1.6 ± 1.0</td>
<td>1.1 ± 0.8</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Anti-thyroid</td>
<td>16.7%</td>
<td>4.2%</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>

A statistically significant difference between case and control children was only seen in the orientation scores. In the linear regression analysis with orientation score as the dependent variable, a statistically significant association was seen for case status (b = 0.173, p = 0.02). The researchers also performed a logistic regression analysis where a “low orientation score” was used as the dependent variable. This was defined as subjects who had scores less than one standard deviation below the mean score. The odds ratio for a low score in controls versus cases was 0.17 (95 percent CI, 0.05 - 0.51). This was adjusted for maternal smoking, alcohol use, gestational age, depression, gender of the child, and maternal education. No difference was seen between case and control children’s mothers fT4 or TSH during the 2nd or 3rd trimester or in the newborns heel stick T4. No associations were seen between Neonatal Behavioral Assessment Scale scores and TSH or fT4 later in pregnancy.

This study is different from some of the other studies discussed above because the children were very young at the time their cognitive status was assessed. The authors argue that this is an advantage because it limits the impact of external socioeconomic
factors that can affect a child’s cognitive development as they age. The authors also note a potential major disadvantage: a test given this early may not be predictive of development later in life.

**Vermiglio et al., 2004.** This was a 10-year prospective study which included 16 healthy women and their offspring from a moderately iodine deficient area (area A, mean urinary iodine levels = 48.1 µg/day) and 11 healthy control women and their offspring from a marginally iodine sufficient area (area B, mean urinary iodine levels = 95.2 µg/day) in Northeastern Sicily. Maternal levels of thyroid hormones were assessed at 8, 13, and 20 weeks of gestation. In the offspring, IQ scores and tests for attention deficit and hyperactivity disorder (ADHD) were done at ages 8-10 years. IQ scores were tested using the Wechsler Intelligence Scale for Children, 3rd Edition, and tests for ADHD were derived from the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.

All children were euthyroid at delivery, age 18-36 months, and at ages 8-10 years. ADHD was diagnosed in 11 of 16 children from the low iodine area and in none of the 11 children from the moderate iodine area. The mean IQ score in the children from the low iodine area was 18 points lower than the mean score in the children from the high iodine area (92.1 ± 7.8 versus 110 ± 10, p < 0.00005). Maternal fT4, T4, and TSH levels at 8, 13, and 20 weeks are presented in figure form and show that fT4 and T4 levels were roughly 10-20 percent lower for those children from the low iodine area (A) compared to children from the moderate iodine area (B) (Figure 11). Eight of the 16 women from the low iodine area had fT4 values that were lower than normal for the gestational week. Seven of these eight generated 8 of the 11 children subsequently diagnosed with ADHD. Only one woman from the control area had a gestational fT4 value outside of normal ranges.

When all children were grouped together, a strong correlation was seen between the child’s IQ score and maternal fT4 (r = 0.56, p < 0.005) and TSH (r = -0.63, p < 0.001). These results and the graph of these data (Figure 3 in their paper and Figure 12 below) suggest that the relationship between T4 and IQ extends into the normal ranges of T4.
Figure 11. Maternal Thyroid Hormone Levels at 8, 13, and 20 Weeks Gestation (Vermiglio et al., 2004). Area A is iodine-deficient, area B is iodine-sufficient.

Figure 12. Associations between IQ Scores and Maternal fT4 and TSH in All Children (Vermiglio et al., 2004)
Other studies: Not all studies have found associations between fetal hypothyroidism and impaired brain development. Several studies examined children exposed to antithyroid drugs such as carbimazole, propylthiouracil, or thiamazole in utero and did not find an association between the treatment and the later intellectual and somatic development of the children (McCarrol et al., 1976; Burrow et al., 1978; Messer et al., 1990). The statistical power of these studies may be limited since they had relatively small sample sizes and the dosage and timing of the treatment were not known in many cases. In the study reported by Burrow et al. (1978), most of the treated children were exposed to propylthiouracil in utero during the third trimester, and only four were exposed during the first and second trimester. The studies reported by Burrow et al. (1978) and Messer et al. (1990) were retrospective studies in which maternal T4 levels during the first and second trimesters were not known. It is possible that the treated women had normal T4 levels during the early part of their pregnancies.

Fenzi et al. (1990) conducted neuropsychological assessments on a group of 384 school children (aged 6-14 years) residing in an area of known iodine deficiency (Tuscany, Italy). A group of 352 sex- and age-matched schoolchildren from an iodine sufficient area was used as a control group. Goiter prevalences in the endemic and control areas were 51.9 percent and 5.6 percent, respectively. No statistically significant differences in serum total T4, total T3, TSH levels between the endemic and control areas were found. Serum thyroglobulin values were higher in the iodine-deficient area. Global neuropsychological performance and cognitive levels were similar between a group of 50 schoolchildren from the endemic area and another group of 50 schoolchildren from the control area, matched for age, sex and socioeconomic conditions. However, Fenzi et al. (1990) also found that some marginal impairment, with particular regard to motor-perceptual functions, was present in areas of moderate iodine deficiency.

New England Congenital Hypothyroidism Collaborative Program (1981) found that there was no correlation of eventual IQs with the severity of the thyroid dysfunction or with the results of biochemical tests at the time treatment was begun, provided it was begun before clinical hypothyroidism appeared. A diagnosis of hypothyroidism was made when an infant’s initial blood concentration of T4 was two or more standard deviations below the mean for newborn infants (6 µg/dL or less) and circulating TSH concentrations were elevated on repeated occasions. 336,000 newborn infants in Connecticut, Maine, Massachusetts, New Hampshire, and Rhode Island born between January 1, 1976 and June 30, 1978 were screened. Sixty-three infants were diagnosed with hypothyroidism and treated with L-thyroxine in doses sufficient to maintain circulating T4 concentration between 10 and 14 µg/dL during the first year of life and between 8 and 11 µg/dL thereafter. The control group consisted of 57 euthyroid children who had low T4 and normal TSH concentrations on neonatal screening. The revised Stanford-Binet examination was given to all the test subjects at 3 or 4 years of age. The authors reported that the mean IQ for the hypothyroid infants with adequate thyroid treatment was 106±16 and the mean for the controls was 106±15. They also reported that half of the patients with the lowest IQs (more than one standard deviation below the mean) had normal bone maturation. It is important to note that the results of Pop et al. (1999) indicated that it is the low maternal T4 level during early gestation (around week 12) that is associated with impaired neurodevelopment in the infant. It is possible that T4 levels at birth are not a
perfectly accurate indicator for thyroid related neurodevelopmental deficiencies occurring in early gestation.

Liu et al. (1994) examined the IQs of eight children (Group 1) who were born to mothers that were hypothyroid during the first trimester of pregnancy. Maternal free T4 values at the fifth to 10th gestation weeks ranged from 2.3 to 6.3 pmol/L (normal range, 11.6 to 24.5 pmol/L) in six of the eight cases. In the other two cases, maternal total T4 values were 52.8 and 30.9 nmol/L (normal range, 92.7 to 218.8 nmol/L). TSH levels of the eight mothers at that time ranged from 25 to 190 mU/L (normal range < 5 mU/L). Maternal T4 and TSH levels became normal after T4 supplementation by 13 to 28 weeks of gestation. Seven of the eight children had nine siblings who had not been exposed to maternal hypothyroidism throughout gestation (Group 2); they were used as controls. Ages of the children in groups 1 and 2 at the time of IQ examination were 4 to 10 years in group 1 and 4 to 15 years in group 2. The investigators reported that all children in group 1 showed normal IQs. There was no statistically significant difference in the mean IQ between the children in group 1 who had siblings (112±11) and their siblings in group 2 (106±8). The study is limited by the small sample size. The administration of T4 supplement to hypothyroid mothers at 13 weeks of gestation might have averted adverse neurological development in the fetuses.

Summary of Data on Thyroid Hormones and Childhood Cognitive Development

While not all studies have reported clear links between maternal or neonatal levels of thyroid hormone and the subsequent neurological development of the child, at least five studies have. Studies by Haddow et al. (1999), Pop et al. (1999, 2003), Kooistra et al. (2006), and Vermiglio et al. (2004) have all reported statistically significant deficits in measures of childhood cognition and development in groups whose maternal gestational levels of T4 or fT4 include values that have traditionally been considered to be within normal reference ranges. For example, in Kooistra et al. (2006), the mean 12-week gestational fT4 in the low fT4 group was 11.4 pmol/L. Since the reference range given by the authors was 8.7-19.6 pmol/L, it is likely that the majority these mothers had fT4 values within the reference range. In addition, all of these studies excluded women with overt clinical thyroid disease, so the effects identified are occurring in the children of women who are asymptomatic. The animal studies by Auso et al. (2004), Gilbert and Sui (2008), Lavado-Autric et al. (2003), and others support the biologic plausibility that relatively mild decreases in maternal thyroid hormone levels in gestation can cause significant and permanent neurological changes in the offspring.

Some of the effects seen in the human studies are difficult to compare from one study to the next since different outcome measures are used in different studies. Despite this, the magnitudes of the effects seen in these studies seem to be markedly consistent across at least several of them. Table 37 shows the effect sizes in four of these studies. In each, a difference in maternal fT4 or T4 of about 11-32 percent is associated with a decrease in the cognitive development score in the offspring of about 7-16 percent.
Table 37. Comparison of Four Studies of Maternal T4 or fT4 in the First Trimester and Subsequent Child Neurologic Development

<table>
<thead>
<tr>
<th>Gestation week</th>
<th>Haddow et al., 1999</th>
<th>Pop et al., 1999</th>
<th>Pop et al., 2003</th>
<th>Vermiglio et al., 2004</th>
<th>Averages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12 weeks</td>
<td>12 weeks</td>
<td>12 weeks</td>
<td>8-13 weeks</td>
<td></td>
</tr>
<tr>
<td>Thyroid measure</td>
<td>T4 (ng/dl)</td>
<td>fT4 (pmol/l)</td>
<td>fT4 (pmol/l)</td>
<td>fT4 (pmol/l)</td>
<td></td>
</tr>
<tr>
<td>Low thyroid group</td>
<td>7.4</td>
<td>9.8a</td>
<td>11.5a</td>
<td>13.9</td>
<td></td>
</tr>
<tr>
<td>Normal thyroid</td>
<td>10.6</td>
<td>13.1a</td>
<td>17.0a</td>
<td>15.7</td>
<td></td>
</tr>
<tr>
<td>group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent difference</td>
<td>30.2%</td>
<td>25.2%</td>
<td>32.4%</td>
<td>11.4%</td>
<td>24.8%</td>
</tr>
<tr>
<td>Outcome measure</td>
<td>IQ</td>
<td>PDI</td>
<td>MDI &amp; PDIb</td>
<td>IQ</td>
<td></td>
</tr>
<tr>
<td>Percent difference</td>
<td>7%</td>
<td>7%</td>
<td>9%</td>
<td>16%</td>
<td>11%</td>
</tr>
</tbody>
</table>

*a*Approximation based on graphs or other data.  
*b*Average of the mean mental and psychomotor scales at ages 1 and 2.

Alterations in Thyroid Hormones and Effects on Serum Lipids and Other Biomarkers of Cardiovascular Disease Risk.

Effects on childhood cognitive development are not the only adverse effects that have been linked with relatively small changes in thyroid hormone levels. The following discussion focuses on the possible cardiovascular effects of relatively minor changes in thyroid hormone levels.

Asvold et al., 2007. This was a cross-sectional population-based study of TSH and serum lipid levels in 30,656 subjects from Norway. All subjects had no known thyroid disease and all had TSH levels within normal reference ranges (0.50 – 3.5 mU/I). The researchers found a linear and statistically significant (p for trend < 0.001) increase in total serum cholesterol, LDL cholesterol, non-HDL cholesterol and triglycerides, and a linear decrease in HDL cholesterol (p for trend < 0.001), with increasing TSH. Results were adjusted for age, smoking, and time since last meal. Adjustments for daily medication use, month of serum collection, diabetes mellitus, heart disease and stroke had no substantial impact on results. Although the changes were associated with very low p-values, the magnitudes of the changes were relatively small. For example, the mean LDL in the lowest TSH group (TSH = 0.50-0.99 mU/I) was 4.11 mmol/L while the mean LDL in the highest TSH group (3.0-3.5 mU/I) was 4.34 mmol/L, about a 5 percent change. Although this level of change might be considered small on an individual basis, a 5 percent shift in cholesterol levels in a large population could represent a large increase in the population risks of diseases associated with cholesterol (e.g. heart disease and stroke). The results of this study are supported by other smaller studies which also
reported similar effects for thyroid hormone levels within normal reference ranges (Pallas et al., 1991; Bakker et al., 2001; Michalopoulou et al., 1998).

**Canaris et al., 2000.** This was a cross-sectional study of serum lipids, thyroid hormones, and reported history of thyroid disease in 25,862 self-selected people who attended a statewide health fair in Colorado. Subjects were divided into five groups based on their TSH and T4 levels, and mean levels of serum lipids were determined for each group. The TSH and T4 levels used to define these groups and the mean lipid levels seen in each group are shown in Table 38. Statistically significant trends were seen across groups for total cholesterol (p-trend < 0.001), LDL cholesterol (p-trend < 0.001), and triglycerides (p-trend = 0.02), but not for HDL cholesterol. It is unclear whether these results were adjusted for any other variables although the authors did note that levels of estrogen use were similar across all thyroid hormone categories. Although the presence of a linear trend within the euthyroid group was not specifically evaluated, the overall trend across all of the thyroid hormone groups suggests that a trend is likely to occur over the entire range of TSH values.

### Table 38. Mean Lipid Levels in Various Thyroid Groups in Canaris et al., 2000

<table>
<thead>
<tr>
<th>Group definitions</th>
<th>TSH (mIU/L)</th>
<th>T4 (nmol/L)</th>
<th>Cholesterol (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothyroid</td>
<td>&gt; 5.1</td>
<td>&lt; 57.9</td>
<td>6.5 4.4 1.4 2.0</td>
</tr>
<tr>
<td>Subclinical hypothyroid</td>
<td>&gt; 5.1</td>
<td>≥ 57.9</td>
<td>5.8 3.8 1.4 1.8</td>
</tr>
<tr>
<td>Euthyroid</td>
<td>0.3-5.1</td>
<td>--</td>
<td>5.6 3.6 1.3 1.7</td>
</tr>
<tr>
<td>Subclinical hyperthyroid</td>
<td>0.01-&lt;0.3</td>
<td>--</td>
<td>5.4 3.4 1.5 1.6</td>
</tr>
<tr>
<td>Hyperthyroid</td>
<td>≤ 0.01</td>
<td>--</td>
<td>5.2 3.4 1.3 1.6</td>
</tr>
</tbody>
</table>

**Dullaart et al. (2007).** This was a cross-sectional study of carotid artery intima media thickness (IMT) in 44 men and 34 women who all that fT4 (11.0-19.5 pmol/L) and TSH (0.5 mU/L -4.0 mU/L) levels within normal reference ranges. IMT is a subclinical measure of potential atherosclerosis. In multiple linear regression analyses adjusted for age, gender, pulse pressure, body mass index, and HDL cholesterol, IMT was inversely related to fT4 (b = -0.19, p = 0.046), but not to TSH or the presence of anti-thyroid antibodies.

While several previous studies have reported that overt thyroid disease is associated with increased cardiovascular disease risks (Boelart and Franklyn, 2005; Vanhaelst et al., 1967, Becker, 1985), the findings from this study and the studies of Asvold et al. (2007) and Canaris et al. (2000), all provide evidence that cardiovascular disease risk is also affected by decreases in thyroid hormone levels within normal reference ranges.
DOSE-RESPONSE ASSESSMENT

Noncarcinogenic Effects

Animal Data

The primary effect of perchlorate exposure is the disruption of thyroid hormone regulation. This mode of action is supported by the results of a number of animal studies that show that perchlorate inhibits thyroidal iodide uptake; changes serum T3, T4, and TSH levels; causes thyroid enlargement; induces thyroid follicular cell hypertrophy and hyperplasia; and increases the risk of thyroid tumors.

Adult rodents might be more susceptible than adult humans to the perturbation of thyroid hormone homeostasis by short-term exposure to perchlorate. Significant changes in serum T3, T4, and TSH levels were observed even at the 0.01 to 0.1 mg/kg-day dose range. Rat fetuses and rat pups are reportedly more sensitive to the effects of perchlorate than adult rats. In several reproductive and developmental studies, colloid depletion of the thyroid, thyroid hypertrophy, and abnormal brain development were found in rat pups exposed to perchlorate \textit{in utero} and after birth. Based on these study results (Springborn Laboratories, 1998; Argus Research Laboratories, 2001), a LOAEL of 0.01 mg/kg-day can be identified.

Using data derived from animal studies, Clewell \textit{et al.} (2001, 2003, 2007) have developed a PBPK model to predict the distribution and the NIS inhibition effect of perchlorate in rats of different life stages (e.g., adult male, pregnant female, fetus, lactating female, and neonate). The model predicts that the fetal rat thyroid is most vulnerable to the inhibitory effect of perchlorate on the uptake of iodine by the thyroid. According to Clewell \textit{et al.} (2007), “the fetus is predicted to receive the greatest dose (per kilogram body weight) due to several factors, including placental sodium-iodide symporter (NIS) activity and reduced maternal clearance of ClO$_4$.”

Human Data

Selecting the Critical Effect: Reduced Thyroid Iodide Uptake

In developing PHGs, OEHHA is required by the California Safe Drinking Water Act of 1996 (Health and Safety Code Section 116365) to consider the existence of groups in the population that are more susceptible to adverse effects of drinking water contaminants than are typical healthy adults. The primary mechanism of perchlorate toxicity is inhibition of iodide uptake by the thyroid. Three groups that may be particularly susceptible to this effect of perchlorate due to alterations in iodine status are pregnant women, the developing fetus or young child, or women with low iodine intake.

Thyroid stress of pregnancy: In his review paper, Glinoer (2001) suggested that pregnancy causes profound changes in thyroid function and represents a stress on the thyroid hormonal system. In the first trimester of gestation, there is an increased need for thyroid hormones and an increased need for iodine from the diet. When iodine nutrition levels are sufficient, physiological adaptation takes place. When iodine is restricted or deficient, adequate physiological adaptation is difficult to achieve and is progressively
replaced by pathological alterations occurring in parallel with the degree of long-term iodine deprivation. Glinoer concluded, “Therefore, pregnancy typically reveals underlying iodine restriction and gestation results in an iodine-deficient status, even in conditions with only a marginally restricted iodine intake, such as is observed in many European regions.”

Results of a prospective study reported by Kung et al. (2000) showed that in a borderline iodine-sufficient area (median urinary iodine level = 9.8 µg/dL), pregnancy can pose a stress on the thyroid, resulting in higher rates of maternal goitrogenesis as well as neonatal hypothyroxinemia and hyperthyrotrophinemia. Thyroid enlargement in these women persisted and failed to revert completely even 3 months after delivery.

**Susceptibility of the fetus and young child:** As reviewed above, several epidemiological studies provide evidence that iodine deficiency during pregnancy may adversely affect brain development and cause neurointellectual deficits in the offspring. These effects are not limited to areas with severe iodine deficiency and endemic cretinism; effects have been associated with levels of thyroid hormone that fall into what have traditionally been considered normal ranges. The severity of effects may depend on the timing and the severity of the iodine deficiency. In several studies conducted in areas with moderate or even mild iodine deficiency, mainly in southern Europe, it was shown that developmental abnormalities may occur in schoolchildren who are clinically euthyroid. Even borderline iodine deficiency might lead to impaired school performance in some children (Glinoer, 2001).

Since the thyroid is dependent on iodide for thyroid hormone production, inadequate iodine intake can lead to decreased thyroid hormone production. Studies in humans that have identified links between relatively small decreases in thyroid hormone levels during pregnancy and significant effects on cognition in the offspring child include Pop et al. (1999, 2003), Haddow et al. (1999), Klein et al. (2001), Kooistra et al. (2006), and Vermiglio et al. (2004). These findings are supported biologically by animal studies that have linked decreases in maternal thyroxine (T4) during pregnancy to permanent structural changes in the brains of the offspring (Lavado-Autric et al., 2003; Auso et al., 2004; Gilbert and Sui, 2008). Importantly, some of these effects are seen at thyroid hormone levels that are within what has been traditionally defined as the normal range, and in pregnant mothers and offspring without any other evidence of clinical hypothyroidism.

One reason why the fetus or the young child may be particularly susceptible to inadequate iodine intake and small changes in thyroid hormone levels is that the fetal and infant periods are critical times of brain and neurological development. Another reason may be that the fetus and infant do not have fully developed thyroids and have stores of thyroid hormone that are much lower than in adults (van den Hove et al., 1999). These low stores may make them more susceptible to temporary decreases in iodine intake or other factors that may inhibit hormone production. Finally, some data suggests that many young children in the U.S. may not have an adequate iodine intake. Pearce et al. (2007) estimated that 47 percent of the breast milk samples in their study of 57 women from the Boston area did not contain enough iodine to meet the infant iodine intake recommended by the Institute of Medicine.
Women with low iodine intake in the U.S.: The rates of most thyroid diseases are much greater in women than in men. The reason for this is unknown, but it suggests that women might be more susceptible to environmentally-caused thyroid problems than men. In Blount et al. (2006), statistically significant associations between perchlorate and T4 and TSH were seen in women but not in men. In addition, effects on T4 were only seen in women with evidence of somewhat reduced iodine intake (urinary iodine concentrations < 100 µg/L), but not in women with evidence of higher iodine intakes. These effects highlight the importance of gender and iodine status when assessing the potential impacts of perchlorate.

Urinary iodine concentration is an indicator of the adequacy of iodine intake for a population. According to the World Health Organization (WHO), the median urinary iodine concentrations in iodine-sufficient populations should be greater than 100 µg/L (WHO, 1994; as cited in Hollowell et al., 1998). In the NHANES 2001-2, the geometric mean urinary iodine concentration in women was 126 µg/dL, which indicates an adequate iodine intake for the population as a whole. However, this level does not mean that every individual member of the population has an adequate iodine intake. In Blount et al. (2006), the perchlorate-T4 association was seen in women with spot urinary iodine levels below 100 µg/L, a group that included 37 percent of all women in the study. The fact that the women in this study were derived from an essentially nationally representative sample of all women in the U.S. suggests that a large number of U.S. women (e.g., 37 percent) have iodine intakes that may put them at risk for effects from perchlorate.

In summary, the primary mechanism of perchlorate toxicity is the inhibition of iodine uptake into the thyroid gland and a subsequent decrease in thyroid hormone production. Iodine deficiency and thyroid insufficiency have been linked to a number of significant adverse health effects including goiter, impaired cognitive development, and increases in cardiovascular risk factors. Some of these links have been seen at levels of iodine and thyroid hormones that have been considered to be within normal reference ranges. OEHHA has chosen to use a reduced thyroidal iodine uptake as the critical effect for the perchlorate PHG. This is the same critical effect used in the OEHHA 2004 PHG perchlorate document and the same one used by the NRC in their report on the health implications of perchlorate exposure (OEHHA, 2004; NAS, 2005). The purpose of this PHG is to help prevent any inhibition of iodine uptake that could potentially lead to the adverse effects described above.

Selecting the Critical Study

OEHHA used the 14 day perchlorate clinical dosing study of Greer et al. (2002) for its dose-response analysis in the 2004 perchlorate PHG document, and the lower confidence limit for five percent inhibition of iodide uptake as the benchmark response (BMR). In this update, to determine a level of perchlorate exposure that would not inhibit thyroidal iodide uptake, OEHHA again has chosen the Greer et al. (2002) study as the critical study and applied the benchmark dose approach for identification of the point of departure. This was selected as the critical study because it was an experimental study in humans where subjects were given known doses of perchlorate and evidence of a dose-response relationship was seen with a critical outcome, iodide uptake in the thyroid. Several other studies have linked perchlorate exposure to changes in thyroid hormones.
and these were evaluated as to whether they could be used for risk assessment. However, these were either based on ecologic measurements of perchlorate exposure or only a single or few urinary perchlorate measurements (e.g., Kelsh et al., 2003; Blount et al., 2006). Basing exposure on only a few measurements could bias true associations towards the null and lead to an underestimation of true risks.

Selecting the Point of Departure

U.S. EPA recommends benchmark dose (BMD) methods to estimate reference doses (RfDs), which are used along with other scientific information to set criteria and standards for noncancer human health effects. Until recently, RfDs have mainly been determined from NOAELs, which represent the highest experimental dose for which no adverse health effects have been documented. Using the NOAEL to determine RfDs has long been recognized as having limitations in that it: 1) is limited to one of the doses in the study and is dependent on study design; 2) does not account for variability in the estimate of the dose-response; 3) does not account for the slope of the dose-response curve; and 4) cannot be applied when there is no NOAEL, except through the application of an uncertainty factor. This is in contrast to the benchmark dose approach which takes into account data from all of the dose levels, as well as the shape of the dose-response curve, and the precision of the finding at each dose level and the precision of the dose-response relationship as a whole. A benchmark dose approach is less dependent on the dose levels selected by the researchers and can be used when a NOAEL is not present. In summary, the benchmark dose approach takes into account a much greater amount of data from an individual study than the NOAEL approach. A goal of the benchmark dose approach is to define a starting point of departure for the computation of a reference value (RfD) or slope factor that is more independent of study design.

The BMD is the dose associated with a predefined level of response, the benchmark response (BMR). For this analysis, a five percent decrease of mean radioactive iodine uptake by the thyroid is used as the BMR. A five percent decrease was selected because this is the lowest level of effect that is commonly detectable with statistical significance in many animal and human studies.

A statistical lower bound of the BMD, the 95 percent lower confidence limit (the BMDL), is used as the point of departure for defining an exposure level that is likely to be without an appreciable risk of deleterious effects in humans. Using the BMDL rather than the BMD helps to account for the uncertainty inherent in a given study and according to the U.S. EPA, “assures (with 95 percent confidence) that the desired response is not exceeded” (U.S. EPA, 2000).

Calculation of the BMD Using Greer et al. (2002)

OEHHA used the BenchMark Dose Software, version 2.0.0.33 (U.S. EPA, 2008) to perform the analyses based on the human data reported by Greer et al. (2002) shown in Table 39. This is the same analysis, using the same data from Greer et al., that was used in the OEHHA 2004 perchlorate PHG document. A detailed discussion of the application of the software is provided in a U.S. EPA (2000) document, “Benchmark Dose Technical Guidance Document, External Review Draft.”
OEHHA tried several curve fitting models provided by the software and found the Hill model\(^1\) adequately describes the data (goodness of fit test, \(p=0.46\)), shown plotted in Figure 13. The fit is generally considered adequate when the \(p\)-value is greater than 0.10. Other models, including linear and polynomial models, fit the data poorly based on visual inspection and goodness of fit \(p\)-values.

The form of the response function estimated by the model is as follows:

\[
\text{Response} = \text{intercept} + (v \times \text{dose}^n) / (k^n + \text{dose}^n)
\]

where:

- \(\text{intercept} = 0\)
- \(v = -67.076\)
- \(n = 1.43546\)
- \(k = 0.0684664\)

\(^1\) The Hill model was run with the following settings: intercept = zero, power parameter restricted to be greater than one, a constant variance model assumed. The BMR was a 5 point decrease in iodide uptake.

---

\[\text{Inhibition of thyroidal iodide uptake (\%)}\]

\[\text{Perchlorate dose (mg/kg-day)}\]

**Figure 13.** Analysis of the Greer *et al.* (2002) Data by the Benchmark Dose Approach.
The estimated BMD and BMDL corresponding to a five percent reduction of the mean thyroidal iodide uptake are 0.0068 mg/kg-day and 0.0037 mg/kg-day, respectively. These are the same BMD and BMDL calculated in the 2004 OEHHA perchlorate PHG document. It should be noted that the BMDL of 0.0037 mg/kg-day is lower than the lowest dose tested, 0.007 mg/kg-day, in the Greer et al. (2002) study.

Table 39. Benchmark Dose Modeling of the Human Data of Greer et al. (2002)

<table>
<thead>
<tr>
<th>Average dose (mg/kg-day)</th>
<th>Change in 24 hr radioactive iodine uptake by the thyroid (%)</th>
<th>Number of subjects in each dose group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>0.007</td>
<td>-1.844</td>
<td>22.019</td>
</tr>
<tr>
<td>0.02</td>
<td>-16.393</td>
<td>12.828</td>
</tr>
<tr>
<td>0.1</td>
<td>-44.693</td>
<td>12.32</td>
</tr>
<tr>
<td>0.5</td>
<td>-67.076</td>
<td>12.114</td>
</tr>
</tbody>
</table>

Carcinogenic Effects

There are two published epidemiological studies that investigated the association between perchlorate in drinking water and cancer (Li et al., 2001; Morgan and Cassady, 2002). Based on the reported data, it does not appear that perchlorate was associated with increased risks of cancer in the two study areas during the study periods, under the limitations of the studies.

Several subchronic oral studies in rodents showed that perchlorate induced hypertrophy and hyperplasia in the thyroid gland (Caldwell et al., 1995; Springborn Laboratories, 1998; Argus Research Laboratories, 1998b, 1998d, 1999, 2001; Keil et al., 1998). In two chronic oral studies, perchlorate at relatively high concentrations (over 1,000 mg/kg-day) was shown to produce tumors in rats (Kessler and Kruskemper, 1966) and mice (Pajer and Kalisnik, 1991). However, only benign tumors were observed in the study reported by Kessler and Kruskemper (1966), and inadequate reporting and low survival of the control and exposed animals lowered confidence in the results reported by Pajer and Kalisnik (1991). In a developmental study reported by Argus Research Laboratories (1999), thyroid follicular cell adenomas were observed in two male Sprague-Dawley rats (2/30) exposed to 30 mg/kg-day perchlorate in utero and after birth. No such tumors were found in the vehicle control (0/30). Though the incidence is not significant using standard tests (e.g., Fisher’s exact test), the fact that the tumors were found in 19-week old rats and the historical incidence of this type of tumor in male Sprague-Dawley rats in 2-year studies reported in the literature is only 3-4 percent makes the finding noteworthy (U.S. EPA, 2002).

Complex anions structurally similar to perchlorate, such as pertechnetate (TcO₄⁻), perrhenate (ReO₄⁻) and tetrafluoroborate (BF₄⁻), are also capable of inducing thyroid follicular cell neoplasia in test animals (Green, 1978, as cited in Paynter et al., 1988).
Based on the limited data available, there are reasons to believe that perchlorate is a potential carcinogen in rodents.

After reviewing thyroid carcinogenesis in rodents and in humans, U.S. EPA (1998b) in the “Assessment of Thyroid Follicular Cell Tumors” stated that “in spite of the potential qualitative similarities, there is evidence that humans may not be as sensitive quantitatively to thyroid cancer development from thyroid-pituitary disruption as rodents. Rodents readily respond to reduced iodide intake with the development of cancer, humans develop profound hyperplasia with “adenomatous” changes with only suggestive evidence of malignancy. Even with congenital goiters due to inherited blocks in thyroid hormone production, only a few malignancies have been found in humans.”

One factor that may play a role in interspecies quantitative sensitivity to thyroid stimulation is the influence of protein carriers of thyroid hormones in the blood. In humans, other primates, and dogs a high affinity thyroxine-binding globulin tightly binds T4 (and T3 to a lesser degree); this protein is missing in rodents, rabbits and lower vertebrates. As a result, T4 bound to proteins with lower affinity in the rodent is more susceptible to removal from the blood, metabolism, and excretion from the body. As shown in Table 40, the estimated serum half-life of T4 is much shorter in rats (<1 day) than in humans (5-9 days). This shorter T4 half-life in rats requires a higher level of serum TSH and T4 production rate than in the adult human (U.S. EPA, 1998b). Thus, it appears that the rodent thyroid gland is chronically stimulated by TSH levels above basal levels to compensate for the increased turnover of thyroid hormones, and this in turn could move the gland towards increased growth and potential neoplastic change more readily than in humans. It is interesting to note that adult male rats have higher serum TSH levels than females, and they are often more sensitive to goitrogenic stimulation and thyroid carcinogenesis. In humans, there is no sex difference in hormone levels, but females more frequently develop thyroid cancer (U.S. EPA, 1998b).

The quantitative difference in the thyroid responses of humans and rodents to perchlorate is also evident in the data provided in this document. Several 14-day drinking water studies showed significant depression in serum T3, T4, and elevation in serum TSH levels in rodents exposed to doses as low as 0.01 or 0.1 mg/kg-day (Caldwell et al., 1995; Springborn Laboratories, 1998; Keil et al., 1998; Yu et al., 2000). By contrast, serum T3, T4, and TSH levels in humans that are not iodine deficient are much less sensitive to perchlorate exposure. For instance, after exposure to perchlorate in drinking water as high as 12 mg/kg-day for 1, 2, or 4 weeks, no significant changes in serum T3 and T4 levels were found in male volunteers. Serum free T4 and TSH levels were significantly depressed following perchlorate exposure when compared to those before exposure (Brabant et al., 1992; Mattie, 2000). A significant reduction in intrathyroidal iodine concentration was also noticed in the study reported by Brabant et al. (1992). Lawrence et al. (2000) found no change in serum T3, T4, and TSH in male volunteers exposed to perchlorate in drinking water at 0.14 mg/kg-day for 1 and 2 weeks. Greer et al. (2002) exposed male and female volunteers to perchlorate in drinking water at 0.02, 0.1, or 0.5 mg/kg-day for 2 weeks and collected blood samples on day 1, 2, 3, 4, 8, and 14. No significant depression in serum T3 and T4 nor elevation in serum TSH was observed. No dose-response relationships were noticed for these thyroid and pituitary hormones. These data show that though a similar mode of action of perchlorate is operative in rodents and
humans, the sensitivities of serum T3, T4, and TSH levels of the two species to perchlorate may not be the same.

**Table 40. Inter- and Intraspecies Differences of T3, T4, and TSH Levels and Sensitivity to Thyroid Cancer (Modified from U.S. EPA, 1998b)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Human</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroxine-binding globulin</td>
<td>Present</td>
<td>Essentially absent</td>
</tr>
<tr>
<td>T4 half-life</td>
<td>5-9 days</td>
<td>0.5-1 day</td>
</tr>
<tr>
<td>T3 half-life</td>
<td>1 day</td>
<td>0.25 day</td>
</tr>
<tr>
<td>T4 production rate</td>
<td>$1 \times$ kg body weight</td>
<td>$10 \times$ kg body weight</td>
</tr>
<tr>
<td>TSH</td>
<td>$1 \times$</td>
<td>$6-60 \times$</td>
</tr>
<tr>
<td>Follicular cell morphology</td>
<td>Low cuboidal</td>
<td>Cuboidal</td>
</tr>
<tr>
<td>Sex differences</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum TSH</td>
<td>Sexes equal</td>
<td>Male $\leq 2 \times$ Female</td>
</tr>
<tr>
<td>Sensitivity to thyroid cancer</td>
<td>Female $= 2.5 \times$ Male</td>
<td>Male $&gt; Female$</td>
</tr>
</tbody>
</table>

In evaluating a thyroid carcinogen, it is important to determine the mode of action as it impacts the choice of models in high-to-low dose extrapolation. In the “Assessment of Thyroid Follicular Cell Tumors,” U.S. EPA (1998b) stated that in order to show the antithyroid activity of a chemical is the cause of thyroid tumors observed in rodents, it is necessary to demonstrate the following:

1. Increases in thyroid growth;
2. Changes in thyroid and pituitary hormones (considered to be the most important);
3. Location of the sites of antithyroid action (documents where in the body the chemical under assessment leads to perturbations in thyroid-pituitary function);
4. Dose correlations among various effects (to determine where the growth curve for the thyroid gland deviates from the normal pattern of cell replacement and how this relates to doses producing tumors); and
5. Reversibility of effects following treatment cessation during the early stages of disruption of the thyroid-pituitary axis (shows that permanent, self-perpetuating processes have not been set into motion).

The available toxicity data of perchlorate appear to have fulfilled the five requirements described above. Several *in vitro* and *in vivo* genotoxicity studies have been performed on perchlorate. Under the testing conditions, none of the tests indicates perchlorate is a genotoxic agent. Perchlorate is known to inhibit the uptake of iodide in the thyroid, thereby causing a reduction in the hormones T3 and T4. Subchronic and chronic drinking water studies showed that perchlorate exposure depressed serum T3 and T4 but elevated serum TSH levels in rodents and rabbits. At higher exposure levels, thyroid follicular cell hypertrophy, thyroid follicular cell hyperplasia, and increased thyroid
weights were also observed in adults as well as postnatal rats (see “Subchronic Toxicity” and “Developmental and Reproductive Toxicity”).

There is also evidence that the thyroid follicular cell hypertrophy and hyperplasia observed in rats exposed to ammonium perchlorate might be reversible. In the study reported by the Springborn Laboratories (1998), absolute and relative thyroid/parathyroid weights were significantly increased in male rats exposed to 10 mg/kg-day for 14 days as well as 90 days. However, no significant increases in both absolute and relative thyroid/parathyroid weights were observed in male rats exposed to 10 mg/kg-day for 90 days, followed by a 30-day recovery period. Similarly, absolute and relative thyroid/parathyroid weights were significantly increased in female rats exposed to 10 mg/kg-day for 90 days, but no significant increases in terms of both absolute and relative thyroid/parathyroid weights were observed in female rats exposed to 10 mg/kg-day for 90 days, followed by a 30-day recovery period.

The available data suggest that thyroid tumors observed in rodents exposed to perchlorate via the oral route are likely to be caused by the disruption of thyroid-pituitary homeostasis. It follows that if there were no thyroid and pituitary hormone changes, and no thyroid follicular cell hypertrophy and hyperplasia, there would be no thyroid tumors. For this reason, the perchlorate dose determined for prevention of a detectable decrease in T4 in humans (non-carcinogenic effect) is reasoned to be protective against thyroid tumors as well.

**CALCULATION OF THE PHG**

**Noncarcinogenic Effects**

*Acceptable Daily Dose (ADD)*

For estimation of a health-protective concentration of perchlorate in drinking water, an acceptable daily dose (ADD) of the chemical from all sources will first be calculated. This involves incorporation of appropriate estimates of uncertainty in the extrapolation of the critical toxic dose from human or animal studies to the estimation of a lifetime ADD that is unlikely to result in any toxic effects. For this purpose, the following equation can be used:

\[
\text{ADD} = \frac{\text{NOAEL}/\text{LOAEL}/\text{BMDL}}{\text{UF}} \text{ in mg/kg-day}
\]

where,

\[
\text{ADD} = \text{estimated maximum daily dose which can be consumed by humans for an entire lifetime without toxic effects;}
\]

\[
\text{NOAEL}/\text{LOAEL}/\text{BMDL} = \text{no-observed-adverse-effect level, lowest-observed-adverse-effect level, or lower limit on the benchmark dose estimated from the critical study;}
\]

\[
\text{UF} = \text{uncertainty factor(s).}
\]
For this case, we have chosen to estimate the ADD from the lower limit of the two-sided 95 percent confidence interval of the perchlorate dose estimated to cause a five percent reduction in iodide uptake in the thyroid gland based on the findings of Greer et al. (2002).

We chose an uncertainty factor of 10 to help account for interindividual variability in the population that was not captured by the Greer et al. (2002) study. The Greer et al. study included only 37 healthy adults so the variability of the study data is likely to be smaller than that in the general population. Furthermore, the study population did not specifically examine individuals with low iodine intake, pregnant women, infants, or people with other potential susceptibility factors. Potentially susceptibility groups include:

- Women with low iodine intakes. In Blount et al. (2006), statistically significant associations between perchlorate and T4 were seen in women with urinary iodine levels below 100 µg/L, but not in women with higher iodine levels. Estimates from NHANES 2001-2 suggest that 37 percent of all women in the U.S. have urinary iodine levels below 100 µg/L (Blount et al., 2006).

- The developing fetus. Studies have shown that decreases in maternal T4 during pregnancy, even relatively small ones, can lead to significant cognitive deficits in the offspring. PBPK modeling data from Clewell et al. (2003) suggest that thyroid iodide uptake inhibition for a given external dose of perchlorate may be up to two times greater in the fetus and neonate than in adults (their Table 5).

- Neonates and young children, who need adequate levels of thyroid hormones for proper physical and cognitive development. Some data suggest that neonates have minimal stores of thyroid hormone and iodide and thus are less able than older children or adults of maintaining normal serum thyroid hormone levels when thyroid hormone production is reduced (Van den Hove et al., 1999). In addition, data obtained from several ecological studies (Kelsh et al., 2003; Brechner et al., 2000; Buffler et al., 2006) show possible links between perchlorate in drinking water during pregnancy and thyroid hormone levels in newborns.

- Breast-fed infants. Several studies have shown that breast milk can contain relatively high levels of perchlorate and that perchlorate can reduce the secretion of iodide into the breast milk by inhibiting the NIS in the mammary gland. The breast milk of many women may not provide an adequate iodine intake for the breast-fed child (Pearce et al., 2007). Since breast milk is the sole source of iodine for some infants and iodine is necessary for normal brain development, an adequate level of iodine in breast milk is vital to the well-being of breast-fed infants.

- Lactating women. Lactating mothers are considered a potentially sensitive subpopulation for effects of perchlorate because their need for iodine is greater than other adults. They are therefore at greater risk of getting an insufficient amount of iodine from the diet. NAS (2001) suggests an Estimated Average Requirement and a Recommended Dietary Allowance of iodine almost two-fold higher for lactating mothers than for other adults.

- Pregnant women, who also have increased iodine requirements.
• People with thyroid diseases.
• People with high levels of thiocyanate, which typically comes from food or tobacco smoking. Data from Steinmaus et al. (2007) suggest that the magnitude by which perchlorate reduces T4 levels is about two times greater in people with high thiocyanate levels than in people with average or low thiocyanate levels (Table 20).

OEHHA considered an additional uncertainty factor of three to account for the short duration of the Greer et al. (2002) study. However, there is evidence in this study that iodine uptake is inhibited fairly quickly after exposure begins and the inhibition does not increase or increases only slightly as exposure continues. That is, in the three highest dose groups (those in which statistically significant reductions in iodine uptake were seen), the greatest proportion of the inhibition occurred by the second day of dosing and either did not worsen or worsened only slightly by day 14 of dosing. Furthermore, it can be argued that if there is no reduction in thyroidal iodide uptake, there is no reduction in stored iodide, and extending the exposure duration is not likely to have an impact on the thyroid function. For this reason, we concluded that no additional factor is necessary to account for the short duration of the critical study.

Given an uncertainty factor of 10,

\[
\text{ADD} = \frac{3.7 \, \mu\text{g/kg-day}}{10} = 0.37 \, \mu\text{g/kg-day}
\]

**Public Health Protective Concentration (C)**

Calculation of a proposed public health-protective concentration (C) for perchlorate in drinking water uses the following equation for non-carcinogenic endpoints:

\[
C = \text{ADD} \, \mu\text{g/kg-day} \times \text{BW/WC} \times \text{RSC}
\]

where:

(BW/WC) = the ratio of body weight (kg) and tap water consumption rate (L/day); the ratio for the 95th percentile of infants age 0-6 months is estimated to be 4.3 kg-day/L (U.S. EPA, 2004); and

RSC = relative source contribution. A value of 0.73 (73 percent from water) is used to account for exposure of infants to perchlorate in their diet.

The upper 95th percentile water consumption rate and body weight ratios are based on water intake from all sources in drinking water consumers (U.S. EPA, 2004; Kahn and Stralka, 2008). This includes both direct water (plain water used for drinking) and indirect water (water intake that occurs as a result of water used in the final preparation of foods at home or restaurants). Water intake rates for various population groups are shown in Table 41. We focus on infants in these calculations based on the data discussed above showing that this group may be particularly susceptible to perchlorate. This is based on the studies from California and elsewhere that provided evidence that thyroid hormone levels in infants were adversely affected by relatively low perchlorate exposure levels (Kelsh et al., 2003; Brechner et al., 2000; Buffler et al., 2006; Steinmaus et al., 2010; Li et al., 2000a; Crump et al., 2000). The increased susceptibility in infants is also
supported by data suggesting that many infants may not be receiving adequate iodine in their diets and that young infants have low stores of thyroid hormone (less than one day's worth compared to several weeks worth in adults) (van den Hove et al., 1999; Pearce et al., 2007).

Food and water are the primary sources of exposure to perchlorate for most people. Perchlorate has been detected in a wide variety of foods, including fruits, vegetables, grains, dairy milk, and human breast milk (Kirk et al., 2005; Pearce et al., 2007; Murray et al., 2008). Perchlorate levels in urine from NHANES, as reflected in the analysis of Blount et al. (2006), are generally supportive of the FDA analysis. Together, these data demonstrate that food is the primary source of perchlorate for the general population.

Estimates of perchlorate intake from food were derived from the U.S. FDA’s Total Dietary Survey 2005–2006 as reported in U.S. EPA, 2008b. The RSC was defined as the proportion of the ADD not derived from food, and was calculated using the following equation:

\[
\text{RSC} = \frac{(\text{ADD} - \text{estimated perchlorate intake derived from food})}{\text{ADD}}
\]

For most adults, including pregnant and lactating women, the mean perchlorate intake from food was estimated to be 0.10 µg/kg-day. At an ADD of 0.37 µg/kg-day, the RSC then equals 0.73, or 73 percent of the acceptable dose available for consumption in tap water.

The U.S. FDA Total Diet Survey did not provide information on perchlorate intake in infants less than 6 months old. However, Schier et al. (2009) measured perchlorate concentrations in 15 different powdered infant formulas (using perchlorate free water) and calculated mean perchlorate intake values based on the estimated daily ingested volume of formula. Perchlorate concentrations in formula varied by formula type and ranged from 0.03-5.05 µg/L, and the estimated geometric mean intake of perchlorate from the different formula types ranged from 0.03 to 0.29 µg/kg-day, with an average of 0.10 µg/kg-day. Using this average and the equation above, an RSC of 0.73 is also estimated for infants.

Using this RSC, the health protective concentration for infants is estimated to be:

\[
\begin{align*}
C &= 0.37 \text{ µg/kg-day} \times 4.3 \text{ kg-day/L} \times 0.73 \\
C &= 1.15 \text{ µg/L} = 1 \text{ µg/L (ppb) (rounded)}
\end{align*}
\]

Table 41 shows the values of C calculated for infants compared to those for other subpopulations. A relative source contribution of 73 percent and an uncertainty factor of 10 were used in all calculations.
**Table 41. Estimated Health Protective Water Concentrations of Perchlorate for Various Subpopulations, Assuming Intakes of Perchlorate in Food of 0.1 µg/kg-day\(^a\) and an RSC of 0.73\(^b\)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Drinking Water Intake (L/kg-day)(^c)</th>
<th>BW/WC (kg-day/L)</th>
<th>C (µg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (&lt; 6 months old)</td>
<td>0.234</td>
<td>4.3</td>
<td>1.15</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>0.044</td>
<td>22.7</td>
<td>6.14</td>
</tr>
<tr>
<td>Lactating women</td>
<td>0.057</td>
<td>17.5</td>
<td>4.74</td>
</tr>
<tr>
<td>Females (age 15-44)</td>
<td>0.046</td>
<td>21.7</td>
<td>5.87</td>
</tr>
<tr>
<td>Adults (20+)</td>
<td>0.044</td>
<td>22.7</td>
<td>6.14</td>
</tr>
</tbody>
</table>

\(^a\)Based on estimated adult intakes using data from the 2005-6 U.S. FDA Total Dietary Study (U.S. EPA, 2008b) and infant intake from the data of Schier et al. (2009).  
\(^b\)Calculated as: (ADD – estimated food perchlorate intake) / ADD).  
\(^c\)95th percentile intake for all drinking water sources in drinking water consumers (includes both direct and indirect water).

Based on these estimates, OEHHA proposes a PHG of 1 ppb (µg/L). We conclude that this level is health protective for lifetime exposure to perchlorate in drinking water, and is protective of sensitive populations including infants, pregnant women and their fetuses, as well as those with low intake of iodine or high intake of other thyroid iodide uptake inhibitors.

A benchmark dose analysis was also done using the NHANES 2001-2 data discussed above (Blount et al., 2006), and this provided results similar to those obtained using the Greer et al. data (See Appendix). The NHANES 2001-2 analysis required several data transformations, which greatly increased its complexity. The analysis using the Greer et al. data was used to calculate the final proposed PHG since it is an experimental study where exposure levels are known for more than just a single point in time.

**Carcinogenic Effects**

There are no adequate data from human studies to evaluate the cancer potency of perchlorate. Several studies in laboratory animals have reported increases in thyroid tumors following perchlorate exposures, although these have involved doses that are orders of magnitude higher than the exposure levels seen in the dose-response data we used for our BMD calculations. Furthermore, there are difficulties in estimating cancer potency of perchlorate based on animal cancer data because of differences in iodine deficiency and thyroid disease status (background rates) in laboratory animals compared to humans. For these reasons, a quantitative dose-response evaluation was not performed for the carcinogenic effects of perchlorate. It is reasoned that by setting the perchlorate PHG low enough to avoid impacts on thyroid hormone status, all other potential adverse thyroid effects, including benign and malignant thyroid tumors, will be prevented.
RISK CHARACTERIZATION

In the most comprehensive survey yet conducted (NHANES 2001-2), perchlorate was detected in the urine of every one of the 2,820 people tested (Blount et al., 2007). This suggests that probably everyone in California, as well as everyone in the U.S., is exposed to perchlorate through some source.

The primary routes of exposure are through food and water. In a recent study by the U.S. FDA, perchlorate was found in many commonly consumed foods including dairy products, fruits, and vegetables (U.S. FDA, 2009). In fact, perchlorate was detected in at least one sample of over 70 percent of the individual food items tested. The U.S. EPA recently estimated that as many as 16.6 million people in the U.S. may be drinking water with perchlorate concentrations greater than 4 ppb (U.S. EPA, 2008a). In California, from 2004 to April 2009, detectable levels of perchlorate were reported in 297 public drinking water sources (DPH, 2009). The Colorado River is also known to be contaminated with perchlorate, and this water source is used by several large public drinking water agencies in California. For both the U.S. EPA and the California DPH surveys discussed above, analyses were based on detection limits of 4 ppb, and it is possible that millions more people are exposed at levels below this (e.g., 2-4 ppb). This highlights the potential widespread perchlorate exposure in California that may be occurring from public drinking water sources.

The current OEHHA PHG of 6 ppb was set in 2004. The methods used to develop the proposed PHG described here are similar to those used to develop the 2004 PHG in that both are based on the same thyroidal iodine uptake inhibition data from the Greer et al. (2002) study, and the BMD and BMDL calculations are the same in both analyses. The major difference between the 2004 PHG calculations and the present proposal is that the 2004 PHG document focused on pregnant women and their fetuses as the primary susceptible population, whereas the proposed PHG focuses on infants. This new focus is based on several factors.

First, studies from California and elsewhere provide evidence that thyroid hormone levels in infants were adversely affected by perchlorate at exposure levels that were much lower than the levels shown to cause no effects in healthy adults (Kelsh et al., 2003; Brechner et al., 2000; Buffler et al., 2006; Steinmaus et al., 2010; Li et al., 2000a; Crump et al., 2000). Second, new data suggests that many infants may not be receiving adequate iodine in their diets. In a study of nursing mothers in Boston, 47 percent of breast milk samples did not contain enough iodine to meet the infant iodine intake recommended by the Institute of Medicine (Pearce et al., 2007). Since the mechanism of perchlorate toxicity is a reduced iodide uptake into the thyroid, perchlorate-related toxicity is likely to be greater in infants who are already deficient in iodine. Third, young infants have low stores of thyroid hormone (less than one day’s worth, compared to several week’s worth in adults) (van den Hove et al., 1999). Because of these low stores, infants may be less able to tolerate transient periods of decreased iodide uptake and decreased thyroid hormone production compared to adults. Fourth, human data show that perchlorate can interact with other contaminants to produce a greater effect (Blount et al., 2006, Steinmaus et al., 2007). Finally, new data available from the U.S. EPA show that drinking water intakes per body weight are higher in infants than previously thought.
This means that infants are likely to have greater perchlorate exposure per body weight for a given concentration of perchlorate in drinking water than was estimated in the 2004 OEHHA PHG.

Incorporation of these new data on infants resulted in two key changes in the proposed PHG compared to the 2004 PHG, and are the reasons why the proposed PHG (1 ppb) is lower than the 2004 PHG (6 ppb). First, based on an enhanced susceptibility in infants, as discussed above, and the fact that the Greer et al. study included only healthy adults, OEHHA has increased the uncertainty factor applied to infants from the factor of 3 used in the 2004 PHG to a factor of 10 used in this proposed PHG. Second, the new drinking water consumption rates for infants are based on both total direct (i.e., from tap water) and indirect water (i.e., tap water added to make foods) intake, and are higher than those used in the 2004 PHG document.

It should be noted that in addition to the use of an uncertainty factor of 10, OEHHA has made a number of decisions to ensure that the PHG is health protective. For instance, the identification of the point of departure, prevention of thyroidal iodide uptake, is a health-protective decision since it is intended to prevent the very first step of a process that leads to thyroid hormone imbalance and other related adverse health effects. Using the 95\textsuperscript{th} percentile of the body weight/water consumption ratios is also health-protective.

The use of data on water intake for all water sources rather than for only community water supplies had only a minor impact on the calculation for infants. The 95\textsuperscript{th} percentile water intake for community water only for infants age 0-6 months (in community water consumers) was 0.221 L/kg-day (versus 0.234 L/kg-day for all sources). This corresponds to a BW/WC ratio of 4.5 kg-day/L (versus 4.3 kg-day/L for all sources) and a C of 1.22 µg/L (versus 1.15 µg/L when data on all water sources is used).

OEHHA uses a BMD\textsubscript{05} (rather than a BMD\textsubscript{10} or a higher response rate) and a BMDL (i.e., the lower 95 confidence level of the BMD) as the point of departure in the benchmark dose modeling. The Greer et al. (2002) study involved only healthy adult volunteers. A large body of evidence suggests that a variety of groups may be particularly susceptible to perchlorate and these groups likely involve a large fraction of the U.S. and California populations. For example, consistent data from several large ecological studies suggest that perchlorate in drinking water may be associated with decreases in thyroid hormone levels in newborns (Kelsh et al., 2003; Brechner et al., 2000; Buffler et al., 2006). Since most of these involved large population-based samples, and since everyone is a newborn at some point in their lives, these findings, if true, are relevant to the entire California population.

Recent evidence from NHANES 2001-2 and other sources suggests that women with low iodine intake also represent a susceptible group (Blount et al., 2006). And, as with infants, this group likely also represents a large fraction of the population. In fact, 37 percent of all women in NHANES 2001-2 had urinary iodine concentrations at the levels where perchlorate-thyroid hormone relationships were identified.

Currently, the actual number of people that are likely to be affected by perchlorate from public drinking water in California is unknown. However, given the data above suggesting that hundreds of public water sources in California contain perchlorate, and given that potential susceptible groups including infants and women with low iodine.
intake represent a large fraction of the entire population, the number of people that may be affected by perchlorate exposure through their public water supplies is likely to be quite large.

The purpose of the proposed perchlorate PHG is to help prevent any perchlorate-related reduction in thyroid iodine uptake that might lead to decreases in thyroid hormone production. As discussed above, recent evidence suggests that even small decreases in thyroid hormone levels may be associated with significant adverse effects, including altered cognitive development in children and increased cardiovascular risk factors in adults. Importantly, these changes have been seen at thyroid hormone levels that are within what have been traditionally defined as normal reference ranges, and have occurred in people without any other evidence of overt thyroid disease. These findings suggest that any change in thyroid hormone levels, no matter how small, may be associated with at least some increased risk of thyroid-related adverse outcomes.

It might be argued that the magnitudes of the effects seen in these studies were relatively small, and might not be noticeable in otherwise healthy individuals. For example, in a person who is otherwise healthy, a 10 percent decrease in thyroid hormone levels, a five percent increase in serum LDL, or a one percent drop in IQ may not be noticeable in that particular person. However, this ignores the impact of these effects on a population basis. Any downward shift in the mean T4 in a population could increase the number of people who fall into the range of T4 values that are associated with high risks of either subtle or overt thyroid-related disease and toxicity. In addition, given the importance of cognitive development and cardiovascular disease to the health and well-being of society, even very small changes in the overall mean population levels of these outcomes are likely to have profound impacts if the causative exposure and its related effects occur on a widespread basis (Miller et al., 2009).

OTHER REGULATORY STANDARDS

Currently, there is no Federal MCL for perchlorate. The methods OEHHA used to calculate the ADD (0.37 μg/kg-day) in this document are similar to those used by the National Research Council (NRC) to calculate its most recent perchlorate RfD of 0.7 μg/kg-day (NAS, 2005) in that both used the data on iodide uptake from Greer et al. (2002) and both used an uncertainty factor or 10 to account for inter-individual variability. The primary difference between the two is OEHHA’s use of the benchmark dose approach rather than the no-observed-effect level approach used by the NRC. The advantages of the benchmark dose approach over the no-observed-effect level approach are that it is less dependent on the study design and the dose levels selected by the researchers, and it takes into account the slope and variability of the dose-response curve. In contrast, the no-observed-effect level approach takes only one dose level into account and is highly dependent on the dose levels selected by the researchers.

In its most recent risk assessment, U.S. EPA (2008a) used the NRC perchlorate RfD of 0.7 μg/kg-day to calculate a health reference level (HRL) for pregnant women of 15 ppb (assuming a 70 kg body weight, drinking water intake of 2 liters per day, and an RSC based on U.S. FDA TDS data of 0.62). U.S. EPA then used current estimates of perchlorate levels in drinking water to estimate that about 16,000-28,000 pregnant
women will be exposed above the HRL at any one time. Based on this, U.S. EPA (2008a) concluded that perchlorate occurs infrequently at levels of health concern in public water systems and therefore a national primary drinking water regulation for perchlorate would not present a “meaningful opportunity for health risk reduction for persons served by public water systems.” The major differences between this U.S. EPA analysis and the OEHHA PHG calculations presented here is that OEHHA used the benchmark dose approach (with the inherent advantages discussed above), and that OEHHA focused on infants rather than pregnant women as the primary susceptible group. This focus on infants resulted in our using a higher drinking water intake rate than was used by U.S. EPA for pregnant women. This higher intake rate, combined with our use of the benchmark dose approach, are the major reasons why the proposed PHG is lower than the U.S. EPA HRL.

The current California State MCL is 6 µg/L. Several other states have action levels in the range of 1-20 µg/L as shown in the table below.

Table 42. State and Tribal MCLs or Advisory Levels for Perchlorate (U.S. EPA, 2003)

<table>
<thead>
<tr>
<th>State</th>
<th>MCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>California</td>
<td>6 ppb</td>
</tr>
<tr>
<td>New York</td>
<td>5 ppb and 18 ppb</td>
</tr>
<tr>
<td>Texas</td>
<td>4 ppb, 7 ppb or 10 ppb</td>
</tr>
<tr>
<td>Arizona</td>
<td>14 ppb</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>2 ppb</td>
</tr>
<tr>
<td>Maryland</td>
<td>1 ppb</td>
</tr>
<tr>
<td>New Mexico</td>
<td>1 ppb</td>
</tr>
<tr>
<td>Nevada</td>
<td>18 ppb</td>
</tr>
</tbody>
</table>
REFERENCES


Argus Research Laboratories (2001). Hormone, thyroid and neurohistological effects of oral (drinking water) exposure to ammonium perchlorate in pregnant and lactating rats and in fetuses and nursing pups exposed to ammonium perchlorate during gestation or via material milk. Protocol no. 1416-003. Argus Research Laboratories, Inc., Horsham, PA.


Brabant G (1994). Personal communication with Dr. G Brabant concerning ongoing perchlorate work in humans by Drs. D Tocco and B Mulholt in March and April 1994 [as cited in U.S. EPA, 2002].


Lawrence JE, Lamm SH, Braverman LE (2001). Low dose perchlorate (3 mg daily) and thyroid function. Thyroid 11:295.


Mattie DR (2000). Consultative letter, AFRL-HE-WP-CL-2000-0039, hormone data from Brabant human perchlorate (1.0 and 12.0 mg/kg-day) kinetics drinking water study [memorandum with attachments to Annie Jarabek]. Wright-Patterson Air Force Base, OH; Air Force Research Laboratory; June 30.


levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol 138(2):141-145.


http://www.oehha.ca.gov/prop65/hazard_ident/pdf_zip/SodNitHID.pdf


Porterfield SP (1994). Vulnerability of the developing brain to thyroid abnormalities: environmental insults to the thyroid system. Environ Health Perspect 102(Suppl. 2):125-130.


Schilt AA (1979). Perchloric acid and perchlorates. GF Smith Chemical Co., Columbus, Ohio.


TERA (2003). External comments submitted by Michael Dourson, Toxicology Excellence for Risk Assessment, Cincinnati, OH.


APPENDIX 1:

PERCHLORATE BENCHMARK DOSE CALCULATIONS USING DATA FROM BLOUNT ET AL., 2006 ("NHANES 2001-2").

STUDY DESCRIPTION
This was a cross-sectional study of urinary perchlorate levels and serum levels of thyroid hormones in 2,299 men and women ≥ age 12 who took part in the 2001-2002 National Health and Nutrition Examination Survey (NHANES) (Blount et al., 2006). NHANES is conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention (CDC) and is designed to assess the health and nutrition status of the non-institutionalized population of the U.S. This survey involves a complex multistage sampling design with some over-sampling in certain areas and among certain subgroups, but is designed to provide results that are nationally representative. Information that is collected as part of this survey includes questionnaire data on demographic information, smoking, health history, and medication use. A single serum measurement of T4 and TSH and a single measurement of urinary perchlorate and iodine concentration were also collected. Other information collected included urinary creatinine, thiocyanate, and nitrate; and serum levels of albumin, cotinine, and c-reactive protein. The authors assessed the relationship between serum thyroid hormone levels and urine perchlorate concentrations using a linear regression analysis adjusted for potential confounding variables and co-variates including age, urinary creatinine, estrogen use, c-reactive protein, cotinine, ethnicity, menopause, premenarche, pregnancy, fasting time, body mass index, and kilocalorie intake. Several factors including urinary perchlorate and creatinine and serum TSH were logarithm transformed to normalize their distributions. Exclusions included subjects with missing data on co-variates, a history of thyroid disease, current use of thyroid medications, extreme values of T4 or TSH (n = 3), and subjects missing perchlorate measurements. No association was found between T4 or TSH and perchlorate in men. In women, separate analyses were done for women with urinary iodine levels above and below 100 µg/L. This level was chosen since it is used by the World Health Organization to define iodine deficiency in a population. Thirty-seven percent of the women in this study had urinary iodine levels below 100 µg/L. The results of the analyses in women are shown in Table A1. A statistically significant association was seen between TSH and perchlorate in women with iodine levels above and below 100 µg/L. A statistically significant association was also seen between T4 and perchlorate in women with urinary iodine levels below 100 µg/L but not in women with iodine levels above 100 µg/L.
Table A1. Associations between Thyroid Hormone Levels and the Logarithm of Urinary Perchlorate in Women with High and Low Levels of Urinary Iodine (Blount et al., 2006)

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>b</th>
<th>SE</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine iodine &lt; 100 µg/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>348</td>
<td>-0.8917</td>
<td>0.1811</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Logarithm of TSH</td>
<td>356</td>
<td>0.1230</td>
<td>0.0373</td>
<td>0.0010</td>
</tr>
<tr>
<td>Urine iodine ≥ 100 µg/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>724</td>
<td>0.2203</td>
<td>0.3687</td>
<td>0.5503</td>
</tr>
<tr>
<td>Logarithm of TSH</td>
<td>697</td>
<td>0.1137</td>
<td>0.0506</td>
<td>0.0249</td>
</tr>
</tbody>
</table>

Abbreviations: b, regression coefficient; N, number of subjects, SE, standard error of the regression coefficient.

Differences in the numbers of subjects with an iodine category are due to differences in the number of subjects missing data on co-variates in each analysis. Except for perchlorate and creatinine, only co-variates with p-values < 0.10 were retained in each model.

SELECTION OF THE CRITICAL EFFECT, CRITICAL STUDY, BENCHMARK RESPONSE (BMR), AND CONTROL GROUP

Defining the Critical Effect

*Thyroid hormones.* As discussed in the previous sections, perchlorate has been associated with a variety of health and physiological effects. We focus our efforts here on its impacts on the thyroid gland for the following reasons:

- These effects have been reported at lower exposure levels than the other significant health effects associated with perchlorate. By preventing low dose thyroid effects, these other effects should also be prevented.
- Thyroid hormone is a very important hormone for homeostatic control in humans and alterations in thyroid hormone production have been associated with serious adverse outcomes, including diminished cognitive development and IQ in children and increased cardiovascular disease risk factors in adults.
- As discussed below, detailed dose-response data on perchlorate and thyroid hormones meeting the major tenets of causal inference are available from Blount et al., 2006.

*Is this adverse?* While some people may not consider a decreased T4 or increased TSH to be an “adverse” health outcome in isolation, as detailed in the PHG document decreases in T4 are very closely associated with outcomes that are clearly adverse such as childhood cognitive development and alterations in lipid metabolism (which are closely linked to cardiovascular diseases). Statistically significant dose-response relationships have been seen between T4 and each of these outcomes in studies which involve at least some subjects with T4 or TSH values at levels traditionally considered to be within normal reference ranges (discussed in previous sections).
Selecting the Critical Study

The data on women with urinary iodine levels below 100 μg/L evaluated in Blount et al. and collected as part of NHANES 2001-2 were used for our point of departure calculations. These data showed a clear, statistically significant dose-response relationship in a group of subjects that are an essentially representative sample of all subjects age 12 and older in the U.S.. Because this is basically a representative sample, the levels of perchlorate exposure seen in this group are likely to be those commonly found in the general U.S. population. Other reasons for selecting this study include:

- Its relatively large sample size, which helps ensure adequate statistical power.
- Its inclusion of a relatively large number of people who are potentially susceptible to perchlorate (i.e. women with low iodine intake). Other clinical dosing or occupational studies did not specifically examine susceptible groups. Using these other studies could therefore underestimate effects in susceptible populations.
- It is a human rather than an animal study.
- The individual data is publicly available.
- The findings linking perchlorate to thyroid effects are consistent with the major tenets of causal inference (reviewed in earlier sections).

In the NHANES 2001-2 dataset, the association between T4 and perchlorate was particularly strong in women with both low iodine levels and high thiocyanate levels (Steinmaus et al., 2007). We did not use the high thiocyanate group for our dose-response analysis since it involved only a relatively small number of subjects (n = 78).

Using raw data from NHANES: The main outcome variables in the Blount et al. study are serum levels of T4 and TSH. Levels of these hormones, as well as urinary levels of perchlorate and data on numerous potential co-variates are available for each individual in the study on the NHANES website. Since these data are publicly available we performed our own calculations using the individual data rather than relying on the grouped data and final results presented by Blount et al.. As we have shown, the results of our analyses are very similar to those of Blount et al. (Steinmaus et al., 2007). The minor differences are probably due to differences in the statistical packages used and differences in the way certain potential co-variates were defined. Performing our own calculations with the raw data allowed us to confirm the statistical analyses of Blount et al. and allowed us to more thoroughly evaluate specific aspects of causal inference (presented previously).

The Benchmark Dose Approach

The benchmark dose (BMD) approach was used to calculate a point of departure (POD). The advantages of this approach over the NOAEL approach are discussed elsewhere (U.S. EPA, 2000). The BMD is defined as the dose (or exposure) that causes a prescribed adverse change in response (Crump, 2002). A statistical lower bound of the BMD, usually the 95% lower confidence limit (the BMDL), is used as the point of departure for defining an exposure level that is likely to be without an appreciable risk of deleterious effects in humans. Using the BMDL rather than the BMD helps to account for the uncertainty inherent in a given study and according to the U.S. EPA, “assures (with
95% confidence) that the desired response is not exceeded.” (U.S. EPA, 2000). The BMD and BMDL are calculated by fitting a mathematical model to dose-response data and determining the dose, and its 95% CI, that is associated with a predefined benchmark response (BMR).

**BMD for continuous data.** In the past, the BMR has been typically defined as a 10 percent increase in the proportion of subjects exhibiting a predefined adverse response over the baseline response (the proportion exhibiting the response in a control or unexposed group). The 10 percent level is based primarily on the level of response that can be detected with sufficient statistical power in typical sized animal and human studies. Benchmark dose calculations can also be done for response data that are continuous. The previous OEHHA 2004 perchlorate PHG which used a 5 percent decrease in radioactive iodine uptake is an example of using a response variable that is continuous.

**Selecting the BMR**

Several approaches can be used to define a BMR:

An absolute level of T4 that is generally considered to be adverse: There is no single value of T4 or TSH that most clinicians would consider to define “adverse”. Sometimes, the upper and lower 2.5th percentiles of T4 values collected in large population samples like NHANES have been used to define “normal” reference ranges. However, these levels are not absolute: some people with T4 levels outside these reference ranges will not exhibit thyroid disease, while some with T4 values within the normal reference range will. As discussed in the PHG document, several studies have shown linear associations between T4 and disease-related markers at T4 values well within normal reference ranges. For these reasons, there is no single absolute value of T4 which can be used to separate those likely to have significant risks of thyroid-related disease from those likely to have no risk of disease. Regardless, T4 percentile cut-off points are related to the risks of thyroid disease. That is, at least at the lower spectrum of T4 levels, the lower the percentile a subject’s T4 value falls into, the greater their risk of thyroid-related disease. Because of this, we evaluated the use various percentiles of T4 in NHANES (the lower 2.5th, 5th, and 10th percentiles) as cutoff points for defining people likely to have a substantial risk of thyroid-related disease. This is discussed in further detail below.

Dichotomizing the data: One way of defining a BMR would be to dichotomize the outcome data; that is, define a level of serum level below which T4 would be considered adverse and above which it would not be considered adverse. As mentioned above, this could be defined as the lower 2.5th or 5th percentiles of T4 levels in a large population sample. Once dichotomized, the BMR can then be defined as an increase of 10 percent in the proportion of subjects that exhibit T4 levels below this cut-off point compared to the proportion seen in an unexposed (or relatively unexposed) control group. The problem with this approach is that much of the detailed information that is part of the continuous data set is lost, with a potential reduction in statistical power. The hybrid approach discussed below is one method for overcoming this problem.

Absolute or percentage change: Another approach for defining a BMR is to use a level of change in T4 that is generally considered to be biologically significant. For example, a 10 percent decrease in T4 from the mean T4 of an unexposed control group might be
considered to be an important change. The BMD would then be the perchlorate dose associated with this 10 percent decline in T4. One problem with this method is that there is no single level of change in T4 that is universally accepted as being adverse or important.

*Any change or any detectable change:* Given the linear relationship between T4 and lipid metabolism and the linear relationship between T4 and childhood cognition that may occur within normal ranges of T4, it might be suggested that *any* decrease in T4 should be considered important. This is especially relevant on a population basis where any measurable decrease in population mean T4 would likely cause an increase in the number of people with T4 levels in the adverse range. For this reason, we evaluated the possibility of defining a BMR as a relatively small decrease in T4 (e.g. 1 percent and 5 percent) from the mean T4 in a unexposed control group. The problem with this method is that the selection of 1 percent or 5 percent could be considered arbitrary. In other words, one might ask why a 0.5 percent decrease or a 0.0001 percent decrease wasn’t selected?

Because of this, we considered another approach: defining a BMR as any decrease in T4 that is detectable statistically. This is similar (albeit not the same) to the BMR approach used for outcome data that are dichotomous, where the BMR is typically defined as an increase of 10 percent in the proportion of subjects eliciting a predefined adverse effect. The value of 10 percent is used because it is the level of response that can be seen with sufficient statistical power in study designs and sample sizes commonly used in animal and human studies (U.S. EPA, 2000). We used standard sample size calculations (Hulley and Cummings, 1988) and the variance in T4 seen in the 385 women with low iodine in NHANES 2001-2 to estimate the change in T4 that is likely to be detectable with sufficient statistical power in this group of women. Our calculations suggest that a study this size would have 86 percent power to detect about a 10 percent decrease in mean T4 comparing a group the size of the lower 10th percentile (i.e. 38 subjects) to the remaining subjects (i.e. 385 – 38 = 347 subjects). This power is close to the 80 percent level that most researchers would consider minimally adequate. The lower 10th percentile was used in these calculations because we used subjects in the lower 10th percentile of urine perchlorate as the “unexposed” control group in our BMD calculations (discussed below). Based on these statistical power estimates, we selected a 10 percent decrease in mean T4 as the BMR, although we assessed other levels of BMR for comparison purposes.

**Selecting an Unexposed or Lesser Exposed Control Group**

Since all of the subjects in NHANES 2001-2 had detectable levels of perchlorate, there is no truly unexposed group. Because of this, we considered the following methods for defining a control group:

a. *Lowest detected dose:* One method is to use the lowest dose detected as the baseline or control dose (0.19 μg/L). The problem with this method is that the control T4 level would be based on only one subject (only one of the 385 low iodine women had a urine perchlorate level of 0.19 μg/L) and therefore it would not be appropriately robust.

b. *Predicted T4 for the lowest detected dose:* Another method is to use the regression model to predict a mean T4 expected for a perchlorate dose of 0.19 μg/L. Since this
T4 estimate is essentially based on the regression model (and all of the data that went into it), it would be more robust. The problem with this method is that the control group mean T4 would be based on a model prediction rather than on an actual set of real values.

c. *Predicted mean T4 for a perchlorate level of zero.* Another method would be to use the regression model and enter perchlorate as zero. The problem with this method is that the model includes the logarithm of perchlorate (log-perchlorate) and there is no logarithm of zero.

d. *A log-perchlorate of zero.* Another method could be to use the regression equation to estimate a mean T4 at a log-perchlorate of zero. The problem with this method is that a log-perchlorate of zero corresponds to a perchlorate level of 1 µg/L, and there is no obvious rational for using a urinary concentration of 1 µg/L as the control level.

e. *Actual data.* The other option we evaluated was using actual data from the low iodine women in NHANES 2001-2 and defining the control group as those subjects below a particular percentile cut-off point for perchlorate dose. Subjects with perchlorate values in the lower 5th, 10th, and 20th percentiles of creatinine-adjusted urinary perchlorate concentrations were used for this. It was decided to use a control group defined as those subjects in the lowest 10th percentile of creatinine-adjusted perchlorate residuals. This was chosen because: 1. The lower 10th percentile was the basis of the statistical power calculations we used to define the BMR of 10 percent (described above). 2. It was necessary to categorize perchlorate into ten equal size dose groups in order to use these data in the BMDS (described below).

The Standard Deviation and Hybrid Approach

*One standard deviation (SD):* The U.S. EPA suggests in the absence of any other idea about what level of response to consider adverse, a change in the mean of the outcome (T4) equal to one standard deviation from the control mean can be used (U.S. EPA, 2000). They also recommend that regardless of what approach is used, the standard deviation approach be presented for comparison. Crump and others have shown that for a response variable that is normally distributed, a decrease of one SD corresponds to an increase of about 10 percent in the proportion of subjects falling below the 2nd percentile value of an unexposed comparison group (Crump, 1995).

*Hybrid approach:* The hybrid approach uses the distribution of a continuous variable (i.e. a mean T4 and its standard deviation) to estimate the proportion of subjects falling below a predefined percentile cutoff point (Gallor and Slikker, 1990; Crump, 1995). This is done by converting the mean T4 in the unexposed group and the BMR into units on the standard normal deviation scale.

Crump and others present a method for determining the fraction of the standard deviation of the mean outcome value (i.e. T4) that corresponds to a particular proportion of subjects that fall below (or above) a particular percentile cutoff point. For example, if a T4 value below the 2.5th percentile in an unexposed control population is considered adverse, then a decrease in T4 corresponding to 0.82 times the T4 standard deviation corresponds to a BMR of 10 percent (i.e. a 10 percent increase in the proportion of people that will fall below the 2.5th percentile cut-off point). The equation is:
BMR = Q x SD, where

\[ Q = N^{-1} [1-P(0)] - N^{-1} [1-P(0) - BMR] \]

\( N^{-1} \) is the inverse of the standard normal distribution (i.e. the z-score for the probability of 1-P(0) or 1-P(0)-BMR), and P(0) = the percentile below which is considered adverse (e.g. P(0) = 0.025 if being below the 2.5th percentile is considered adverse).

The Hybrid Approach Calculations

**Standard deviations:** The standard deviation in T4 for the 385 low iodine women in NHANES 2001-2 in the lower 5th, 10th, and 20th percentiles of creatinine-adjusted perchlorate residuals were 1.87, 1.86, and 1.72, respectively. The similarity of these numbers shows that the variance in T4 is essentially independent of perchlorate dose. **Calculating Q.** Values of Q were calculated for several levels of P(0) and BMR. Values for P(0) corresponding to the lower 2.5th and 5th percentiles of T4 were used since these have traditionally been used to define the lower bounds of “normal” T4 reference ranges. A P(0) value corresponding to the lower 10th percentile was also evaluated since significant cognitive effects in children were seen in children in the lowest 10th percentile of T4 or fT4 (Pop et al., 1999, 2003; Kooistra et al., 2006). BMRs of 5 and 10 percent were chosen since 5 and 10 percent are thought to represent levels that can be detected statistically in typical sized animal and human studies (U.S. EPA, 2000). Values of Q for these levels of BMR and P(0) are shown in Table A2.

**Table A2. Hybrid Table: Calculating Values of Q**

<table>
<thead>
<tr>
<th>T4 considered adverse</th>
<th>P(0)</th>
<th>1-P(0)</th>
<th>( N_A^{-1} )</th>
<th>BMR</th>
<th>1-P(0)-BMR</th>
<th>( N_B^{-1} )</th>
<th>Q</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 2.5th percentile</td>
<td>0.025</td>
<td>0.98</td>
<td>1.960</td>
<td>5%</td>
<td>0.93</td>
<td>1.440</td>
<td>0.52</td>
</tr>
<tr>
<td></td>
<td>0.025</td>
<td>0.98</td>
<td>1.960</td>
<td>10%</td>
<td>0.88</td>
<td>1.150</td>
<td>0.81</td>
</tr>
<tr>
<td>&lt; 5th percentile</td>
<td>0.05</td>
<td>0.95</td>
<td>1.645</td>
<td>5%</td>
<td>0.90</td>
<td>1.282</td>
<td>0.36</td>
</tr>
<tr>
<td></td>
<td>0.05</td>
<td>0.95</td>
<td>1.645</td>
<td>10%</td>
<td>0.85</td>
<td>1.036</td>
<td>0.61</td>
</tr>
<tr>
<td>&lt; 10th percentile</td>
<td>0.1</td>
<td>0.90</td>
<td>1.282</td>
<td>5%</td>
<td>0.85</td>
<td>1.036</td>
<td>0.25</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>0.90</td>
<td>1.282</td>
<td>10%</td>
<td>0.80</td>
<td>0.842</td>
<td>0.44</td>
</tr>
</tbody>
</table>

Abbreviations: BMR, the benchmark response or the increase in the proportion of people who fall below the T4 level considered adverse; \( N_A^{-1} \), standard normal deviate for 1-P(0); \( N_B^{-1} \), standard normal deviate for 1-P(0)-BMR; P(O), the percentile of T4 in the control group below which would be considered adverse.

BENCHMARK DOSE CALCULATIONS

Transforming NHANES 2001-2 Data for the BMDS

The U.S. EPA benchmark dose software (BenchMark Dose Software (BMDS) version 2.0) was used for our POD calculations. The following data transformations were required:

**Creatinine adjustment:** The BMDS does not allow the use of co-variates such as urine creatinine concentration. As we have shown above, urine creatinine was the only...
individual co-variates that cause a greater than 10 percent change in the perchlorate-T4 regression coefficient (Table 22). Because the addition of urinary creatinine appears to improve the model, it was decided that this variable should be incorporated into the POD calculations. This was done by calculating creatinine-adjusted perchlorate residuals (“perchlorate residuals”) using the Proc Reg statement in SAS with the logarithm of urinary perchlorate concentration (log-perchlorate) as the dependent variable and the logarithm of urinary creatinine concentration as the independent variable (logarithm of creatinine or log-creatinine). The association between serum T4 and the creatinine-adjusted perchlorate residuals was only slightly different than the association seen in the fully adjusted model.

We considered using the urine perchlorate:creatinine ratio. However, the association between T4 and this ratio in the low iodine women was not as strong as when perchlorate residuals were used and was only borderline statistically significant (unadjusted regression coefficient between T4 and the perchlorate:creatinine ratio = -1.18; SE = 0.66; p = 0.07). This is likely due to the factors discussed previously for the iodine/creatinine ratio. That is, it creates a variable that is not only dependent on perchlorate, but also on all the factors that determine an individual’s urinary creatinine level (e.g. muscle mass, diet, physical activity...). Including all these other influences into the perchlorate exposure variable can lead to misclassification of true perchlorate exposure.

*Other co-variates and potential modifying factors:* None of the other co-variates used in Blount et al. caused important changes in the perchlorate-T4 regression coefficient so these were not used in our BMD calculations. In addition, we did not use the NHANES complex sampling weights because they had only a small impact on regression coefficients and their standard errors (Table A3), and the incorporation of these weights would have significantly complicated the model.

### Table A3. T4-Log-Perchlorate Regression Coefficients Using Different Methods of Analysis

<table>
<thead>
<tr>
<th>Method</th>
<th>Adjusted</th>
<th>Weights&lt;sup&gt;a&lt;/sup&gt;</th>
<th>B</th>
<th>SE</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blount et al., 2006</td>
<td>Full</td>
<td>Yes</td>
<td>-0.89</td>
<td>0.18</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Steinmaus et al., 2007</td>
<td>Full&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Yes</td>
<td>-0.73</td>
<td>0.22</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td>Full&lt;sup&gt;b&lt;/sup&gt;</td>
<td>No</td>
<td>-0.87</td>
<td>0.27</td>
<td>0.0016</td>
</tr>
<tr>
<td></td>
<td>Creatinine Only</td>
<td>No</td>
<td>-0.81</td>
<td>0.27</td>
<td>0.0026</td>
</tr>
<tr>
<td></td>
<td>Unadjusted</td>
<td>No</td>
<td>-0.67</td>
<td>0.23</td>
<td>0.0041</td>
</tr>
<tr>
<td>BMDS</td>
<td>Creatinine Only</td>
<td>No</td>
<td>-0.79</td>
<td>0.28</td>
<td>na&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*Abbreviations: BMDS, benchmark dose software; B, regression coefficient; SE, standard error; na, not available.*

<sup>a</sup>NHANES sampling weights applied

<sup>b</sup>Only independent variables with p-values < 0.20 were entered and retained in the model except for log-creatinine which was retained in the model regardless.

<sup>c</sup>p-value not given. The 95% CI of the regression coefficient is -1.34 to -0.24
Figure A1 shows the linear relationship between serum T4 and the creatinine-adjusted perchlorate residuals. We assessed the effects of possible outlying values by removing certain data points. Removing the leftmost point in this figure (T4 = 10.1 µg/dl, urine perchlorate = 0.24 µg/L, urinary creatinine = 146 mg/dl) changed the regression coefficient from 0.8122 to 0.7924. Removing the rightmost data point in this figure (T4 = 7 µg/dl, perchlorate = 100 µg/L, creatinine = 40 mg/dl) changed the regression coefficient from 0.8122 to 0.8135.

Figure A1. Serum T4 and Creatinine-Adjusted Perchlorate Residuals in 385 Women with Urinary Iodine Levels < 100 µg/L, NHANES 2001-2

Categorizing dose: The BMDS allows for the use of individual data on dose and response and both can be entered as continuous variables. In controlled human trials, such as the Greer et al. (2002) study, doses are usually categorized into a relatively small number of dose groups. In NHANES 2001-2, each individual subject had their own urinary perchlorate concentration. Since there were 385 subjects in this study, this resulted in hundreds of “dose groups”. Entering this many dose groups into the BMDS led to implausibly wide confidence intervals around the BMD and implausibly low BMDL values. To make the calculations computationally easier, we ranked the perchlorate residuals into 10 equal sized dose groups and assigned each individual in each group the mean perchlorate residual value for that group. Categorizing data into groups such as this can potentially cause a loss of information and decrease study power but this did not seem to be the case here. Table A4 compares the perchlorate-T4 model parameters calculated in SAS Proc Reg using the individual data versus those calculated by the BMDS using the 10 dose groups. As seen, the regression coefficient and its standard error are essentially the same in both models. This shows that using the 10 dose groups instead of the 385 individual dose points resulted in little loss in statistical power and essentially no loss in our ability to accurately measure the dose-response relationship.
Since the choice of using 10 dose groups was somewhat arbitrary, we evaluated the effects of using more or fewer dose groups. Table 45 shows the results of the BMDS calculations using 5 or 20 equal size dose groups. As seen, when five dose groups were used it appears that too much information was lost and the dose-response relationship becomes less strong. Using 20 dose groups didn’t substantially change the model compared to when 10 groups were used.

Table A4. Association between T4 and Perchlorate Residuals: Comparing Individual Data to Dose Groups

<table>
<thead>
<tr>
<th>Method</th>
<th>Intercept (SE)</th>
<th>B (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAS Proc Reg: individual data</td>
<td>8.04 (0.56)</td>
<td>-0.81 (0.27)</td>
</tr>
<tr>
<td>BMDS linear model:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 dose groups</td>
<td>8.88 (0.17)</td>
<td>-0.79 (0.28)</td>
</tr>
<tr>
<td>5 dose groups</td>
<td>8.68 (0.16)</td>
<td>-0.54 (0.30)</td>
</tr>
<tr>
<td>20 dose groups</td>
<td>8.99 (0.20)</td>
<td>-0.83 (0.27)</td>
</tr>
</tbody>
</table>

Abbreviations: B, regression coefficient; SE, standard error

Positive numbers for dose: The BMDS does not accept negative values for dose. Our dose metric was perchlorate residuals, which had a mean of zero and some positive and some negative values. So that we would not have any negative values for dose, we subtracted the mean of the lowest dose group from the means of each dose group to obtain a new dose variable for each group. This resulted in a value of zero for the lowest dose group and positive values of dose for all other groups. Since this maintained the absolute difference between doses it did not affect the perchlorate-T4 residual slope or its standard error.

Following these transformations, we used the BMDS to calculate a BMD and BMDL. The BMD and BMDL are creatinine-adjusted logarithm of urine perchlorate residuals minus the perchlorate residuals in the lowest dose group. These numbers were converted back into a urinary perchlorate level in µg/L using the following steps:

1. Adding the mean perchlorate residual in the lowest dose group (note that this is actually a negative number so adding it is the same as subtracting its absolute value). This gives the creatinine-adjusted residuals of the logarithm of urine perchlorate concentration.

2. Because the residuals have a mean of zero, and some positive and some negative values they have no practical meaning in terms an actual perchlorate concentration. To convert the residuals back to an actual value of log perchlorate we added the log-perchlorate concentration that was predicted for the mean log-creatinine level of the study population as a whole using the method recommended in Willett and Stampfer, (1998). The predicted log-perchlorate concentration was calculated using SAS Proc Reg with log-perchlorate as the dependent variable and log-creatinine as the independent variable (the same equation we used to calculate the residuals).
3. This number was then converted to a urine perchlorate level in µg/L by taking the inverse log.

Using the BMDS

The linear model using the continuous data option was selected in the BMDS. The individual data for serum T4 was entered as the response variable and the mean values for each dose group (as described above) were entered as the dose variable. As discussed above, subjects in the lowest 10th percentile of perchlorate residuals were used as our “unexposed” control group and had a transformed dose value of zero. The BMR was set at a relative decrease in T4 of 10 percent. Other options selected were: The constant variance and BMD calculation boxes were checked. Parameter assignments were all set at “default”, the degree of polynomial was set at 1, the confidence level was set at 95%; and the adverse direction was set at “down”.

BMDS Results

The following table shows the BMD and BMDL calculations where the BMR is defined as a 10 percent decrease in T4 from the mean T4 in our “unexposed” control group. For comparison purposes, BMD calculations are also shown for other definitions of BMR:

- We used the hybrid approach and Q values corresponding to a 5 percent (Q = 0.25) or 10 percent (Q = 0.44) increase in the proportion of subjects below the lower 10th percentile of T4 in our “unexposed” control group. The lower 10th percentile was chosen because this was the cut-off used to define the “low” fT4 group in Kooistra et al. (2006), Pop et al. (1999), and Pop et al. (2003), three studies that found statistically significant associations between low maternal gestational fT4 and childhood cognitive deficits.

- Calculations are shown for BMRs defined as 20-30 percent decreases in T4 because this was the level of difference in T4 and fT4 associated with statistically significant declines in child cognitive development in other studies.

- Calculations for a BMR equal to a one standard deviation change in the mean T4 of the control group are shown because U.S. EPA recommends that these always be shown for comparison purposes.
### Table A5. BMD and BMDL Results for Various Levels of BMR

<table>
<thead>
<tr>
<th>BMR</th>
<th>1%</th>
<th>5%</th>
<th>10%</th>
<th>20%</th>
<th>30%</th>
<th>0.25SD&lt;sup&gt;a&lt;/sup&gt;</th>
<th>0.44SD&lt;sup&gt;a&lt;/sup&gt;</th>
<th>1SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMD (from the BMDS)</td>
<td>0.11</td>
<td>0.56</td>
<td>1.13</td>
<td>2.26</td>
<td>3.38</td>
<td>0.56</td>
<td>0.98</td>
<td>2.23</td>
</tr>
<tr>
<td>BMDL (from the BMDS)</td>
<td>0.07</td>
<td>0.37</td>
<td>0.73</td>
<td>1.46</td>
<td>2.19</td>
<td>0.35</td>
<td>0.62</td>
<td>1.40</td>
</tr>
</tbody>
</table>

**Step 1: Add the lowest dose**

- Lowest dose: -0.544
- BMDL log-perchlorate residual: -0.471

**Step 2: Convert residual to log-perchlorate**

- log-perc at mean log-creat: 0.251
- Add mean log-perc to residual: -0.220

**Step 3: Take inverse log**

- BMDL in µg/L (urine): 0.60

**Convert urine µg/L to intake**

- Age<sup>b</sup>: 35
- Weight<sup>b</sup>: 66.7
- Height<sup>b</sup>: 160.9
- k (constant, for females): 1.64
- Gram creatinine/day estimate: 1.190
- Creatinine g/L<sup>b</sup>: 0.53
- Intake at BMDL (in µg/day): 1.4
- Intake at BMDL (in µg/kg-day): 0.020

<sup>a</sup>The T4 standard deviation (SD) in the control group was 1.87 so 0.25SD = 0.4675 and 0.44SD = 0.8228.

<sup>b</sup>The median levels in all 385 low iodine women in NHANES 2001-2 were used for these values.
Converting urinary perchlorate concentrations to levels of perchlorate intake

In all of our POD calculations perchlorate dose is expressed in terms of a urinary concentration of perchlorate. These values were used to calculate the BMD and BMDL. We converted these into an estimated daily intake of perchlorate using the method presented in Blount et al., 2007. This method is based on equations from Crockcroft and Gault (1976) and modified by Mage et al. (2004) and estimate perchlorate intake using urinary perchlorate and creatinine concentrations combined with estimates of daily creatinine output which are based on age, height, gender, and weight. This equation is:

\[
\text{Daily perchlorate intake} = \frac{\mu g \text{ urine perchlorate}}{\text{gram urine creatinine}} \times \frac{\text{gm creatinine}}{\text{Day}} \times \frac{1}{\text{kg}}
\]

Where \( \text{gm creatinine / day} \) is estimated by:

\[10^{-6} \times k \times (140 - \text{age(year)}) \times \text{weight(kg)}^{1.5} \times \text{height(cm)}^{0.5}\]

Where \( k = 1.64 \) for females. The median values in the 385 low iodine women were used for age (35), height (160.9 cm), weight (66.7 kg), and urine creatinine concentration (53 mg/dl). The results of these calculations are shown at the bottom of Table A5.

Summary

We calculated an intake BMDL of 0.092 µg/kg-day for a 10 percent decrease in T4. This BMDL is reasonably close to that calculated using the hybrid approach corresponding to an increase of 10 percent in the proportion of subjects with T4 values below the lower 10\(^{th}\) percentile. The BMDS graphical displays of both of these analyses are shown in Figures A2 and A3.
Figure A2. BMDS Output for Serum T4 (Mean Response) and Transformed Log Perchlorate Residuals (Dose) for a BMR of 10 percent Decrease in T4

Figure A3. BMDS Output for Serum T4 (Mean Response) and Transformed Log Perchlorate Residuals (Dose) for a BMR of 0.44 x the T4 Standard Deviation of the Control Group
CALCULATION OF THE PHG USING NHANES 2001-2 DATA

Acceptable Daily Dose

For estimation of a health-protective concentration of perchlorate in drinking water, an acceptable daily dose (ADD) of the chemical from all sources will first be calculated. This involves incorporation of appropriate estimates of uncertainty in the extrapolation of the critical toxic dose from human or animal studies to the estimation of a lifetime ADD that is unlikely to result in any toxic effects. For this purpose, the following equation can be used:

\[
\text{ADD} = \frac{\text{NOAEL/LOAEL/BMDL in mg/kg-day}}{\text{UF}}
\]

where,

\[
\text{ADD} = \text{estimated maximum daily dose which can be consumed by humans for an entire lifetime without toxic effects;}
\]

\[
\text{NOAEL/LOAEL/BMDL} = \text{no-observed-adverse-effect level, lowest-observed-adverse-effect level, or lower limit on the benchmark dose estimated from the critical study;}
\]

\[
\text{UF} = \text{uncertainty factor(s).}
\]

For this case, we have chosen to estimate the ADD from the lower limit of the two-sided 95 percent confidence interval of the perchlorate dose estimated to cause a 10 percent reduction in serum T4 levels, as observed in Blount et al. (2006). In this study, statistically significant associations between perchlorate and T4 were seen in women with urinary iodine levels below 100 µg/L but not in women with higher iodine levels.

An uncertainty factor of four is proposed, including a factor of 2 to account for uncertainty due to the use of cross-sectional data to derive the dose-response estimates, and a factor of two to account for uncertainty due to possible increased susceptibility related to factors that were not already taken into account (e.g. exposure to other thyroid-inhibiting agents like thiocyanate, thyroid diseases, additional susceptibility in the fetus and young children...). Thus,

\[
\frac{0.092 \mu g/kg-day}{2 \times 2} = 0.023 \mu g/kg-day
\]

Public Health Protective Concentration

Calculation of a proposed public health-protective concentration (C, in mg/L) for perchlorate in drinking water uses the following equation for non-carcinogenic endpoints:

\[
C = \text{ADD } \mu g/kg-day \times \text{BW/WC} \times \text{RSC}
\]

\[
C = 0.023 \mu g/kg-day \times 25.2 \text{ kg-day/L} \times 1
\]
C = 0.58 µg/L = 0.6 µg/L (ppb) (rounded)

where:

\[(BW/WC) = \text{the ratio of body weight (kg) and tap water consumption rate (L/day); the ratio for the 95th percentile of the pregnant woman population is estimated to be 0.0252 kg-day/mL or 25.2 kg-day/L (OEHHA, 2000); and}\]

\[RSC = \text{relative source contribution; a value of 1 is used for pregnant women. See the explanation for this value below.}\]

**Uncertainty factors**

**Susceptibility:** Potential susceptible subpopulations were listed previously. We have likely already incorporated much of the susceptibility due to inadequate iodine intakes by using data on women with low iodine levels for our BMD calculations. In addition, some of the susceptibility due to several of the other factors listed above is likely already included in our calculations since NHANES is a population based study and involves at least some subjects who fall into the susceptible subgroups listed above. Because of this, we did not use the uncertainty factor of 10 that would typically be applied to account for inter-individual variability when dose-response data are derived from healthy individuals. However, some potentially susceptible groups were not included or were not specifically evaluated in the NHANES data set we used. These include fetuses, infants and young children, people with thyroid diseases, and subjects exposed to high levels of other NIS inhibitors. We added an uncertainty factor to account for the potential susceptibility in these groups. Data from Steinmaus et al. (2007) suggest that the magnitude by which perchlorate reduces T4 levels is about 2 times greater in people with high thiocyanate levels than in people with average or low thiocyanate levels. PBPK modeling data from Clewell et al. (2003) suggest that thyroid iodine uptake inhibition for a given external dose of perchlorate may also be up to 2 times greater in the fetus and neonate compared to adults (their Table 5). Based on these findings we added an uncertainty factor of 2.

**Database weaknesses:** We also added an uncertainty factor to account for the fact that our dose-response assessment is based on cross-sectional data. As discussed above, the single measurements of serum T4 and urinary perchlorate that were collected in NHANES 2001-2 may not be completely accurate measures of true long-term T4 levels or perchlorate exposure. Because this bias is most likely to be non-differential, the resulting impact on the perchlorate-T4 regression coefficient is likely to be towards a regression coefficient of zero, and true associations might actually be stronger than the one observed. Beaton et al. (1978) published an equation for predicting the magnitude of this bias:

\[b_t = b_0 (1 + R^2_x/n_x)\]

Where \(b_t\) is the estimated true regression coefficient after correcting for misclassification, \(b_0\) is the observed regression coefficient, \(R^2_x\) is the ratio of intra- to inter-individual variances for the misclassified variable \(x\), and \(n_x\) is the number of replicate measures of \(x\) per subject that were collected in the study. Since only a single urine and serum sample were collected from each subject in NHANES, \(n_x = 1\), and the degree of bias is primarily
related to $R^2_x$. Information on the value of $R^2_x$ are not available in the NHANES 2001-2 data set, and we could not find a similar published study that specifically provided values of $R^2_x$ for urinary perchlorate concentrations in humans.

In one study however, Ohira et al. (2008) compared 24-hour urine perchlorate measurements to creatinine-adjusted spot urine perchlorate concentrations in 14 breastfeeding mothers and reported that the average deviation between these two measures was 105 percent. In our NHANES study group, the mean spot urine perchlorate concentration was 2.86 µg/L. If we assume the average deviation in the NHANES population was similar to that of Ohira et al., then the average deviation between a single spot urine perchlorate concentration and 24-hour sample concentrations in the NHANES study group would be about 3.0 µg/L (i.e., 105 percent x 2.86 µg/L).

If we assume that:

1. The mean perchlorate concentration in spot samples from a large group of subjects ($x_m$) will be about equal to the mean perchlorate concentration in 24-hour samples from this same large group (this is probably a valid assumption because while a spot concentration may vary from a 24-hour concentration in any given individual, the spot concentration and 24-hr concentration means in the group should be about the same), and

2. The mean perchlorate concentration in 24-hour samples is a much better reflection of true perchlorate intake than perchlorate concentration from a spot urine sample (more on this later).

Then an estimate of the variance due to intra-individual variability associated with the use of spot samples might be estimated as:

\[
\text{Variance} = \frac{\sum (x_m - x_i)^2}{n - 1},
\]

where $n$ is the number of subjects in the study, and $x_m - x_i$ is the average deviation between spot urine and 24-hour urine concentrations (3.0 µg/L). Given this, the estimate of intra-individual variance is:

\[
= 385 \times (3.0 \, \mu g/L)^2 / (385-1)
\]

\[
\approx 9 \, \mu g/L
\]

The total variance (intra- and inter-individual variance) in the spot urine perchlorate concentrations in the NHANES 2001-2 data set (all 385 low iodine women) was 32.9 µg/L. These data suggest that $R^2_x$ might be somewhere near:

\[
R^2_x = \frac{\text{variance intra-individual}}{\text{variance inter-individual}}
\]

\[
= 9 \, \mu g/L / (32.9 \, \mu g/L - 9 \, \mu g/L) = 0.38
\]

The corrected regression coefficient could be somewhere near:

\[
b_t = b_0 (1 + R^2_x/n_x)
\]

\[
= 0.79 (1 + 0.38/1) = 1.09
\]

That is, the corrected regression coefficient between perchlorate and T4 is about 1.09 times larger than the observed coefficient.
It should be noted that these calculations are estimates. They are based on the assumptions that 24-hour perchlorate levels are an accurate indicator of true long-term exposure and that the variance in the NHANES population is similar to that of Ohira et al. (2008). In addition, they do not take into account other sources of variance like laboratory imprecision. Despite this, these estimates do provide some general idea of the likely magnitude of the bias due to the use of spot urine samples and provide at least some assurance that a factor of 2 is likely to cover the uncertainty associated with this database insufficiency.

With regards to intra-individual variability in serum T4 measurements, Andersen et al. (2002) examined this issue in 16 healthy men by collecting monthly measurements of serum T4 over a period of 1 year. They reported an individuality index (defined as $SD_{\text{analytical+intraindividual}} / SD_{\text{interindividual}}$) of 0.54. A ratio of the respective variances (i.e. $R_x^2$) would be about $(0.54)^2 = 0.29$. This possible 29 percent increase in the perchlorate-T4 regression coefficient is also within the 2-fold uncertainty factor we incorporated.

**Relative source contribution**

Recent food analyses have greatly expanded the data available on exposures to perchlorate in food, as described in the Exposure section of this document. Perchlorate has been detected in a wide variety of foods, including fruits, vegetables, grains, dairy milk, and human breast milk (Kirk et al. 2005, Pearce et al., 2007; Murray et al., 2008). Perchlorate levels in urine from NHANES, as reflected in the analysis of Blount et al. (2006), are generally supportive of the FDA analysis. Together, these data demonstrate that food is the primary source of perchlorate for the general population.

At an ADD of 0.023 µg/kg-day and a range of average perchlorate exposure levels in food of about 0.09 to 0.39 µg/kg-day, the health-protective level is already exceeded by perchlorate from food. Mean exposures from food for women of childbearing age are about 0.1 µg/kg-day, according to the estimates of Murray et al. (2008). Thus it does not seem appropriate to allocate any specific fraction of total exposure to drinking water; all sources should be limited because the threshold of effect is already exceeded by the exposures derived from food. The concept of zero as a relative source contribution from water is unattainable. We have used 1 as a placeholder, indicating that no specific “acceptable” fraction can be calculated.

Drinking water at a PHG level of 0.6 ppb would provide about one/tenth the average exposure to perchlorate that would be obtained from food, for women of child-bearing age. One could say that this is equivalent to a relative source contribution of 0.1, which is below the guidelines of 0.2 to 0.8 recommended by U.S. EPA. However, these guidelines are intended for exposures that yield total daily doses below the effect threshold. In this case, since effects on thyroid hormone homeostasis are observed at common environmental exposures, the operating principle should merely be to decrease exposure to perchlorate as much as practical, and ensure adequate dietary iodide.